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1 SUMMARY 
Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has yielded 
remarkable response rates in melanoma patients. This treatment cannot be easily 
applied to other tumor entities as isolation of TILs and their expansion is not always 
possible. The transfer of genetically engineered T cells can overcome the limitations 
of TIL therapy. However, clinical trials reported response rates lower than expected. 
The drawbacks of adoptive T cell therapy include short persistence and loss of 
function of transferred T cells. Co-stimulation can enhance T cell proliferation and 
survival and can restore cytotoxicity. As effector T cells are largely CD28 negative 
and most epithelial tumors do not express CD80 or CD86, T cells cannot receive co-
stimulation in the tumor environment. In this thesis, a strategy was developed to 
facilitate co-stimulation of T cells in the tumor environment independent on CD28-
CD80/86 interaction. Chimeric receptors were designed based on joining the PD-1 
extracellular domain with the intracellular signaling domains of CD28 or 4-1BB. The 
chimeric receptors should initiate a co-stimulatory signal when ligated by PD-L1, 
which is highly expressed in most tumor environments. 
The results demonstrate that T cells can be engineered to express the chimeric 
receptors whereby those receptors with the intracellular domain of CD28 were found 
to be better expressed than those with the 4-1BB signaling domain. PD-1:28 
engineered T cells showed enhanced cytokine secretion (IL-2 and IFN-γ) and 
stronger TCR signaling (phosphorylation of ERK and RPS6) when stimulated with 
PD-L1 expressing target cells.  
PD-1:28 engineering upgraded low-avidity T cells enabling them to secrete cytokine 
at levels comparable to high-avidity T cells when stimulated with PD-L1 positive 
target cells. This result is of specific interest for potential clinical application, since it 
suggests that PD-1:28 engineering of T cells might be a strategy to increase the anti-
tumor activity of T cells without modifying the T cell receptor affinity and risking loss 
of specificity.  
Furthermore it could be demonstrated that PD-1:28 engineering of anergic TILs from 
human renal cell carcinoma enabled them to secrete anti-tumoral IFN-γ indicating 
that PD-1:28-mediated co-signaling can overcome tumor-inflicted functional 
unresponsiveness. 
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Finally, using in vivo tumor models, it was observed that chimeric PD-1:28-
expressing T cells proliferated more strongly in a human melanoma xenograft model 
and were resistant to the induction of a tumor-promoting Th2 cytokine profile in an 
autochthonous hepatocellular carcinoma model.  
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2 ZUSAMMENFASSUNG 
Durch adoptiven Transfer von tumorinfiltrierenden Lymphozyten (TIL) können 
bemerkenswerte Ansprechraten in Melanompatienten erzielt werden. Diese Art der 
Therapie kann jedoch nicht bei allen Tumorentitäten angewandt werden, da die 
Isolierung von TIL und deren Expansion nicht immer möglich ist. Verwendet man T-
Zellrezeptor-transgene T-Zellen, so kann man diese Einschränkungen umgehen, die 
erzielten Ansprechraten waren jedoch geringer als erwartet. Eine geringe Persistenz 
sowie der Funktionsverlust der transferierten T-Zellen können für den geringen 
Therapieerfolg verantwortlich sein. Kostimulation kann die Proliferation und das 
Überleben sowie die zytotoxische Aktivität von T-Zellen verbessern. Jedoch verlieren 
Effektor-T-Zellen ihre CD28 Expression und die meisten Karzinome exprimieren 
weder CD80 noch CD86. Ziel dieser Arbeit war es, eine Strategie zu entwickeln, die 
eine von der CD28-CD80/CD86-Interaktion unabhängige Kostimulation von T-Zellen 
im Tumormilieu  ermöglicht. Dazu wurden chimäre Kostimulationsrezeptoren 
entwickelt, die aus der extrazellulären Domäne von PD-1 und der intrazellulären 
Signaldomäne von entweder CD28 oder 4-1BB bestehen. Diese chimären 
Rezeptoren sollten ein kostimulatorisches Signal in der T-Zelle auslösen, wenn die 
extrazelluläre PD-1-Domäne an PD-L1 bindet.  
Es wurde beobachtet, dass chimäre Kostimulationsrezeptoren mit der CD28-Domäne 
besser exprimiert werden als solche mit der 4-1BB-Domäne. Weiterhin konnte 
gezeigt werden, dass T-Zellen, die PD-1:28 Rezeptoren exprimierten und mit PD-L1 
positiven Zielzellen stimuliert wurden, mehr Zytokin (IL-2 und IFN-γ) sezernierten und 
die T-Zellrezeptor-Signalkaskade stärker aktivierten (erhöhte Spiegel an 
phosphoryliertem ERK und RPS6) als vergleichbare T-Zellen ohne PD-1:28.  
 
Weiterhin wurde beobachtet, dass niedrig-avide T-Zellen durch PD-1:28 vergleichbar 
hohe Zytokinspiegel sezernieren konnten wie hoch-avide T-Zellen. Gentechnisches 
Engineering mit chimären Kostimulationsrezeptoren könnte also eine Strategie sein, 
um die Funktion von niedrig-aviden T-Zellen zu erhöhen, ohne die 
T-Zellrezeptoraffinität zu verändern und dadurch Spezifitätsverlust zu riskieren. 
Weiterhin konnte gezeigt werden, dass Engineering von anergen TIL aus humanem 
Nierenzellkarzinom mit PD-1:28 die TIL dazu befähigte, IFN-γ zu sezernieren, wenn 
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sie mit PD-L1 positiven Zielzellen stimuliert wurden. Offensichtlich kann die 
Kostimulation über PD-1:28 Rezeptoren den tumor-induzierten Funktionsverlust von 
TIL überwinden.  
Letztendlich konnten auch in In-vivo-Tumormodellen T-Zell-unterstützende Effekte 
von PD-1:28-vermittelter Kostimulation gezeigt werden. So wurde in einem Melanom-
Xenograftmodell beobachtet, dass PD-1:28-exprimierende T-Zellen im Tumormilieu 
besser proliferieren. In einem autochthonen hepatozellulären Karzinommodell wurde 
gezeigt, dass der adoptive Transfer von PD-1:28-exprimierenden T-Zellen die Th2-
Polarisierung von TIL im Tumormilieu verhindert.  
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3 INTRODUCTION 
3.1 Innate and adaptive immunity 
The immune system provides protection from toxins, infectious microorganisms and 
endogenous degenerated cells. Epithelial tissues form a barrier to separate the body 
from its environment. Antimicrobial substances within these epithelia are the first line 
of immune defense. If infectious microorganisms or toxins cross this barrier they are 
confronted by soluble and cellular components of the innate immune system. Soluble 
components, like the complement system, mark invaders as foreign to facilitate their 
recognition and elimination by cellular components. The main cellular components of 
innate immunity are natural killer cells, dendritic cells (DCs), macrophages and 
granulocytes. Granulocytes and macrophages phagocytize and digest 
microorganisms. NK cells can directly lyse infected or degenerated cells by disrupting 
their membranes and transferring lytic enzymes. The cross-talk between NK cells 
and DCs leads to a reciprocal enhancement of functionality. DCs are the connective 
element between innate and adaptive immunity. They induce the differentiation of 
naïve T cells into effector cells by presenting pathogen- or tumor-derived epitopes on 
major histocompatibility molecules (MHC). T cells together with B cells represent the 
cellular components of adaptive immunity. CD4+ T cells function as helper cells by 
producing stimulatory and regulatory cytokines. CD8+ T cells act as cytolytic T cells 
with the capacity of direct target cell elimination (1). 
 
3.1.1 CD8+ T cell characteristics and repertoire selection 
T cells derive from a lymphoid progenitor and complete their development in the 
thymus. Naïve T cells leave the blood stream through high endothelial venules and 
enter secondary lymphoid organs. Antigen presenting cells (APCs) residing in 
peripheral tissues also migrate to these organs and carry antigens from self-proteins, 
altered self-proteins, mutations or infectious encounters. CD8+ T cells recognize 
peptides presented on MHC class I molecules by APCs. MHC class I molecules 
consist of an α-chain non-covalently linked to β2-microglobulin and are expressed on 
all nucleated cells. MHC-I present peptides produced by the cell itself and are hence 
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very important for the elimination of virus-infected and degenerated cells. The 
recognition of the peptide-MHC complex (pMHC) is mediated through the T cell 
receptor (TCR). The TCR is a heterodimer consisting of an α- and a β-polypeptide 
chain. The variable region of the TCR determines its specificity and the constant 
region translates cognate pMHC binding into a stimulatory signal. The specificity of a 
T cell is determined by the amino acid sequence of the TCR’s variable region (v-
region). The complementarity determining regions (CDR) 1-3 within the v-region are 
implicated in antigen binding. Their amino acid sequence is assembled from different 
gene segments during the development of a T cell in the thymus. Only CD8+ T cells 
recognizing endogenous MHC class I molecules receive a survival signal (positive 
selection). In a second (negative) selection, CD8+ T cells recognizing self-derived 
epitopes are deleted from the repertoire. These selection processes lead to the 
development of a self-MHC-restricted T cell pool tolerant to self but capable of 
recognizing foreign harmful structures and degenerated or infected endogenous 
cells.  
Ligation of the TCR by cognate pMHC initiates a signaling cascade leading to 
differentiation of naïve T cells into effector cells if in addition to the TCR signal (signal 
1), a second co-stimulatory signal (signal 2) is provided. Additionally, the cytokine 
milieu (signal 3) shapes the strength and polarization of the differentiation. 
Once activated, CD8+ effector T cells can exert various functions. By expression of 
Fas ligand, they can induce apoptosis in cells expressing the Fas receptor. 
Moreover, CD8+ effector T cells can permeabilize the cell membrane of target cells 
by perforin and release proteases into target cells. Those proteases activate 
caspases leading to apoptosis. Through secretion of cytokines such as interferons 
activated T cells can enhance MHC class I expression and inhibit viral replication (1). 
 
3.1.2 T cell receptor and co-stimulatory signaling 
The TCR is associated with CD3 proteins, which are essential to communicate the 
TCR/pMHC interaction to the cell interior. Immunoreceptor tyrosine-based activation 
motifs (ITAMs, YxxL) within the intracellular domains of all CD3 proteins (CD3γ, 
CD3δ, CD3ε and CD3ζ) translate pMHC binding into a stimulatory signal (figure 1). 
Tyrosine residues within the ITAMs are phosphorylated by leukocyte C-terminal Src 
kinase (Lck) and Fyn kinase when the TCR recognizes the presented epitope. CD3ζ 
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binds to phosphorylated ITAMs and is activated by phosphorylation, which recruits 
“CD3ζ associated protein of 70 kDA” (ZAP-70). ZAP-70 transmits the activatory 
signal to “linker for activation of T cells” (LAT) and “SH2 domain-containing leukocyte 
protein of 76 kDa” (SLP-76). Both LAT and SLP-76 in return activate various 
signaling molecules such as phospholipase C-γ (PLC-γ). PLC-γ cleaves 
phosphatidylinositol-3,4-bisphosphate (PIP2) creating second messenger molecules 
inositol-1,4,5-trisphosphate (IP3) and diacylglycerol. IP3 induces calcium release by 
binding to the endoplasmic reticulum. The induced increase in calcium opens calcium 
release-activated calcium channels in the plasma membrane further enhancing the 
intracellular concentration of calcium through influx of calcium from the extracellular 
space. Calcium-calmodulin complexes form and activate the phosphatase 
calcineurin. Calcineurin dephosphorylates “nuclear factor of activated T cells” 
(NFAT). This transcription factor in concert with transcription factors AP1 and 
“nuclear factor of kappa light polypeptide gene enhancer in B cells” (NFκB) promotes 
the transcription of cytokines including interleukin-2 (IL-2) and interferon-γ (IFN-γ).  
NFκB is activated by translocation to the nucleus through protein kinase C-θ 
(PKC-θ), which is activated by the second messenger DAG. NFκB induces 
transcription of cytokines and anti-apoptotic proteins such as Bcl-2 and Bcl-xL.  
AP-1 is generated by activation of “mitogen activated protein” (MAP) kinase pathway 
specifically “extracellular signal related kinase” (ERK), which requires DAG. ERK 
signaling, moreover, facilitates degranulation, a process that is required for cytotoxic 
activity (1, 2). 
The second, co-stimulatory, signal required for optimal development of effector 
function, is mediated through the receptor CD28 on T cells. Co-stimulation converges 
with and enhances TCR signaling leading to superior effector function in addition to 
cell proliferation, protein translation and T cell survival (figure 1). CD28 is expressed 
on the surface of T cells as a homodimer. In humans, around 50% of naïve CD8+ 
T cells express CD28. During the differentiation from naïve into effector into 
terminally differentiated cells human CD8+ T cells lose CD28 expression (3). 
The co-stimulatory ligands CD80 and CD86 have restricted expression patterns 
primarily limited to APCs. CD28 contains an intracytoplasmic signaling domain with 
the motifs YMNM, PRRP and PYAP. CD28 interaction with CD80 or CD86 leads to 
phosphorylation of the YMNM motif and recruitment of the p85 subunit of 
“phosphatidylinositol-4-phosphate 3-kinase” (PI3K) to the plasma membrane, which 
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produces phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 recruits pleckstrin 
homology domain containing proteins such as “phosphoinositide-dependent 
kinase 1” (PDK1), “protein kinase B” (AKT), and the guanine nucleotide exchange 
factor Vav. AKT activates the “mechanistic target of Rapamycin” (mTOR) signaling 
pathway leading to phosphorylation of “40S ribosomal protein S6” (RPS6). RPS6 is 
implicated in protein synthesis and T cell proliferation (4). Additionally, AKT inhibits 
the transcription factor “forkhead box protein” (FOXO), which transcribes genes 
leading to cell cycle arrest, and inhibits pro-apoptotic proteins such as “Bcl-2 
associated agonist of cell death” (Bad) (5).  
PDK1 enhances NFκB activity and Vav augments the MAPK pathway. Both PDK1 
and Vav are additionally activated through the PYAP motif.  
The ”IL-2-inducible T cell kinase” (ITK) binds the CD28 motif PRPP and activates 
PLC-γ. The CD28 pathway converges with those TCR signals that lead to T cell 
proliferation and T cell effector functions such as cytokine secretion and 
degranulation (1, 5). 
4-1BB (CD137) is another co-stimulatory receptor capable of augmenting TCR 
signaling. 4-1BB is a member of the tumor necrosis factor receptor (TNFR) 
superfamily and is absent in naïve T cells but induced following T cell stimulation (6). 
The expression peaks within 48-72 hours after activation. Signals transmitted through 
4-1BB have been shown to have the greatest impact on sustaining immune 
responses - in contrast to CD28, which is required for initial activation of naïve T cells 
(6, 7). 
The intracellular domain of 4-1BB contains the QEE motif, which, upon ligation with 
4-1BBL, expressed on APCs, recruits TNFR associated factor 2 (TRAF2) (8, 9). 
TRAF2 activates MAPK pathways including ERK and activates nuclear translocation 
of NFκB (10). It thereby enhances cytokine production and T cell survival (figure 1). 
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3.2 T cell therapy for cancer 
T cells with anti-tumor specificities are found within the tumor and can be isolated, 
cultivated ex vivo and re-infused into the patient (11). This so called adoptive therapy 
(ATT) with tumor-infiltrating lymphocytes (TILs) can yield durable remission in 
patients with metastatic cancer who are refractory to other cancer-related therapies 
(12). The clinical response has been shown to be closely linked to an anti-tumor 
activity of the TILs that are used for ATT (13). Shorter ex vivo cultivation of TILs and 
pre-conditioning patients before ATT using non-myeloablative lymphodepleting 
chemotherapy and radiation further enhanced response rates (13, 14). 
Lymphodepletion eliminates T and B cells and thereby reduces the competition of 
 
 
Figure 1: Simplified illustration of TCR, CD28 and 4-1BB signaling cascades in T cells. 
Co-stimulatory CD28 and 4-1BB signaling cascades converge with TCR signaling to induce and 
foster T cell effector functions, proliferation and survival. Arrowheads indicate activation and 
slashes inhibitory effects. For detailed description see text. Signaling motifs are indicated with Y: 
tyrosine; M: methionine; N: asparagine; P: proline; R: arginine; Y: tyrosine; A: alanine; L: leucine; 
Q: glutamine; E: glutamic acid; x: any amino acid. 
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transferred TILs with endogenous lymphocytes for cytokines. In addition, it reduces 
the amount of regulatory T cells, which might counteract the effect of TILs (15). In 
clinical trials with metastatic melanoma patients, response rates of up to 56% are 
reported (16). The drawbacks of TIL therapy are the requirement of specialized 
centers with the capability of T cell culture, the fact that tumor-reactive TILs cannot 
always be isolated and that some TILs cannot be sufficiently expanded.    
The limitations of TIL availability can be overcome by the generation of tumor-
reactive T cells using genetic engineering techniques. Thereby, peripheral T cells or 
other T cells are genetically engineered to express a tumor-specific TCR or chimeric 
antigen receptor. In one of the first clinical trials Morgan et al. reported in 2006 (17) 
that transfer of autologous T cells engineered with a TCR specific for “melanoma 
antigen recognized by T cells 1” (MART-1) achieved a response rate of 13%. An 
explanation for the rather low response rate compared to TIL therapy might be that 
transferred TIL populations are composed of T cells with specificities against various 
tumor antigens (18), while TCR-engineered T cells carry only one specificity, which 
narrows their anti-tumor capacity to those cells expressing the target antigen. In 
addition, the strength of the engineered TCR might not have been sufficient. The 
strength of the interaction between a single pMHC and one TCR is described by the 
so-called TCR affinity (19). However, as one T cell carries around 40.000 TCR 
molecules (20), T cell avidity seems to be the more suitable characteristic. Avidity is 
defined as the strength of the binding of multiple pMHCs and TCR molecules (19). In 
a clinical trial of metastatic melanoma patients receiving T cells engineered to 
express a MART-1 specific TCR it was observed that T cells of high avidity yielded 
higher response rates (30%) compared to T cells of lower avidity (13%) (21). The 
explanation for the better clinical responses might be stronger activation of the TCR 
signaling cascade (22) and more efficient recruitment of lytic granules to the target 
cell contact site (23) by high-avidity T cells. However, TCRs isolated from patients’ 
T cells recognizing tumor-overexpressed self-antigens are often of low-affinity (24) as 
they derive from a repertoire that has gone through negative selection in the thymus 
where mostly low-avidity T cells egress from the thymus to the periphery. The affinity 
of a TCR can be increased by site-directed mutagenesis within the CDR of the TCR 
(25). This manipulation might pose the risk that a TCR can gain reactivity against 
new pMHC structures, including unwanted recognition of self-proteins. This is 
exemplified by recent observations where autologous PBLs transduced with an 
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affinity-enhanced MAGE-A3 reactive TCR caused neurological toxicities through 
cross-reactivity with MAGE-A12, expressed in the brain (26). In another clinical trial 
using T cells with a MAGE-A3 TCR, patients died from cardiac toxicities due to 
unpredicted cross-reactivity to cardiomyocyte-expressed protein titin (27).  
 
Adoptive therapy using T cells engineered with chimeric antigen receptors (CARs) 
allows MHC-independent recognition of target structures. The extracellular antigen-
binding domain is derived from the variable region of an antigen-specific antibody. 
The extracellular domain is linked via a spacer to the transmembrane and 
cytoplasmic domains of the CAR. CARs recognizing membrane-proximal epitopes 
require flexible hinge regions to allow antigen-binding (28). The most commonly used 
hinge regions are derived from the constant region (Fc-region) of antibodies such as 
IgG1 (29). However, the use of IgG Fc-derived hinge regions can cause severe 
adverse effects due to activation of NK cells, which secrete high amounts of 
inflammatory cytokines. This interaction can also induce an off-target activation of 
CAR-expressing T cells leading to lytic activity against NK cells and other cell types 
expressing IgG Fc receptors (30). Modifying IgG1-derived hinge regions to prevent 
activation of IgG Fc receptor positive cells (30) or the use of hinge regions derived 
from the extracellular domains of CD8α (29) can prevent off-target activation. To 
translate antigen-binding into a T cell activating signal, CARs contain CD3ζ-derived 
signaling domains. CARs could be expressed on human T cells and induced anti-
tumor responses. However, CAR-engineered T cells showed only transient and 
rather poor activation (29). To increase the persistence and strengths of CAR-
mediated T cell responses, so-called 2nd and 3rd generation CARs were designed. 
They contain additional signaling domains derived from co-stimulatory molecules 
such as CD28 and 4-1BB. T cells expressing CARs with 2 (2nd generation) or 3 (3rd 
generation) intracellular signaling domains secreted higher amounts of IL-2 as well 
as IFN-γ and proliferated to a greater extent (29). A mesothelin-directed CAR with 
CD3ζ, CD28 and 4-1BB signaling domains mediated control of large mesothelioma 
xenograft tumors (31). In a xenograft model of pre-B-cell acute lymphoblastic 
leukemia, T cells expressing a CD19-directed CAR with CD3ζ and 4-1BB domains 
achieved higher anti-leukemic effects and transferred T cells survived longer 
compared to T cells expressing a CD19-directed CAR with CD3ζ and CD28 domains 
(32). High response rates of CAR-therapy were achieved in leukemia and lymphoma 
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patients. Kochenderfer et al. reported in 2012 (33) response rates of 75% among 
patients with B-cell malignancies treated with a CD19-directed CAR with CD3ζ plus 
CD28 domains. In a clinical trial reported by Maude et al. 2014 (34), therapy of 
relapsed or refractory acute lymphoblastic leukemia patients with CD19-directed 
CARs containing CD3ζ and 4-1BB signaling domains achieved a response rate of 
90%. Transferred cells remained detectable in the patients up to 2 years. 
The simultaneous triggering of CD3ζ and co-stimulatory signals can be a benefit, 
however, if healthy tissues express target structures, co-stimulation might increase 
unwanted side effects. Morgan et al. (35) and Lamers et al. (36) reported severe side 
effects of CAR-engineered T cells due to activation by antigen positive healthy tissue. 
As 2nd and 3rd generation CARs are activated more strongly and at a lower threshold, 
antigen expression at low levels by healthy tissue is more likely to induce T cell 
activation compared to CARs containing a CD3ζ signaling domain only. In addition, in 
contrast to antibodies, TCRs recognizing self-antigens have undergone negative 
selection in the thymus. Those T cells bearing TCRs with anti-self specificity are only 
of low avidity. Therefore, a safer approach might be to use T cells expressing low-
avidity TCRs and deliver co-stimulatory signals to enhance their activity to elicit 
stronger anti-tumor response.  
 
3.3 Tumor strategies to evade T cell cytotoxicity 
Although significant response rates are achieved by ATT still only a fraction of 
patients responds and some tumor entities are largely refractory to this therapy (37). 
The strongest factor limiting the efficacy of immunotherapy is the tumor environment, 
which creates a milieu that counteracts immune response on multiple levels. By 
down-regulating MHC class I expression, tumor cells make themselves invisible for 
T cells. Myeloid-derived suppressor cells (MDSCs) secrete peroxynitrite, which alters 
TCR-peptide binding and thereby prevents T cell activation (38).  
In addition to preventing recognition, the tumor environment can induce different 
types of immune cell unresponsiveness, including T cell tolerance such as 
exhaustion and anergy. Exhaustion develops when T cells are chronically stimulated. 
Exhausted T cells are unable to respond to stimulation and show only poor effector 
functions (39). T cell exhaustion is mediated through inhibitory receptors such as 
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“Programmed cell death protein 1” (PD-1). PD-1 is up-regulated on activated T cells 
and binds PD-L1, expressed on tumor cells, MDSCs and TILs. When PD-1 is ligated 
protein tyrosine phosphatase-1 and -2 (SHP-1, SHP-2) are recruited, which 
counteract TCR signaling. Through inhibition of PI3K and the MAPK pathway, PD-1 
can directly attenuate T cell effector function and proliferation (40). Exhausted T cells 
were detected in melanoma (41), hepatocellular carcinoma (42), breast cancer, renal 
cell carcinoma and lung cancer patients (40). Anti-PD-1 antibody treatment achieved 
response rates of 18% in non-small-cell lung cancer, 28% in melanoma and 27% in 
renal cell carcinoma. 87% of responses in followed-up patients lasted >1 year (43). 
The anti-PD-1 antibody Nivolumab (Opdivo) was approved by the FDA in December 
2014 for patients with unresectable or metastatic melanoma and in March 2015 for 
non-small cell lung cancer.  
In addition to becoming exhausted, T cells can also acquire an anergic phenotype in 
the tumor environment. T cells become anergic when they receive TCR stimulation 
without proper co-stimulation or/and high co-inhibition mediated through “Cytotoxic T-
lymphocyte-associated antigen 4” (CTLA-4; (44). The anergic phenotype has been 
primarily described for CD4+ T cells. It is characterized by cell cycle arrest and 
reduced IL-2 response (45). The transcription factor NFAT and diacylglycerol kinase-
α (DGK-α) are key mediators of anergy (46). Moreover, Zheng et al. (2012) (47) 
identified the transcription factor “Early growth response gene 2” (Egr2) as another 
regulator of anergy. They showed that deletion of Egr2 restored IL-2 production and 
proliferation. 
Recently, it was described in human renal cell carcinoma that CD8+ T cells in the 
tumor microenvironment express high levels of DGK-α. Moreover, TILs showed 
reduced phosphorylation of ERK as well as JNK and were unresponsive to TCR 
stimulation with poor degranulation and IFN-γ secretion (48). IFN-γ and “tumor 
necrosis factor alpha” (TNF-α), secreted by cytotoxic T cells, are important cytokines 
for tumor control, not only because they can directly destroy tumor cells but 
additionally by elimination of tumor stroma (49, 50). Strong forces in the tumor 
microenvironment, including lactic acidosis, prevent T cells from secreting these 
cytokines (51). In addition to preventing Th1 cytokine secretion, Th2 cytokines and 
IL-10 are often induced, which can inhibit cytotoxic T cells and support MDSCs, 
which in turn inhibit maturation of DCs and foster angiogenesis (52). 
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The tumor environment cannot only induce a reduction of anti-tumoral cytokines but 
can also induce cytokines that are associated with tumor progression. MDSCs as 
well as “transforming growth factor beta” (TGF-β) can shift the balance towards 
tumor-promoting cytokines such as IL-4, IL-5 and IL-10.  
Therefore, a major aim of immune therapy is to utilize a T cell product for ATT with 
strong anti-tumor reactivity, long-term persistence in the patient and the capacity to 
maintain an anti-tumor response despite tumor-mediated inhibition. 
 
 
OBJECTIVE OF THIS THESIS                                                                                           15 
4 OBJECTIVE OF THIS THESIS 
The loss of function and poor persistence of adoptive transferred T cells are major 
limitations of successful T cell therapy. In addition, TCRs isolated from cancer 
patients are mostly of low affinity. Higher response rates can be achieved with high-
avidity T cells (21), but affinity-enhanced T cells pose increased risks of unwanted 
side effects (26). Therefore, there is a need for strategies to boost the response of 
low-avidity T cells without interfering with the TCR. Moreover, TILs showed deficits in 
signaling molecules (48) that might be reverted by co-stimulation. As co-stimulation is 
also reported to enhance T cell persistence and degranulation capacity (53), I 
hypothesized that it might be efficacious to engineer T cells or TILs for adoptive 
transfer with the capacity to receive co-stimulation in the tumor environment.  
However, a large proportion of effector T cells are CD28 negative (54) and most 
carcinomas express only low levels of CD80 or CD86 (55, 56). Thus, co-stimulation 
cannot be provided via CD28-CD80/CD86 interaction. However, various tumors 
showed high expression of PD-L1 (57). Engineering T cells or TILs with a chimeric 
signaling receptor consisting of the extracellular domain of PD-1, the receptor for PD-
L1, joined with the intracellular domain of a co-stimulatory molecule, CD28 or 4-1BB, 
might allow co-stimulation of transferred cells in the tumor environment. The 
extracellular PD-1 domain would bind PD-L1 presented on tumor cells and initiate co-
stimulatory signaling in chimeric receptor expressing cells. 
It was the main objective of this thesis to develop a chimeric receptor that can 
improve T cell function and proliferation. To this end, various chimeric co-stimulatory 
receptors were designed using different transmembrane and signaling domains. 
CD28- and 4-1BB-derived signaling domains were compared given that results from 
in vivo studies and clinical trials utilizing CD19-CAR T cells suggested superior 
activity of 4-1BB over CD28 (32, 34). To address the issue of improving low-avidity 
T cells, the effect of chimeric receptors on the functional performance of low-avidity 
T cells was assessed and compared to high-avidity T cells. The effects of chimeric 
signaling receptors on T cell performance was further assessed in several mouse 
models and in TILs of human renal cell carcinoma. 
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5 MATERIAL 
5.1 Consumables and equipment 
 
CONSUMABLES/EQUIPMENT COMPANY 
Balance 
PC 400 DeltaRange 
 
Mettler, Gießen, GERMANY 
BioPlex reader BIO-RAD, Munich, GERMANY 
Cell strainer 
40 µm, 100 µm 
 
Becton Dickinson, Heidelberg, GERMANY 
Centrifuges 
Megafuge 2.0 R 
Rotanda 460R 
Centrifuge 5417 R 
Centrifuge 4K15 
 
Heraeus Instruments, Hanau, GERMANY 
Hettich, Ebersberg, GERMANY 
Eppendorf, Hamburg, GERMANY 
Sigma Laboratory Centrifuges 
Electrophoresis chamber and power supply BIO-RAD, Munich, GERMANY 
Electroporator Gene Pulser Xcell BIO-RAD, Munich, GERMANY 
Electroporation cuvettes, 4 mm  
Filter 
0.45 µm 
Millipore, Schwalbach, GERMANY 
Flow cytometer and cell sorter 
LSR II 
BD FACSAriaTM IIIu 
 
Becton Dickinson, Heidelberg, GERMANY 
Freezing vials 
1.5 ml 
Nunc, Wiesbaden, GERMANY 
Incubator Hereaus Instruments, Hanau, GERMANY 
Integral water purification system Milli-Q® Millipore, Schwalbach, GERMANY 
Light microscope 
Leica DMIL 
 
Leica Microsystems, Heidelberg, GERMANY 
Luma plates TM96 Canberra-Packard, Dreieich, GERMANY 
Magnetic cell separation columns 
LS columns, pre-separation columns 
MiltenyiBiotec, Bergisch Gladbach, 
GERMANY 
Multistepper Eppendorf, Hamburg, GERMANY 
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CONSUMABLES/EQUIPMENT COMPANY 
Multi-well plates, polystyrene 
24-well plates 
  Tissue culture treated 
  Non-tissue culture treated 
96-well plates 
  Tissue culture treated 
Becton Dickinson Falcon, Heidelberg, 
GERMANY  
 
 
 
 
Nanodrop ND-1000-Spektrophotometer Peqlap Biotechnologie GmbH, Erlangen 
Needles, 26G NeoLab, Heidelberg, GERMANY 
Neubauer counting chamber            
Depth 0.1 mm 
Gesellschaft für Laborbedarf Würzburg, 
Würzburg, GERMANY 
Nitrogen tank Messer Griesheim, Krefeld, GERMANY 
Parafilm® Pechiney Plastic Packaging, Menasha, USA 
Pasteur pipettes, glass Josef Peske GmbH & Co KG, Munich, 
GERMANY 
Petri dishes polystyrene 
100 mm  
Becton Dickinson Falcon, 
Heidelberg, GERMANY 
Picture frame glasses for Neubauer counting 
chambers 
20 x 26 mm, depth 0.4 mm 
Hirschmann Laborgeräte, Eberstadt, 
GERMANY 
 
Pipettes 
Single- and multi-channel 
Eppendorf, Hamburg, GERMANY 
Thermo Scientific, Waltham, USA 
Pipettor Pipetus® Hirschmann Laborgeräte, Eberstadt, 
GERMANY 
Pipette tips 
With/without filter 
1-10 µl, 10-200 µl, 200-1000 µl 
Eppendorf, Hamburg, GERMANY 
 
 
Pipette tips for pipettor 
Disposable 
 10 ml, 25 ml 
Glass 
  2 ml, 5 ml, 10 ml, 20 ml 
 
Greiner bio-one, Frickenhausen,   
GERMANY 
Hirschmann Laborgeräte, Eberstadt, 
GERMANY 
Polymerisation chain reaction machine 
Flex Cycler 
Analytik Jena, Jena, GERMANY 
Rotator VWR, Darmstadt, GERMANY 
Scalpels Braun, Tuttlingen, GERMANY 
Scintillation counter TopCount NXT Canberra-Packard, Dreieich, GERMANY 
Scissors and tweezers for preparation NeoLab, Heidelberg, GERMANY 
MATERIAL                                                                                                                                 18 
 
CONSUMABLES/EQUIPMENT COMPANY 
Shaker  
Polymax 1040 
Innova 4200 
 
Heidolph  
New Brunswick Scientific, Edison, USA 
Spectrophotometer Tecan Group AG, Männedorf, 
SWITZERLAND 
Sterile laminar flow hood BDK Luft- und Reinraumtechnik GmbH, 
Sonnenbühl-Genkingen, GERMANY 
Syringes 
1 ml, 10 ml, 50 ml 
Eppendorf, Hamburg, GERMANY 
Syringes for multistepper 
5 ml 
 
Eppendorf, Hamburg, GERMANY 
Thermomixer 5436 Eppendorf, Hamburg, GERMANY 
Tissue culture flasks 
75 cm2,175 cm2 
Greiner bio-one, Frickenhausen, GERMANY 
 
Tubes 
Polypropylene 
1.5 ml, 2 ml 
15 ml, 50 ml 
 
 
Eppendorf, Hamburg, GERMANY 
Becton Dickinson Falcon, Heidelberg, 
GERMANY 
Tubes for flow cytometry, poly-propylene 
1 ml 
5 ml 
 
Greiner bio-one, Frickenhausen,  
GERMANYBecton Dickinson Falcon, 
Heidelberg, GERMANY 
Tubes for sterile filtration (0.2 µm) 
50 ml 
Becton Dickinson Falcon, Heidelberg, 
GERMANY 
UV light imaging system InGenius Syngene Bio Imaging, Cambridge, UK 
Vortexer MS1 Minishaker IKA Werke GmbH &Co KG, Staufen, 
GERMANY 
Water bath Köttermann Labortechnik, Uetze, 
GERMANY 
Winged infusion set Dispomed Witt oHG, Gelnhausen, 
GERMANY 
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5.2 Reagents, kits and bacteria 
5.2.1 Reagents 
REAGENT COMPANY 
7-Aminoactinomycin D (7-AAD) Sigma-Aldrich, Taufkirchen, GERMANY 
51Cr Sodium chromate Hartmann Analytic, Braunschweig, GERMANY 
Ampicillin Sigma-Aldrich, Taufkirchen, GERMANY 
Acetic acid Merck, Darmstadt, GERMANY 
Accutase® PAA Laboratories, Cölbe, GERMANY 
Agarose, electrophoresis grade GIBCO, Thermo Fisher Scientific, Schwerte, 
GERMANY 
Ammonium chloride  Merck, Darmstadt, GERMANY 
Beads for compensating fluorescence 
activated cell sorting (FACS) data 
Becton Dickinson Pharmingen, Heidelberg, 
GERMANY 
Biocoll® separating solution (Ficoll®) Biochrom AG, Berlin, GERMANY 
Bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen, GERMANY 
Carboxyfluorescein diacetate succinimidyl 
ester (CFDA-SE) 
Invitrogen, Karlsruhe, GERMANY 
CD3/CD28 mouse T-activator beads Invitrogen, Karlsruhe, GERMANY 
Collagenase IV Sigma-Aldrich, Taufkirchen, GERMANY 
Diethylpyrocarbonate (DEPC) Sigma-Aldrich, Taufkirchen, GERMANY 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Taufkirchen, GERMANY 
Disodium hydrogen phosphate Sigma-Aldrich, Taufkirchen, GERMANY 
DNA ladder, 1kb Thermo Fisher Scientific, Schwerte, 
GERMANY 
DNA loading dye, 6x Thermo Fisher Scientific, Schwerte, 
GERMANY 
DNAse I, type IV Sigma-Aldrich, Taufkirchen, GERMANY 
Ethanol, 99% Merck, Darmstadt, GERMANY 
Ethidium bromide 10 mg/ml Roth, Karlsruhe, GERMANY 
Ethylenediaminetetraacetic acid (EDTA),  
0.5 M 
Sigma-Aldrich, Taufkirchen, GERMANY 
EDTA disodium Roth, Karlsruhe, GERMANY 
Fetal bovine serum (FBS) GIBCO, Thermo Fisher Scientific, Schwerte, 
GERMANY 
Human serum (23) In-house production 
L-glutamine GIBCO, Thermo Fisher Scientific, Schwerte, 
GERMANY 
Luria Broth and agar powder Roth, Karlsruhe, GERMANY 
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REAGENT COMPANY 
Heparin-sodium B. Braun, Melsungen, GERMANY 
4-(2-hydroxyethyl)-1-piperazine-
ethanesulfonic acid (HEPES) 
Biochrom AG, Berlin, GERMANY 
Ionomycin 0.5 mg/ml Sigma-Aldrich, Taufkirchen, GERMANY 
Isopropanol Sigma-Aldrich, Taufkirchen, GERMANY 
β-Mercaptoethanol GIBCO, Thermo Fisher Scientific, Schwerte, 
GERMANY 
Milk powder Roth, Karlsruhe, GERMANY 
Mucocit disinfectant cleaner Mucocit disinfectant cleaner 
Non-essential amino acids GIBCO, Thermo Fisher Scientific, Schwerte, 
GERMANY 
Paraformaldehyde (PFA) Merck, Darmstadt, GERMANY 
PCR MasterMix, 2x Promega, Mannheim, GERMANY 
Penicillin/streptomycin GIBCO, Thermo Fisher Scientific, Schwerte, 
GERMANY 
Percoll, density 1.13 g/ml GE Healthcare, Freiburg GERMANY 
Phorbol 12-myristate 13-acetate (58) Sigma-Aldrich, Taufkirchen, GERMANY 
Phosphoric acid, 1M Sigma-Aldrich, Taufkirchen, GERMANY 
Potassium hydrogen carbonate Roth, Karlsruhe, GERMANY 
Propidium iodide Sigma-Aldrich, Taufkirchen, GERMANY 
Recombinant human PD-L1 Fc chimera R&D Systems, Wiesbaden, GERMANY 
Recombinant human IL-2 
Cross-reactive to mouse 
Cancernova GmbH, Reute, GERMANY 
Chiron Novartis, USA 
Recombinant human IFN-γ Boehringer Ingelheim, Ingelheim, 
GERMANY 
Recombinant murine IL-15 MiltenyiBiotec, Bergisch Gladbach, 
GERMANY 
Recombinant fibronectin CH-296 
RetroNectin® 
Takara Bio Incorporation, Shiga, JAPAN 
RNA ladder Thermo Scientific, Schwerte, GERMANY 
RNA loading dye, 2x Thermo Scientific, Schwerte, GERMANY 
Saponin Merck, Darmstadt, GERMANY 
Sodium acetate, 3 M Sigma-Aldrich, Taufkirchen, GERMANY 
Sodium pyruvate GIBCO, Thermo Fisher Scientific, Schwerte, 
GERMANY 
Sodium chloride Sigma-Aldrich, Taufkirchen, GERMANY 
Thy1.1 MicroBeads MiltenyiBiotec, Bergisch Gladbach, 
GERMANY 
TAE, 10x GIBCO, Thermo Fisher Scientific, Schwerte, 
GERMANY 
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REAGENT COMPANY 
TransIT®-LT1 Reagent Mirus Bio LLC, Madison, USA 
Trypan blue Sigma-Aldrich, Taufkirchen, GERMANY 
Trypsin-EDTA GIBCO, Thermo Fisher Scientific, Schwerte, 
GERMANY 
Tween20 Sigma-Aldrich, Taufkirchen, GERMANY 
Water 
Milli-Q® purified  
Nuclease-free 
 
In-house production 
Promega, Mannheim, GERMANY 
 
 
5.2.2 Kits 
KIT COMPANY 
Cytokine Bio-Plex 
Human Th1, Th2 
Murine Th1, Th2 + IL17 
BIO-RAD, Munich, GERMANY 
ELISA Kit, human/mouse IFN-γ, 
human/mouse IL-2 
BD Biosciences, Heidelberg GERMANY 
Gel Extraction Kit Quiagen, Hilden, GERMANY  
JetStar 2.0 preparation kit Genomed GmbH, Löhne, GERMANY 
MinElute® Reaction Cleanup Kit Quiagen, Hilden, GERMANY 
mMESSAGEmMACHINE Kit Ambion®, Schwerte, GERMANY 
RNeasy Mini Kit Quiagen, Hilden, GERMANY  
 
5.2.3 Bacteria 
BACTERIA COMPANY APPLICATION 
TOP10 and MACH1 E.coli 
(+ SOC medium) 
Life Technologies, Schwerte, 
GERMANY 
Transformation with Geneart, 
pGEM and pMP71 vectors 
 
 
 
MATERIAL                                                                                                                                 22 
5.3 Media and buffers 
5.3.1 Basic media and buffers 
 
5.3.2 Prepared media and buffers 
MEDIUM/BUFFER FORMULA 
Cell freezing medium RPMI-1640 
+ 1% L-glutamine 
+ 1% non-essential amino acids        
+ 1% sodium pyruvate  
+ 20% DMSO 
Digestion buffer for human and murine 
tumors (except liver tumors) 
RPMI-1640 
+ 0.1% BSA 
+ 1% penicillin/streptomycin        
+ 10 mM HEPES  
+ 218 U/ml collagenase IV 
+ 435 KunitzU/ml DNAse I, type IV 
 
 
MEDIUM/BUFFER COMPANY 
AIM-V Invitrogen, Karlsruhe, GERMANY 
Dulbecco’s modified eagle medium (DMEM) GIBCO Invitrogen, Darmstadt, GERMANY 
Dulbecco’s phosphate buffered saline 
(PBS), 1x, 10x 
GIBCO Invitrogen, Darmstadt, GERMANY 
Freezing medium for TILs IBIDI, Munich, GERMANY 
Hank’s buffered salt solution  
(HBSS) w/o and w Ca Mg 
GIBCO Invitrogen, Darmstadt, GERMANY 
Opti-MEM GIBCO Invitrogen, Darmstadt, GERMANY 
Phosflow Cytofix Buffer® BD Biosciences, Heidelberg GERMANY 
Phosflow Perm Buffer III® BD Biosciences, Heidelberg GERMANY 
Roswell Park Memorial Institute 
(RPMI)-1640 medium 
GIBCO Invitrogen, Darmstadt, GERMANY 
RPMI  
basic 
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MEDIUM/BUFFER FORMULA 
Digestion buffer for murine liver tumors RPMI-1640 
+ 0.1% BSA 
+ 1% penicillin/streptomycin        
Digestion buffer for murine liver tumors RPMI-1640 
+ 0.1% BSA 
+ 1% penicillin/streptomycin        
+ 10 mM HEPES  
+ 800 U/ml collagenase IV 
Enzyme-linked-immunosorbent assay 
(ELISA) buffers 
Coating buffer, pH 9.5 
 
 
Washing buffer 
 
 
Milli-Q® purified water 
+ 8.4 g sodium hydrogen carbonate 
+ 3.56 g sodium carbonate 
PBS 
+ 0.05% Tween20 
Erythrocyte lysis buffer 
pH 7.2-7.4 
Milli-Q® purified water 
+ 0.15 M ammonium chloride 
+ 1 mM potassium hydrogen carbonate 
+ 0.1 mM EDTA disodium 
Human embryonic kidney cell 293 medium 
(HEK medium) 
DMEM 
+ 1% L-glutamine 
+ 1% non-essential amino acids        
+ 1% sodium pyruvate  
+ 12% FCS 
LB Medium 500 ml Milli-Q® water 
+ 12.5 LB powder 
+ 100 µg/ml Ampicillin 
Magnetic cell separation buffer (MACS 
buffer) 
PBS 
+ 0.5% FCS 
+ 2 mM EDTA 
Murine embryonic kidney cell 
293 medium (mHEK medium) 
DMEM 
+ 1% L-glutamine 
+ 1% non-essential amino acids        
+ 1% sodium pyruvate  
+ 12% FCS 
+ 0.05% β-mercaptoethanol 
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MEDIUM/BUFFER FORMULA 
Fluorescence activated cell sorting  
(FACS) buffer 
PBS 
+ 2 mM EDTA 
+ 2% HS 
+ 0.1% sodium azide 
FACS permeabilization buffer 
(0.1%; 0.35%) 
PBS 
+ 0,1 or 0.35 % saponin 
+ 2% HS 
FACS fixation buffer PBS 
+ 1% PFA 
Human tumor-infiltrating lymphocyte medium 
(TIL medium) 
AIM-V 
+ 1% L-glutamine 
+ 10% HS 
Medium for human T cells (TCM) RPMI basic 
+ 10% HS 
Medium for murine T cells  and the murine 
hepatocellular carcinoma cell line 434 
(MTM)  
RPMI basic 
+ 12% FCS 
+ 0.05% β-mercaptoethanol 
Percoll 
100 x 
80% 
40% 
 
90% Percoll in 10x PBS 
1x PBS + 80% 100x Percoll 
1x PBS + 40% 100x Percoll + 250 IU 
Heparin 
Transfection buffer  
pH 6,76 
100 ml Milli-Q® purified water 
+ 50 mg disodium hydrogen phosphate 
+ 74 mg potassium chloride 
+ 1.6 g sodium chloride 
+ 1 g HEPES 
Tumor cell medium  
(RCC medium) 
RPMI basic 
+ 12% FBS 
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5.4 Plasmids, primers and restriction enzymes 
5.4.1 Plasmids 
PLASMIDS CHARACTERISTICS/ 
SOURCE 
pGEM vectors: 
pGEM-EGFPA120 
 
 
 
PD-1:8:28tm-pGEM, PD-1:cys28tm-pGEM, PD-1:28tm-
pGEM, PD-1trunc-pGEM, PD-1:BBtm-pGEM, PD-1tm:BB-
pGEM 
 
Kindly provided by Slavoljub 
Milosevic, Medigene GmbH, 
Martinsried, GERMANY 
Coding for green fluorescent 
protein, the vector’s backbone 
contains a T7 polymerase 
binding site for the generation 
of in vitro transcribed (ivt) RNA 
and a poly-A-tail of 120 base 
pairs 
  
 
 
 
 
 
 
 
 
Sequences of the chimeric 
singaling receptors PD-
1:8tm:28, PD-1:cys28tm, PD-
1:28tm, PD-1trunc, PD-1:BBtm, 
PD-1tm:BB cloned into the 
pGEM-A120 vector backbone 
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PLASMIDS CHARACTERISTICS/ 
SOURCE 
 
pMP71 vectors: 
pMP71 backbone 
 
 
 
PD-1:28tm-pMP71 
 
 
 
 
 
 
T58 (b23m-p-a7m)-pMP71,  
D115 (b8m-p-a22m)-pMP71 
 
 
Kindly provided by Wolfgang 
Uckert, Max Delbrück Center 
Berlin, GERMANY 
Vector for retroviral 
transduction combining the 
MPSV-LTR promoter-enhancer 
sequences and improved 5’ 
untranslated sequences 
derived from MESV 
MPSV: murine 
myeloproliferative sarcoma 
virus; LTR: long terminal 
repeats; MESV: murine 
embryonic stem cell virus  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sequence of the chimeric 
signaling receptor PD-1:28tm 
cloned into the pMP71 
backbone, kindly provided by 
Matthias Leisegang, Max 
Delbrück Center Berlin, 
GERMANY 
 
Kindly provided by Matthias 
Leisegang, Max Delbrück 
Center Berlin, GERMANY 
Sequences of the HLA-A2 
restricted, tyrosinase-specific 
TCRs T58 an D115 cloned into 
the pMP71 backbone 
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5.4.2 Primers
PRIMERS SEQUENCE 5’->3’ COMPANY 
 
Primers for cloning 
chimeric receptors into 
the pGEM-vector 
 
PD-1:8tm:28 
 
 
PD-1:cys28tm, PD-1:28tm, 
PD-1trunc, PD-1:BBtm, 
PD-1tm:BB 
 
PD-1:8tm:28  
 
 
PD-1:cys28tm, PD-1:28tm, 
PD-1trunc 
 
PD-1:BBtm, PD-1tm:BB 
 
 
 
 
 
 
 
 
Forward 
ATAAAGCTTATGCAGATTCCTCAGGCCC 
 
Forward 
ATAGTCGACACCGGTGCCACC 
 
 
Reverse 
ATAGAATTCTCAGGATCTGTAGGCGGCG 
 
Reverse 
ATAGGTACCGAATTCGGATCCTC  
 
Reverse 
ATAGGTACCGAATTCGGATCCTTAGAGCTC 
Metabion, 
Planegg, 
GERMANY 
 
Primers for cloning the 
PD-1:28tm chimeric 
receptor into the pMP71-
vector 
 
 
 
 
 
Forward 
ATAGCGGCCGCGCCACCATGCAGATTCCTC 
 
Reverse 
ATAGAATTCTCAGCTTCTGTAGGCGGCG 
Metabion, 
Planegg, 
GERMANY 
 
Primer for sequencing 
Geneart plasmids 
 
 
ATACACTATAGGGCGAATTGGCG 
Metabion, 
Planegg, 
GERMANY 
 
Primer for sequencing 
pGEM plasmids 
 
 
AATACGACTCACTATAG 
Provided by 
MWG Eurofins, 
Ebersberg, 
GERMANY 
 
Primer for sequencing 
pMP71 plasmids 
 
 
TGAAAATTAGCTCGACAAAGTTAAGTAATAG
TCCCTC 
Metabion, 
Planegg, 
GERMANY 
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5.4.3 Restriction enzymes  
ENZYMES & BUFFERS RECOGNITION 
SITES 5’->3’ 
COMPANY 
 
Enzymes for cloning PD-1:8tm:28 into the 
pGEM-vector: 
HindIII-high fidelity (CutSmart Buffer) 
EcoRI-high fidelity (CutSmart Buffer) 
 
Enzymes for cloning PD-1:cys28tm, PD-
1:28tm, PD-1trunc, PD-1:BBtm, PD-1tm:BB 
into the pGEM-vector: 
HincII (CutSmart Buffer) 
EcoRI-high fidelity (CutSmart Buffer) 
 
 
 
AAGCTT 
GAATTC 
 
 
 
 
GTCGAC 
GAATTC 
 
New England Biolabs, 
Frankfurt am Main, 
GERMANY 
 
Enzymes for cloning PD-1:28tm and 
mPD-1:28tm  into the pMP71-vector: 
NotI-high fidelity (CutSmart Buffer) 
EcoRI-high fidelity (CutSmart Buffer) 
 
 
 
 
GCGGCCGC 
GAATTC 
 
New England Biolabs, 
Frankfurt am Main, 
GERMANY 
 
Ligation of inserts and vector backbones 
T4 Ligase (T4 Ligase Buffer) 
 
Not applicable 
 
New England Biolabs, 
Frankfurt am Main, 
GERMANY 
 
 
Linearization of pGEM plasmids:  
SpeI-high fidelity (CutSmart Buffer) 
 
 
 
ACTAGT 
 
New England Biolabs, 
Frankfurt am Main, 
GERMANY 
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5.5 Chimeric receptor sequences 
5.5.1 Human chimeric receptor DNA sequences 
PD-1:8tm:28 
5’ -> 3’ 
ATGCAGATTCCTCAGGCCCCCTGGCCCGTGGTCTGGGCTGTGCTGCAGCTGGG
ATGGCGGCCTGGCTGGTTCCTGGACAGCCCCGACAGACCCTGGAACCCCCCTA
CCTTCAGCCCTGCCCTGCTGGTGGTGACAGAGGGCGACAACGCCACCTTCACC
TGTAGCTTCAGCAACACCAGCGAGAGCTTCGTGCTGAACTGGTACAGAATGAGC
CCCAGCAACCAGACCGACAAGCTGGCCGCCTTCCCCGAGGACAGAAGCCAGC
CCGGCCAGGACTGCCGGTTCAGAGTGACCCAGCTGCCCAACGGCCGGGACTT
CCACATGAGCGTGGTGCGCGCCAGACGGAACGACAGCGGCACATACCTGTGC
GGCGCCATCAGCCTGGCCCCCAAGGCCCAGATCAAAGAGAGCCTGCGGGCCG
AGCTGAGAGTGACCGAGAGAAGGGCCGAGGTGCCCACAGCCCACCCCAGCCC
ATCTCCAAGACCTGCCGGCCAGTTCCAGACCCTGGTGTTCGTGCCCGTGTTCCT
GCCCGCTAAGCCCACCACAACCCCTGCCCCTAGGCCTCCTACCCCAGCCCCTA
CAATCGCCAGCCAGCCCCTGTCTCTGCGGCCTGAGGCTTGTAGACCTGCCGCT
GGCGGAGCCGTGCACACCAGAGGGCTGGACTTCGCCTGCGATATCTACATCTG
GGCCCCTCTGGCCGGCACCTGTGGCGTGCTGCTGCTGTCCCTGGTGATCACCC
TGTACTGCAACCACCGGAACAGAAGCAAGCGGAGCCGGCTGCTGCATAGCGA
CTACATGAACATGACCCCCAGACGGCCTGGCCCCACCAGAAAGCACTACCAG
CCCTACGCCCCTCCCCGGGACTTCGCCGCCTACAGATCCTGA 
ATG start codon 
TGA stop codon 
PD-1 domains 
CD8α domains 
CD28 domains 
 
pGEM vector: 
AAGCTTATG…TGAGAATTC 
AAGCTT HindIII restriction site 
GAATTC EcoRI restriction site 
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PD-1:cys28tm 
5’ -> 3’ 
ATGCAGATTCCTCAGGCCCCTTGGCCTGTCGTGTGGGCTGTGCTCCAGCTGGG
ATGGCGGCCTGGCTGGTTTCTGGACAGCCCCGACAGACCCTGGAACCCCCCTA
CATTTTCCCCTGCCCTGCTGGTCGTGACCGAGGGCGACAATGCCACCTTCACCT
GTAGCTTCAGCAACACCAGCGAGAGCTTCGTGCTGAACTGGTACAGAATGAGC
CCCAGCAACCAGACCGACAAGCTGGCCGCCTTCCCCGAGGATAGATCTCAGCC
CGGCCAGGACTGCCGGTTCAGAGTGACCCAGCTGCCCAACGGCCGGGACTTC
CACATGTCTGTCGTGCGGGCCAGACGGAACGACAGCGGCACATATCTGTGCGG
CGCCATCAGCCTGGCCCCCAAGGCCCAGATCAAAGAGAGCCTGAGAGCCGAG
CTGAGAGTGACCGAGAGAAGGGCCGAAGTGCCTACCGCCCACTGTCCCAGCC
CTCTGTTTCCTGGCCCTAGCAAGCCCTTCTGGGTGCTGGTGGTCGTGGGCGGA
GTGCTGGCCTGTTACAGCCTGCTCGTGACCGTGGCCTTCATCATCTTTTGGGT
GCGCAGCAAGCGGAGCCGGCTGCTGCACAGCGACTACATGAACATGACCCC
CAGACGGCCAGGCCCCACCAGAAAGCACTACCAGCCTTACGCCCCTCCCAGA
GACTTCGCCGCCTACAGAAGCTGA 
ATG start codon 
TGA stop codon 
PD-1 domains 
CD28 domains 
 
pGEM vector: 
GTCGAC…ATG…TGAGAATTC 
GTCGAC HincII restriction site 
GAATTC EcoRI restriction site 
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PD-1:28tm 
5’ -> 3’ 
ATGCAGATTCCTCAGGCCCCTTGGCCTGTCGTGTGGGCTGTGCTCCAGCTGGG
ATGGCGGCCTGGCTGGTTTCTGGACAGCCCCGACAGACCCTGGAACCCCCCTA
CATTTTCCCCTGCCCTGCTGGTCGTGACCGAGGGCGACAATGCCACCTTCACCT
GTAGCTTCAGCAACACCAGCGAGAGCTTCGTGCTGAACTGGTACAGAATGAGC
CCCAGCAACCAGACCGACAAGCTGGCCGCCTTCCCCGAGGATAGATCTCAGCC
CGGCCAGGACTGCCGGTTCAGAGTGACCCAGCTGCCCAACGGCCGGGACTTC
CACATGTCTGTCGTGCGGGCCAGACGGAACGACAGCGGCACATATCTGTGCGG
CGCCATCAGCCTGGCCCCCAAGGCCCAGATCAAAGAGAGCCTGAGAGCCGAG
CTGAGAGTGACCGAGAGAAGGGCCGAAGTGCCTACCGCCCACCCTAGCCCATC
TCCAAGACCTGCCGGCCAGTTCTGGGTGCTGGTGGTCGTGGGCGGAGTGCTG
GCCTGTTACAGCCTGCTCGTGACCGTGGCCTTCATCATCTTTTGGGTGCGCAG
CAAGCGGAGCCGGCTGCTGCACAGCGACTACATGAACATGACCCCCAGACG
GCCAGGCCCCACCAGAAAGCACTACCAGCCTTACGCCCCTCCCAGAGACTTC
GCCGCCTACAGAAGCTGA 
ATG start codon 
TGA stop codon 
PD-1 domains 
CD28 domains 
 
pGEM vector: 
GTCGAC…ATG…TGAGAATTC 
GTCGAC HincII restriction site 
GAATTC EcoRI restriction site 
 
pMP71 vector: 
GCGGCCGC...ATG…TGAGAATTC 
GCGGCCGC NotI restriction site 
GAATTC EcoRI restriction site 
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PD-1trunc 
5’ -> 3’ 
ATGCAGATTCCTCAGGCCCCTTGGCCTGTCGTGTGGGCTGTGCTCCAGCTGGG
ATGGCGGCCTGGCTGGTTTCTGGACAGCCCCGACAGACCCTGGAACCCCCCTA
CATTTTCCCCTGCCCTGCTGGTCGTGACCGAGGGCGACAATGCCACCTTCACCT
GTAGCTTCAGCAACACCAGCGAGAGCTTCGTGCTGAACTGGTACAGAATGAGC
CCCAGCAACCAGACCGACAAGCTGGCCGCCTTCCCCGAGGATAGATCTCAGCC
CGGCCAGGACTGCCGGTTCAGAGTGACCCAGCTGCCCAACGGCCGGGACTTC
CACATGTCTGTCGTGCGGGCCAGACGGAACGACAGCGGCACATATCTGTGCGG
CGCCATCAGCCTGGCCCCCAAGGCCCAGATCAAAGAGAGCCTGAGAGCCGAG
CTGAGAGTGACCGAGAGAAGGGCCGAAGTGCCTACCGCCCACCCTAGCCCATC
TCCAAGACCTGCCGGCCAGTTCCAGACACTGGTCGTGGGAGTCGTGGGCGGA
CTGCTGGGATCTCTGGTGCTGCTCGTGTGGGTGCTGGCCGTGATCTGTAGCAG
AGCCGCCAGAGGCACCATCGGCTGA 
ATG start codon 
TGA stop codon 
PD-1 domains 
 
pGEM vector: 
GTCGAC…ATG…TGAGAATTC 
GTCGAC HincII restriction site 
GAATTC EcoRI restriction site 
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PD-1:BBtm 
5’ -> 3’ 
ATGCAGATTCCTCAGGCCCCTTGGCCTGTCGTGTGGGCTGTGCTCCAGCTGGG
ATGGCGGCCTGGCTGGTTTCTGGACAGCCCCGACAGACCCTGGAACCCCCCTA
CATTTTCCCCTGCCCTGCTGGTCGTGACCGAGGGCGACAATGCCACCTTCACCT
GTAGCTTCAGCAACACCAGCGAGAGCTTCGTGCTGAACTGGTACAGAATGAGC
CCCAGCAACCAGACCGACAAGCTGGCCGCCTTCCCCGAGGATAGATCTCAGCC
CGGCCAGGACTGCCGGTTCAGAGTGACCCAGCTGCCCAACGGCCGGGACTTC
CACATGTCTGTCGTGCGGGCCAGACGGAACGACAGCGGCACATATCTGTGCGG
CGCCATCAGCCTGGCCCCCAAGGCCCAGATCAAAGAGAGCCTGAGAGCCGAG
CTGAGAGTGACCGAGAGAAGGGCCGAAGTGCCTACCGCCCACCCTAGCCCATC
TCCAAGACCTGCCGGCCAGATTATCTCATTCTTCCTGGCCCTGACCTCTACCGC
CCTGCTGTTTCTGCTGTTCTTTCTGACCCTGCGGTTCAGCGTCGTGAAGCGGG
GCAGAAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGGCCCGTGCA
GACCACCCAGGAAGAGGACGGCTGCTCCTGCCGGTTTCCCGAGGAAGAAGA
GGGGGGCTGCGAGCTCTAA 
ATG start codon 
TAA stop codon 
PD-1 domains 
4-1BB domains 
 
pGEM vector: 
GTCGAC…ATG…TAAGAATTC 
GTCGAC HincII restriction site 
GAATTC EcoRI restriction site 
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PD-1tm:BB 
5’ -> 3’ 
ATGCAGATTCCTCAGGCTCCTTGGCCTGTCGTGTGGGCCGTGCTCCAGCTGGG
ATGGCGGCCTGGATGGTTCCTGGACAGCCCCGACAGACCCTGGAACCCCCCTA
CATTTTCCCCTGCCCTGCTGGTCGTGACCGAGGGCGACAATGCCACCTTCACCT
GTAGCTTCAGCAACACCAGCGAGAGCTTCGTGCTGAACTGGTACAGAATGAGC
CCCAGCAACCAGACCGACAAGCTGGCCGCCTTCCCCGAGGATAGATCTCAGCC
CGGCCAGGACTGCCGGTTCAGAGTGACCCAGCTGCCCAACGGCCGGGACTTC
CACATGTCTGTCGTGCGCGCCAGACGGAACGACAGCGGCACATATCTGTGCGG
CGCCATCAGCCTGGCCCCCAAGGCCCAGATCAAAGAGAGCCTGAGAGCCGAG
CTGAGAGTGACCGAGAGAAGGGCCGAAGTGCCTACCGCCCACCCTAGCCCATC
TCCAAGACCTGCCGGCCAGTTCCAGACACTGGTCGTGGGAGTCGTGGGCGGC
CTGCTGGGATCTCTGGTGCTGCTCGTGTGGGTGCTGGCCGTGATCAAGCGGG
GCAGAAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGGCCCGTGCA
GACCACCCAGGAAGAGGACGGCTGCTCCTGCCGGTTTCCCGAGGAAGAAGA
GGGGGGCTGCGAGCTCTAA 
ATG start codon 
TAA stop codon 
PD-1 domains 
4-1BB domains 
 
pGEM vector: 
GTCGAC…ATG…TAAGAATTC 
GTCGAC HincII restriction site 
GAATTC EcoRI restriction site 
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5.5.2 Murine chimeric receptor DNA sequence 
 
mPD-1:28tm 
5’ -> 3’ 
ATGTGGGTCCGCCAGGTGCCATGGTCCTTCACCTGGGCCGTGCTGCAGCTGTC
CTGGCAGAGCGGCTGGCTGCTGGAAGTGCCCAACGGCCCTTGGAGAAGCCTG
ACCTTCTACCCCGCCTGGCTGACCGTGTCTGAGGGCGCCAACGCCACCTTCAC
CTGTAGCCTGAGCAATTGGAGCGAGGACCTGATGCTGAACTGGAACAGACTGA
GCCCCAGCAACCAGACCGAGAAGCAGGCCGCCTTCTGCAACGGCCTGAGCCA
GCCTGTGCAGGACGCCAGATTCCAGATCATCCAGCTGCCCAACAGACACGACT
TCCACATGAACATCCTGGACACCCGCAGAAACGACAGCGGCATCTACCTGTGC
GGCGCCATCAGCCTGCACCCCAAGGCCAAGATCGAGGAAAGCCCTGGCGCCG
AGCTGGTGGTGACAGAGAGAATCCTGGAAACCAGCACTAGATACCCCAGCCCC
AGCCCTAAGCCCGAGGGCAGATTCCAGGGCATGTTCTGGGCTCTGGTGGTGGT
GGCCGGCGTGCTGTTTTGTTACGGCCTGCTCGTGACCGTGGCCCTGTGCGTGA
TCTGGACCAACAGCAGAAGAAACAGACTGCTGCAGAGCGACTACATGAACAT
GACCCCCAGAAGGCCTGGCCTGACCAGAAAGCCCTACCAGCCTTACGCCCCT
GCCAGAGACTTCGCCGCCTACAGACCT TGA 
 
ATG start codon 
TGA stop codon 
PD-1 domains 
CD28 domains 
 
pMP71 vector: 
GCGGCCGC...ATG…TAAGAATTC 
GCGGCCGC NotI restriction site 
GAATTC EcoRI restriction site 
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5.6 Antibodies for cell culture and flow cytometry analyses 
5.6.1 Antibodies with anti-human specificities for cell culture 
SPECIFI-
CITY 
SPECIES/ 
ISOTYPE 
CLONE COMPANY CONCENTRATION 
CD3 Mouse IgG2a OKT3 In-house 
production 
5 μg/ml (T cell activation) 
5 μg/1 x 106 P815 (P815 
loading for co-culture) 
CD28 Mouse IgG1 CD28.2 BD 1 μg/ml (T cell activation) 
5 μg/1 x 106 P815 (P815 
loading for co-culture) 
PD-1 
(CD279) 
Mouse IgG1 EH12.2H7 BioLegend 20 μg/ml (blocking 
experiments) 
PD-L1 
(CD274) 
Mouse IgG2b 29E.2A3 BioLegend 20 μg/ml (blocking 
experiments) 
 
5.6.2 Antibodies with anti-human specificities for flow cytometry 
SPECIFI-
CITY 
FLUORO-
CHROME 
SPECIES/ 
ISOTYPE 
CLONE COMPANY DILUTION 
CD3ε 
 
PB Mouse IgG1 SK7 BioLegend 1:17 
PE-Cy7 Mouse IgG1 SK7 BioLegend 1:20 
CD4 APC-eF780 Mouse IgG1 RPA-T4 eBioscience 1:25 
CD8α PB Mouse IgG1 RPA-T8 BD 1:25 
V500 Mouse IgG1 RPTAT8 BD 1:25 
CD11c APC Mouse IgG1 B-Ly6 BD 1:5 
CD45 PE-Cy7 Mouse IgG1 HI30 BioLegend 1:50 
HLA-A2 Unconju-
gated 
Mouse IgG1 HB54 In-house 
production 
undiluted 
Isotype FITC Mouse IgG1 MOPC21 BD 1:10 
PD-1  APC Mouse IgG1 MIH4 eBioscience 1:25 
PE Mouse IgG1 MIH4 eBioscience 1:25 
PD-L1 
(CD274) 
FITC Mouse IgG1 M1H1 BD 1:5 
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SPECIFI-
CITY 
FLUORO-
CHROME 
SPECIES/ 
ISOTYPE 
CLONE COMPANY DILUTION 
p-ERK 
(pT202/ 
pY204) 
Unconju-
gated 
Rabbit IgG D13.14.4E Cell Signaling 1:300 
p-RPS6 
(pS235/236) 
APC Rabbit IgG D57.2.2E Cell Signaling 1:50 
Tyrosinase Unconju-
gated 
Mouse 
IgG2a 
T311 Upstate Biotech-
nology 
1:50 
 
A647: Alexa 647     APC: Allophycocyanin  
APC-eF780: Allophycocyanin – eFluor 780  FITC: Fluorescein isothiocyanate   
P: Phosphorylated     PB: Pacific Blue     
PE: Phycoerythrin     PE-Cy7: Phycoerythrin – Cyanine 7  
PerCP-Cy5.5: Peridinin-chlorophyll – Cyanine 5.5  S: Serine      
T: Threonine      Y: Tyrosine     
V500: Violet 500 
 
5.6.3 Antibodies with anti-mouse specificities for cell culture 
SPECIFI-
CITY 
SPECIES/ 
ISOTYPE 
CLONE COMPANY CONCENTRATION 
CD3 Armenian 
hamster IgG1 
145-2C11 BD 1 μg/ml (T cell activation) 
CD28 Syrian hamster 
IgG2 
37.51 BD 0.1 μg/ml (T cell 
activation) 
 
5.6.4 Antibodies with anti-mouse and anti-rabbit specificities for flow 
cytometry 
SPECIFI-
CITY 
FLUORO-
CHROME 
SPECIES/ 
ISOTYPE 
CLONE COMPANY DILUTION 
CD3 APC-Cy7 Armenian 
Hamster IgG 
145-2C11 Biolegend 1 :50 
CD4 A700 Rat IgG2a RM4-5 BD 1:100 
CD8 BV421 Rat IgG2a 53-6.7 BioLegend 1:100 
CD19 V450 Rat IgG2a 1D3 eBioscience 1:100 
CD45 PE-Cy7 Rat IgG2b 30-F11 BD 1:100 
H2-Db PE Mouse IgG2b KH95 BD 1:100 
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SPECIFI-
CITY 
FLUORO-
CHROME 
SPECIES/ 
ISOTYPE 
CLONE COMPANY DILUTION 
Large and 
small T 
antigens 
FITC Mouse IgG2a Pab108 BD 1 :50 
Mouse 
IgG1 
FITC Rabbit IgG Poly-clonal Dako 1:20 
Mouse 
IgG2a 
A647 Rabbit IgG Poly-clonal Invitrogen 1:500 
PD-1 PerCP-Cy5.5 Rat IgG2a 29F.1A12 BioLegend 1:100 
PD-L1 PE Rat IgG2a MIH5 BD 1:50 
Rabbit IgG A647 Goat IgG Poly-clonal Invitrogen 1:500 
TCRβ 
constant 
region 
PB Armenian 
Hamster IgG 
H57-597 BioLegend 1:25 
Thy1.1 A647 Mouse IgG1 OX7 BioLegend 1:100 
 
A647: Alexa 647     A700: Alexa 700     
APC-Cy7: Allophycocyanin – Cyanine 7  BV421: Brilliant violet 421    
PB: Pacific blue     PE-Cy7: Phycoerythrin – Cyanine 7  
PerCP-Cy5.5: Peridinin-chlorophyll – Cyanine 5.5  
V450: Violet 450 
5.7 Primary cells and cell lines 
CELL LINE CHARACTERISTICS CULTURE 
MEDIUM 
SOURCE 
HEK293 A2 Transduced to express 
HLA-A2 
 
RCC medium Kindly provided by 
Matthias Leisegang, Max 
Delbrück Center Berlin, 
GERMANY 
HEK GaLV 
 
Retroviral packaging 
cell line expressing 
gag, pol and env genes  
HEK medium Kindly provided by 
Wolfgang Uckert, Max 
Delbrück Center Berlin, 
GERMANY 
HEK/Tyr 
 
Transduced to express 
HLA-A2 and tyrosinase 
 
RCC medium Kindly provided by 
Matthias Leisegang, Max 
Delbrück Center Berlin, 
GERMANY 
HEK/Tyr/PD-L1 
 
Transduced to express 
HLA-A2, tyrosinase 
and PD-L1 
RCC medium Kindly provided by 
Matthias Leisegang, Max 
Delbrück Center Berlin, 
GERMANY 
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CELL LINE CHARACTERISTICS CULTURE 
MEDIUM 
SOURCE 
FM3 
 
Melanoma cell line RCC medium Kindly provided by Per 
thor Straten, Herlev 
Hospital, Herlev, 
DENMARK 
FM55 
 
Melanoma cell line RCC medium Kindly provided by Per 
thor Straten, Herlev 
Hospital, Herlev, 
DENMARK 
FM86 
 
Melanoma cell line RCC medium Kindly provided by Per 
thor Straten, Herlev 
Hospital, Herlev, 
DENMARK 
SKMel23 
 
Melanoma cell line RCC medium Monica C. Panelli, NIH, 
Bethesda, USA 
P815 
 
Murine mastozytoma cell 
line 
RCC medium ATCC, Rockville, 
Maryland, USA 
PlatE 
 
Retroviral packaging cell 
line expressing gag, pol 
and env genes  
HCC medium Kindly provided by 
Wolfgang Uckert, Max 
Delbrück Center Berlin, 
GERMANY 
TCR-I  
TCR-I/mPD-1:28tm 
T cells of TCR-I trans-
genic mice, MOCK- or 
mPD-1:28tm- transduced 
TCR-I recognizes epitope 
I of simian virus large T 
antigen (SAINNYAQKL) 
MTM Kindly provided by 
Matthias Leisegang, Max 
Delbrück Center Berlin, 
GERMANY 
434 
 
Murine hepatocellular 
carcinoma cell line 
HCC medium Kindly provided by 
Gerald Willimsky, Max 
Delbrück  
Center Berlin, 
GERMANY 
 
 
5.8 Blood samples 
Drawing of blood samples from healthy donors was performed by trained personnel 
and approved by the local Ethics Committee. Donors gave their consent. 
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5.9 Patient samples 
Clear cell renal cell carcinoma tissues and blood samples were kindly provided by 
the Urologische Klinik Dr. Castringius, Planegg, Germany. Tissue collection was 
approved by the local Ethics Committee and patients gave their consent. Tumors 
were classified according to the TNM system published by the UICC 2010.  
 
 
PATIENT ID TNM STATUS 
RCC102 pT3a N0 M0 G2 
RCC105 pT3a N0 M0 G3 
RCC106 pT1a N0 M0 G2 
RCC110 pT1b N0 M0 G2 
RCC112 pT1a N0 M0 G2 
 
5.10 Mice 
The animal experiments were approved by the local authorities according to the legal 
regulations for animal experiments. 
 
5.10.1 NSG mice 
NOD/scid IL2Rgnull (NSG) mice were bred on the genetic background of non-obese 
diabetic (NOD) mice characterized by reduced innate immunity. NSG mice carry the 
prkdcscid mutation, a loss-of-function mutation in the PRKDC gene, leading to 
defective repair of DNA strand breaks during V(D)J recombination in the 
development of B and T cells. This severe combined immunodeficiency (scid) is 
characterized by a major reduction of T and B cells. Additionally, NSG mice carry a 
null mutation in the IL-2 receptor gamma chain (IL2Rgnull) blocking NK cell 
differentiation. The impairment of innate immunity and absence of adaptive immunity 
render NSG mice a good model system for adoptive T cell therapy of human tumor 
xenografts. 
NSG mice were obtained from Charles River. 
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5.10.2 LoxP-TAg mice 
LoxP-TAg mice were bred on the background of C57BL/6 mice. They are transgenic 
for the oncogene simian virus large T antigen (TAg) that is separated from its β-
actin/β-globin promoter by a stop cassette preventing TAg expression (59) t. I.v. 
injection of adenovirus coding for Cre recombinase (Ad.Cre) leads to deletion of the 
stop cassette in the liver due to the tropism of adenovirus. Eight to 24 weeks after 
Ad.Cre injection, mice develop multinodular hepatocellular carcinoma (60, 61). 
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6 METHODS 
6.1 Molecular biology methods 
6.1.1 Cloning of chimeric co-stimulatory receptors into pGEM and 
pMP71 vectors 
Chimeric co-stimulatory constructs were ordered at Geneart, Life Technologies, 
delivered as a lyophilized powder and dissolved in nuclease-free water at a 
concentration of 0.5 μg/μl.  
For amplification TOP10 or MACH1 E.coli were chemically transformed with the 
Geneart constructs. Bacteria were thawed on ice, 1 μl of plasmid was added to the 
bacteria and incubated for 30 minutes on ice. Heat shock for 30 seconds at 42°C 
caused uptake of the DNA by the bacteria. They were placed on ice for 2 minutes, 
350 μl of SOC medium was added and the bacteria incubated with gentle agitation at 
37°C for 1 hour. 20 μl of transformed bacteria were plated on agar-coated Petri 
dishes containing 100 μg/ml Ampicillin. The plates were incubated over night at 37°C. 
After incubation separate colonies were picked using a pipette tip and added to a 10 
ml tube containing 4 ml LB medium. The bacteria were incubated over night with 
agitation at 37°C. 200 μl of densely grown cultures were added to 300 ml of LB 
medium and again incubated over night with agitation at 37°C. Plasmid DNA was 
isolated using the Jetstar preparation kit. The bacteria cultures were centrifuged at 
3400 g for 10 minutes at room temperature, the supernatant discarded and the pellet 
re-suspended in 10 ml re-suspending buffer E1 and transferred to a 50 ml tube. 10 
ml of lysis buffer E2 was added and the collection tube inverted 10 times, thereafter 
10 ml precipitation buffer E3 was added and the tube inverted again for 10 times. The 
suspension was centrifuged at 5000 g for 10 minutes at room temperature and the 
supernatant applied through a 70 μm filter onto an equilibrated column. The column 
was filled up with washing buffer E5 and the flow-through discarded. The column was 
placed on top of a 50 ml collection tube and the DNA eluted by adding 15 ml of 
elution buffer E6. 10.5 ml isopropanol was added to the DNA, mixed and centrifuged 
at 5000 g for 45 minutes at 4°C. The supernatant was discarded, the pellet 
dehydrated with 1 ml 75% ethanol, air-dried and re-suspended in nuclease-free 
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water. The concentrations of the plasmid DNAs were determined by quantification of 
UV absorbance at 260 nm using NanoDrop® spectrophotometer. UV absorbances at 
230 nm and 280 nm were also detected to determine DNA purity. 260/280 and 
260/230 ratios were above 1.8 indicating no contamination with proteins or salts, 
respectively. The plasmid DNAs were sent to Eurofins MWG for sequencing. 
To clone the chimeric co-stimulatory receptors into the pGEM and pMP71 vector 
backbones 5-9 μg of plasmid DNA were mixed with the appropriate forward and 
reverse primers (see 5.4.2 Primers, final concentration 1.5 pmol/μl), 5% DMSO and 
1x PCR Master Mix. Nuclease-free water was added to yield a final volume of 100 μl. 
Chimeric signaling receptor DNAs were amplified using the following program: 
 
# OF 
CYCLES 
STEP TEMPERATURE DURATION 
1 Denaturation 94°C 5 minutes 
35 Denaturation 
Annealing 
Polymerisation 
94°C 
62°C 
72°C 
5 minutes 
30 seconds 
1 minute 
1 Final extension 72°C 5 minutes 
 Hold 4   Infinite    
  
The PCR products were run on a 1% agarose gel (in 1x TAE) containing ethidium 
bromide at 130 V for 45 minutes. To determine the size of the products, 1 kb DNA 
ladder was run simultaneously. The PCR products were cut out and purified using 
the Gel Extraction Kit from Quiagen. 1 ml of QG buffer was added to the gel pieces, 
incubated for 10 minutes in a water bath at 50°C. The liquid gel-buffer-mix was 
loaded onto a column and centrifuged for 30 seconds at 20000 g. The column was 
washed with 750 μl PE buffer and centrifuged for 30 seconds at 20000 g. To remove 
remaining buffer, the column was centrifuged twice for 1 minute at 20000 g. The 
column was placed on top of a 1.5 ml tube and DNA eluted by adding 45 μl of 
nuclease-free water onto the column. The column was incubated for 1 minute at 
room temperature and centrifuged for 30 seconds at 20000 g. This step was 
repeated to yield a final volume of 90 μl.  
The pGEM and pMP71 vectors as well as the chimeric signaling receptor PCR 
products were digested using the appropriate enzymes (see 5.4.3 Enzymes). 10 μg 
of vector were mixed with CutSmart buffer (1:10) and 60 units of either EcoRI-high 
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fidelity (HF) and NotI-HF (pMP71) or EcoRI-HF and HindIII-HF or HincII (pGEM). 
Nuclease-free water was added to the vector-enzyme-mix to yield a final volume of 
106 μl. The vectors were digested for 1 hour at 37°C. The digested vectors were 
applied to a 1% agarose gel containing ethidium bromide at 130 V for 45 minutes. 
The vector backbones were cut out and purified using the Gel Extraction Kit from 
Quiagen (see above). 
PCR products of chimeric signaling receptors were mixed with CutSmart buffer (1:10) 
and 60 units of either EcoRI-HF and NotI-HF (pMP71) or EcoRI-HF and HindIII-HF or 
HincII (pGEM). PCR products were digested for 1 hour at 37°C, applied to a 1% 
agarose gel containing ethidium bromide at 130 V for 45 minutes, cut out of the gel 
and purified using the MinElute® Reaction Cleanup Kit from Quiagen (procedure see 
purification above). 
Vectors and PCR products were ligated by mixing 7 μl of vector and 1 μl of DNA 
coding for chimeric signaling receptors plus 400 units T4 ligase and T4 ligase buffer 
(1:10). The ligation mix was incubated ~ 16 hours at 16°C. TOP10 or MACH1 E.coli 
were transformed with 1 μl of the ligation and plasmids were obtained from bacteria 
cultures (see above).  
 
6.1.2 Generation of in vitro transcribed RNA from pGEM plasmids 
PGEM plasmids coding for the chimeric signaling receptors were linearized by 
incubating 40 μg of pGEM plasmid with 80 units SpeI-HF and CutSmart buffer (1:10). 
Nuclease-free water was added to a final volume of 100 μl. The SpeI-HF recognition 
site is located behind a poly-A tail of ~ 116 bp. This poly-A tail is meant to increase 
the stability of in vitro transcribed (ivt) RNA. The linearization mix was incubated ~ 16 
hours at 37°C. Then, 4 mM EDTA, 48 mM sodium acetate and 67% ethanol (all final 
concentration) were added to the DNA, incubated for 45 minutes at -20 °C and 
centrifuged for 15 minutes at 20000 g and 4°C. 
Ivt-RNA was generated from linearized pGEM plasmids using the 
mMESSAGEmMACHINE Kit from Ambion. 3 μg of linearized DNA was mixed with 
NTP/CAP (1x, 7-methyl guanosine cap and nucletotides), reaction buffer (1x) and T7 
polymerase (1:10). Nuclease-free water was added to a final volume of 40 μl. The 
mix was incubated for 2 hours at 37°C. DNAse was added (1:20) and incubated for 
30 minutes at 37°C. Ivt-RNA was purified using the RNeasy Mini Kit from Quiagen. 
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350 μl RLT buffer and 250 μl 100% ethanol were added to the ivt-RNA and loaded 
onto a column. The column was centrifuged at 20000 g for 30 seconds and washed 3 
times with 500 μl PE buffer. For the first 2 washing steps the column was centrifuged 
at 20000 g for 30 seconds and for the last washing step at 20000 g for 2 minutes. 
The column was placed onto a 1.5 ml tube and the ivt-RNA eluted by adding 40 μl 
nuclease-free water onto the column. The column was incubated for 1 minute at 
room temperature and centrifuged for 1 minute at 20000 g. Concentrations of the ivt-
RNAs were determined by quantification of UV absorbance at 260 nm using 
NanoDrop® spectrophotometer. The ivt-RNAs were run on 1% agarose gels (in 1 x 
TAE, DEPC-water) for quality control. 
 
6.2 Cell culture techniques 
6.2.1 Cultivation of human and murine cell lines and primary cells 
All primary cells and cell lines were handled under sterile conditions and were grown 
at 37°C and 6.5% CO2. 
The human melanoma cell lines SKMel23, FM3, FM55 and FM86 as well as the 
murine mastocytoma cell line P815 were grown in T75 cm2 tissue culture flasks with 
RCC medium until confluent and passaged 1:3-1:8 by detaching adherent cells with 
2 x trypsin/EDTA.  
HEK/Tyr and HEK/Tyr/PD-L1 were grown in T75 cm2 tissue culture flasks with RCC 
medium until confluent and passaged 1:3 by detaching adherent cells by pipetting up 
and down. 
The murine hepatocellular carcinoma cell line 434 and the retroviral packaging cell 
line PlatE were grown in T75 cm2 culture flasks with MTM medium until confluent and 
passaged 1:8 by detaching adherent cells with 2 x trypsin/EDTA or by pipetting up 
and down, respectively.  
The retroviral packaging cell line HEK GaLV was grown in T75 cm2 culture flasks with 
HEK medium until confluent and passaged 1:8 by detaching adherent cells by 
pipetting up and down. 
Human T cells of healthy donors were cultivated at 1-1.5 x 106 cells/ml in T cell 
medium supplemented with 50 U/ml IL-2 and split every 2-3 days. They were 
cultivated in 24-well plates or in T75 cm2 culture flasks. 
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Murine T cells were cultivated at 1-1.5 x 106 cells/ml in MTM medium supplemented 
with 50 U/ml IL-2. They were cultivated in 24-well plates or in T75 cm2 culture flasks. 
 
6.2.2 Thawing, counting and freezing of cells 
For thawing, freezing vials containing frozen cells were placed in a water bath at 
37°C. The suspension was transferred to a 15 ml tube containing FCS and 
centrifuged at 472 g for 5 minutes at room temperature. TILs were centrifuged at 
300 g for 10 minutes. The supernatant was discarded and cell pellet re-suspended in 
the appropriate medium. 
Cell numbers were determined using Neubauer counting chambers. To allow 
discrimination of viable and dead cells, cell suspensions were diluted with trypan blue 
(1:2 in PBS). Trypan blue is excluded from viable cells but passes the cell membrane 
of dead cells. TILs and peripheral blood mononuclear cells isolated from blood were 
counted in trypan blue (1:2 in PBS) containing 3% acetic acid to exclude 
erythrocytes. 
The following formula was applied to determine cell numbers: 
Cell number/ml = mean of cells counted in 4 big quadrants x dilution factor x chamber 
factor (104) 
For long-term storage, cell pellets were re-suspended in ice-cold FCS and mixed with 
equal amounts of ice-cold cell freezing medium. Cells were frozen in 1 ml aliquots in 
freezing vials and stored at -80 °C until transfer to the gas phase of liquid nitrogen 
tanks. 
 
6.2.3 Isolation of peripheral blood mononuclear cells from human 
blood samples 
Syringes were supplemented with 10 IU heparin-sodium/ml blood. Blood samples 
were diluted 1:2 with RPMI-1640, layered over 20 ml Ficoll® 50 ml tubes and 
centrifuged without break for 20 minutes at 840 g and room temperature. Peripheral 
blood mononuclear cells (PBMCs) gather in the interphase between plasma and 
ficoll. PBMCs were transferred to 50 ml tubes, diluted 1:2 with RPMI-1640 and 
centrifuged at 758 g with break for 12 minutes at room temperature. The cell pellet 
was re-suspended in T cell medium, counted and used in experiments or frozen.  
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6.2.4 Isolation of TILs from human renal cell carcinoma 
Human renal cell carcinoma (RCC) tissues were obtained from patients who 
underwent nephrectomy. Tumor and healthy tissues were dissected by pathologists 
and infiltrating lymphocytes were directly isolated. To this end, tissue samples 
(average size 4 cm x 2 cm x 1.5 cm) were placed in Petri dishes and cut into small 
pieces using scalpel and scissors. Dehydration of the tissue was prevented by 
adding HBSS (containing Ca2+, Mg2+). The cut tissue was transferred to a 50 ml tube 
and centrifuged with HBSS (containing Ca2+, Mg2+) for 2 minutes at 472 g and room 
temperature. This washing step was repeated until the supernatants appeared 
bloodless. Those supernatants contained cells, which did not deeply infiltrate into the 
tumor and are called tumor circulating lymphocytes (TCLs). To obtain TILs, the tissue 
was then digested for 30 minutes on a shaker at room temperature in digestion 
medium (6 ml buffer/ml tissue pellet). After centrifugation for 5 minutes at 472 g and 
room temperature the supernatant was placed on ice and the cell pellet re-
suspended in HBSS without Ca2+ and Mg2+ and centrifuged as before. The 
supernatant was placed on ice and the pellet re-suspended in 5 mM EDTA in HBSS 
without Ca2+ and Mg2+ (6 ml/ml tissue pellet). After incubation for 30 minutes on a 
shaker at room temperature, the suspension was centrifuged as before, the 
supernatant placed on ice, the pellet re-suspended in HBSS (containing Ca2+, Mg2+) 
and centrifuged again. The supernatant was placed on ice, the tissue digested a 
second time in digestion buffer as described above. The suspension was centrifuged 
and the pellet transferred to a Petri dish. The tissue was squeezed between two Petri 
dished until homogenous and filtered through a 70 μm filter. All supernatants were 
centrifuged at 472 g for 10 minutes at room temperature. All pellets were pooled but 
the ones containing TCLs separately from those containing TILs.  
 
6.2.5 Transduction of human T cells 
The transduction of human T cells comprised a 14 days-lasting protocol with day 0 
being the day of PBMCs activation. The transduction was performed in a laboratory 
of S2 standard. All centrifugation steps of T cells or PBMCs were performed at 472 g 
and room temperature for 5 minutes, unless otherwise stated. 
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Day -1 
The retroviral packaging cells HEK GaLV were seeded at 1.5 x 106 cells per Petri 
dish (100 mm) in 10 ml HEK medium. 
Tissue culture treated 24-well plates were coated with 5 μg/ml anti-human CD3 and 
1 μg/ml anti-human CD28 antibodies in 500 μl PBS per well. Plates were sealed with 
Parafilm® and kept at 4°C until the next day. 
 
Day 0 
470 μl of DMEM medium was mixed with 30 μl of TransIT®-LT1 transfection reagent 
and incubated for 5 minutes at room temperature. 12.5 μg of plasmid coding for the 
transgenes (TCR-T58 or –D115, chimeric co-stimulatory receptors) were added to 
the medium-transfection reagent-mix and incubated for 15 minutes at room 
temperature. The medium of HEK GaLV cells was replaced by RPMI basic 
supplemented with 10% FCS and the DNA-transfection-mix was added dropwise to 
the HEK GaLV cells.  
The antibody mix on the 24-well plates was replaced with 2% BSA (in PBS). After 
incubation for 30 minutes at room temperature the plates were washed once with 
PBS. PBMCs of healthy donors were thawed, re-suspended in TCM supplemented 
with 100 U/ml IL-2 and seeded at 1 x 106  cells in 1 ml per well in antibody coated 24-
well plates. Cultivation of PBMCs in anti-CD3 and anti-CD28 antibody coated wells 
with medium containing IL-2 induced activation and proliferation of T cells, a 
prerequisite for successful transduction. 
 
Day 1 
Non-tissue culture treated 24-well plates were coated with 10 μg/ml RetroNectin® in 
500 μl PBS per well. Plates were sealed with Parafilm® and kept at 4°C until the next 
day. 
 
Day 2 
RetroNectin® on the 24-well plates was replaced with 2% BSA (in PBS). After 
incubation for 30 minutes at room temperature the plates were washed once with 
PBS. The virus-containing medium of the HEK GaLV cells was harvested and 
centrifuged at 200 g for 10 minutes at 32°C. The supernatant was added to the 
RetroNectin® coated plates at 1 ml/well, plates were sealed with Parafilm® and 
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centrifuged for 90 minutes at 3200 g at 32°C. The plates for the second transduction 
were kept at 4°C.  
Activated T cells were harvested and seeded at 0.5 x 106 cells in 1 ml per well in 
TCM supplemented with 100 U/ml IL-2 in virus-coated plates. As a control some 
T cells were seeded on plates coated with HEK GaLV medium not containing virus 
particles. These T cells are referred to as MOCK. 
 
Day 3 
T cells were split 1:4 into virus-coated plates from day 2 and provided with 750 μl 
TCM and a final concentration of 100 U/ml IL-2. 
 
Day 6 
Transduced T cells were harvested, re-suspended in TCM supplemented with 100 
U/ml IL-2 and seeded at 1-1.5 x 106 cell/ml in T75 cm2 culture flasks. 
 
Day 8  
Transduced T cells were provided with fresh TCM supplemented with 100 U/ml IL-2. 
 
Day 10 and day 13 
Transduced T cells were provided with fresh TCM supplemented with 50 U/ml IL-2. 
 
Day 15 
Transduced T cells were harvested and used in experiments or frozen at 5-10 x 106 
cells per vial. 
 
6.2.6 Electroporation of human T cells and TILs 
Electroporation cuvettes and Opti-MEM were cooled and ivt-RNA was thawed on ice. 
For experiments with T cells only, a 24-well plate was prepared with 1 ml/well TCM 
supplemented with 50 U/ml IL-2 and pre-warmed in the incubator. For experiments 
with TILs a 24-well plate was prepared with 1 ml/well TIL medium and pre-warmed in 
the incubator. 
Human activated T cells MOCK-transduced or transduced to express the tyrosinase 
specific TCRs T58 or D115 were thawed, re-suspended in Opti-MEM and adjusted to 
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a concentration of 1.8 x 106/200 μl. T cells sorted from TILs (see 6.5.2) were re-
suspended in 400 μl Opti-MEM. Sorting yielded cell number between 0.4-0.8 x 106. 
200 μl of cells were transferred to an electroporation cuvette, incubated for 10 
seconds on ice, 20 μg (unless otherwise stated) ivt-RNA coding for the co-stimulatory 
receptors was added and the cuvette was incubated for 10 seconds on ice. The 
cuvette was placed in the electroporator and the cells were pulsed with 900 V for 2.3 
ms. The cuvette was removed from the electroporator and 200 μl of TCM 
supplemented with 50 U/ml IL-2 (for experiments with T cells only) or 200 μl of TIL 
medium was added to the cuvette. The cuvette was tilted and the cells poured into 
the 24-well plates with pre-warmed medium. The cuvette was rinsed 3 times with the 
appropriate medium. Electroporated cells were incubated 3-4 hours before use in 
experiments. 
 
6.3 Functional assays 
6.3.1 Loading of P815 with OKT3, anti-CD28 or PD-L1/Fc chimera 
P815 cells were detached with accutase, centrifuged at 472 g for 5 minutes at room 
temperature, re-suspended in Opti-MEM, counted and loaded at 5 μg/1 x 106 cells 
with each OKT3 and PD-L1/Fc chimera. P815 were incubated on a shaker for 30 
minutes at room temperature, washed once with Opti-MEM, re-suspended in TIL 
medium, counted and used in experiments. 
 
6.3.2 Co-culture of human T cells or TILs with target cells 
Target cells were detached by trypsination (melanoma cell lines), accutase (P815) or 
pipetting up and down (HEK/Tyr, HEK/Tyr/PD-L1), centrifuged at 472 g for 5 minutes 
at room temperature, re-suspended in either TCM (experiments with transduced 
T cells) or TIL medium (experiments with TILs) and counted.  
Transduced and electroporated T cells, TILs and PBMCs were harvested or thawed, 
re-suspended in either TCM (experiments with transduced T cells) or TIL medium 
(experiments with TILs) and counted. Transduced and electroporated T cells as well 
as PBMCs used in experiments with TILs served as controls and were cultivated in 
TIL medium. 
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Transduced and electroporated T cells were cultivated in 96-well plates at 0.025 x 
106 cells in 100 μl with 0.05 x 106 target cells in 100 μl TCM with or without 20 μg/ml 
blocking antibodies to PD-1 and PD-L1.  
TILs and transduced and electroporated T cells as well as PBMCs used in the same 
experiment were cultivated in 96-well plates at 0.1 x 106 cells in 50 μl with 0.1 x 106 
target cells in 50 μl TIL medium. As a control effector and target cells were cultivated 
alone. Co-culture supernatants were harvested after ~ 16 hours and stored at -20 °C 
until analysis by ELISA or Bio-Plex. 
 
6.3.3 Chromium release assays 
The lytic activity of T cells was assessed by cell mediated lysis assays. Target cells 
labeled with radioactive 51Chromium release 51Chromium when they are lysed by 
T cells. The amount of lysed cells is calculated from the amount of radioactivity in the 
co-culture supernatant. 
One x 106 target cells were re-suspended in 100 μl FCS and labeled with 50 μCi 
51Chromium for 1 hour at 37°C. Target cells were washed twice with CML medium. 
T cells were added 50 μl/well in CML medium to 96-well plates at the respective 
effector:target cell ratio. 51Chromium-labeled target cells were added to T cells at 
2000 cells in 50 μl/well. T and target cells were co-cultured at 37°C. To determine the 
maximal amount of radioactivity, 50 μl of 51Chromium-labeled target cells were 
directly pipetted to a filter plate (Luma plate). After 4 hours of co-culture 50 μl of the 
supernatant were pipetted to the filter plate. Target cells cultivated alone served as 
an indicator of spontaneous lysis. 
The filter plates were allowed to dry overnight. The scintillator within in the plates is 
excited by the Gamma radiation of released 51Chromium and emits light that was 
detected by the scintillation counter TopCount. The following formula was applied to 
calculate specific cell lysis: 
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6.3.4 Detection of cytokines by enzyme-linked-immunosorbent assays 
(ELISA) 
Culture and co-culture supernatants were analyzed for IL-2 and IFN-γ by “sandwich” 
ELISA. Capture antibodies against IL-2 or IFN-γ are bound to 96-well plates and bind 
cytokines within the samples to be analyzed. Bound cytokine can be detected by a 
second biotin-labeled antibody recognizing a different epitope of the cytokine. The 
biotin-labeled antibody is bound by peroxidase-conjugated avidin which in turn 
converts the substrate 3,3’,5,5’-tetramethylbenzidine and hydrogen peroxide into a 
colored product, which is detected by a spectrophotometer set to 405 nm. The color 
intensity of the product is proportional to bound cytokine. A standard cytokine 
solution is diluted serially and the standard curve is plotted as the standard cytokine 
concentration against detected optical density. The concentrations (pg/ml) of cytokine 
within the samples tested can be interpolated from the standard curve.  
IL-2 and IFN-γ ELISAs were performed according to the manufacturer’s protocol. 96-
well plates were coated with 50 μl/well capture antibody (1:250 in coating buffer) at 
4°C for ~ 16 hours. The plates were washed 5 times with 300 μl/well washing buffer, 
blocked with 1% milk powder (in Milli-Q® purified water) for 1 hour at room 
temperature and washed again 3 times. 50 μl culture and co-culture supernatants as 
well as serially diluted standard were incubated on the plates for 1 hour at room 
temperature, the plates were washed 5 times and 100 μl detection antibody plus 
peroxidase-conjugated avidin (both 1:250 in 1% milk powder) were incubation on the 
plates for 1 hour at room temperature. To remove unbound enzyme the plates were 
washed 5 times. 50 μl/well of substrate were added to the plates and incubated for 
15 minutes at room temperature. The reaction was stopped by adding 50 μl/well 1 M 
phosphoric acid. The optical density of the samples was detected using the “ELISA 
reader sunshine” and concentration of cytokine calculated by the software Tecan. 
Culture and co-culture supernatants of human and murine transduced T cells were 
acquired as duplicates. Co-culture supernatants of human TILs were acquired as 
single measurements due to insufficient cell yield.  
 
The transduced TCRs T58 and D115 are only functional in CD8+ T cells. To 
compensate for varying transduction efficiencies and CD8+/CD4+ T cell ratios, the 
percentage of TCR+CD8+ T cells within the cell suspension was analyzed by flow 
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cytometry (FC) and used to calculate the amount of produced cytokine by a cell 
population being 100% TCR+CD8+: 
 
 
 
 
 
6.3.5 Detection of cytokines by Bio-Plex analysis 
Co-culture supernatants of human TCR-transduced chimeric receptor-electroporated 
T cells and target cells as well as of murine TILs/splenocytes and target cells or 
PMA/I were analyzed for cytokine content by Bio-Plex. Capture antibodies coupled to 
beads containing fluorescent dyes bind cytokines within the sample. Biotinylated 
detection antibodies bind a different epitope of the cytokines and react with 
streptavidin-PE conjugates. The fluorescent dyes within the beads allow distinction of 
different beads and thus facilitate the simultaneous detection of various cytokines.  
Cytokine Bio-Plex was performed according to the manufacturer’s protocol. Cytokine 
standard was dissolved in 500 μl of the according culture medium (TCM or MTM) and 
incubated for 30 minutes at 4°C. 128 μl of the dissolved standard were mixed with 
72 μl culture medium and serially diluted. 100 μl of assay buffer were pipetted onto 
the filter plates and flushed through the filter with a vacuum pump. 50 μl of 1:10 
diluted fluorescently dyed beads conjugated with antibodies recognizing specific 
cytokines were added to the plates which were immediately washed twice with 100 μl 
washing buffer. 50 μl of standard solutions (in duplicates) and 50 μl of samples 
(single measurements) were added to the plates and incubated for 30 minutes on a 
shaker at room temperature. The plates were washed as described above, 25 μl/well 
of biotinylated detection antibody (1:10 in detection antibody diluent) were added and 
incubated 30 minutes on a shaker at room temperature. The plates were washed as 
described, 50 μl/well of streptavidin-PE (1:100 in assay buffer) were added and 
incubated for 10 minutes on a shaker at room temperature. The plates were washed 
as described and 125 μl/well of washing buffer were added and the amount of 
cytokine detected using Bio-Plex-Array-Reader. The fluorescent dyes within the 
beads allow identification of detected cytokine and the signal emitted by PE is 
translated in concentration of cytokine (pg/ml).  
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The amount of cytokines secreted by human TCR-transduced chimeric signaling 
receptor-electroporated T cells was calculated as cytokine produced by a cell 
population being 100% TCR+CD8+ (see section 6.3.4). 
 
6.4 Flow cytometry 
6.4.1 Principle of flow cytometry 
Flow cytometry allows the detection of physical properties as well as surface and 
intracellular marker expression of cells or particles. Cells or particles within the 
suspension to be analyzed are separated in a laminar flow and pass through laser 
beams individually. The emitted light provides information on the size of cells 
(forward scatter) and their granularity (sideward scatter). In addition, the expression 
of surface and intracellular markers can be analyzed with the help of fluorochrome-
conjugated antibodies. The photons emitted by different fluorochromes are detected 
and digitalized by photomultiplier tubes. Filters separating the photons of different 
fluorochromes allow simultaneous analysis of various markers.  
In this thesis the cytometer LSRII by BD was used for flow cytometry analysis of 
cells. The LSRII contains 4 different lasers (355 nm, 405 nm, 488 nm and 633 nm) 
allowing simultaneous detection of 18 fluorochromes. Table 1 shows characteristics 
of used fluorochromes, lasers and filters.  
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Table 1: Characteristics of used fluorochromes, lasers and filters for detection at the LSRII. 
FLUORO-
CHROME 
EXCITATION 
MAXIMUM 
(NM) 
EMISSION 
MAXIMUM 
(NM) 
LASER LASER 
WAVE-
LENGTH (NM) 
DETECTION 
FILTER (NM) 
7-AAD 543 655 Blue laser 488 630/30 
A647 650 668 Red laser 633 660/20 
A700 696 719 Red laser 633 660/20 
APC 650 660 Red laser 633 660/20 
APC-eF780 650 780 Red laser 633 780/60 
APC-Cy7 650 785 Red laser 633 780/60 
BV421 407 421 Violet 
laser 
405 450/50 
FITC 494 520 Blue laser 488 530/30 
PB 401 452 Violet 
laser 
405 450/50 
PE 496 578 Blue laser 488 575/26 
PE-Cy7 496 785 Blue laser 488 780/60 
PerCP-
Cy5.5 
482  695  
Blue laser 488 695/40  
PI 535  617  UV laser 355 610/20  
V450 404 448 Violet 
laser 
405 450/50 
V500 415 500 Blue laser 488 525/20 
 
7-AAD: 7-Actinomycin    A647: Alexa 647     
A700: Alexa 700    APC: Allophycocyanin 
APC-Cy7: Allophycocyanin – Cyanine 7 APC-eF780: Allophycocyanin – eFluor 780 
BV421: Brilliant violet 421   FITC: Fluorescein isothiocyanate 
PB: Pacific blue    PE: Phycoerythrin     
PE-Cy7: Phycoerythrin – Cyanine 7  PerCP-Cy5.5: Peridinin-chlorophyll – Cyanine 5.5  
PI: Propidium iodide    V450: Violet 450     
V500: Violet 500 
 
 
If more than one fluorochrome is detected, the fluorescence spillover of one 
fluorochrome into the detector of another one has to be compensated. To this end, 
along with the analyzed samples beads labeled with only one fluorochrome have to 
be acquired. Those so-called CompBeads® are polystyrene microparticles binding 
any κ light chain bearing immunoglobulin of mouse, rat or hamster origin. In addition, 
there are negative CompBeads® with no binding capacity. Both types of beads were 
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mixed 1+1 and stained with 1 fluorochrome labeled antibody that was used in the 
respective staining combination. CompBeads® were acquired for all fluorochromes 
used and with the same PMT settings as the labeled samples. Data acquired with the 
LSRII was analyzed using FlowJo® software. 
 
6.4.2 Staining of cell surface and intracellular markers 
All centrifugation steps were performed at 472 g for 5 minutes at room temperature. 
However, TILs were centrifuged at 300 g for 10 minutes at room temperature. 
Incubation was performed in the dark and on ice unless otherwise stated. 
Cells (0.05-0.2 x 106) were transferred into 1 ml FACS tubes, washed with 500 μl 
FACS buffer and the supernatant removed leaving 50 μl in the tube. Antibodies to 
surface markers (see 6.4.3 Staining combinations) and 7-AAD discriminating live and 
dead cells were added and incubated for 30 minutes. Cells were washed as 
described above and acquired on the LSRII. When intracellular markers were 
included in the analysis it was proceeded as follows: For fixation cells were re-
suspended with 500 μl 1% paraformaldehyde and incubated for 20 minutes. After 
centrifugation cells were permeabilized with 0.1% saponin, incubated for 30 minutes, 
centrifuged, incubated with 0.35% saponin for 30 minutes and centrifuged again. The 
supernatant was removed leaving 50 μl in the tube. Antibodies to intracellular 
markers were added and incubated for 30 minutes. Cells were washed with 500 µl 
0.1% and 0.35% saponin and when staining included non-labeled primary antibodies 
incubated with secondary antibodies for 30 minutes. Finally, cells were washed with 
500 µl 0.35% saponin and acquired on the LSRII. 
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6.4.3 Staining combinations and gating strategies 
6.4.3.1 Analysis of transduction and electroporation efficiency of human 
T cells and TILs 
Table 2: Staining combination for analysis of transduction and electroporation efficiency of human 
activated T cells 
MARKER/FEATURE FLUOROCHROME STAINING 
CD3 PE-Cy7 Cell surface 
CD4 APC-eF780 Cell surface 
CD8 V500 Cell surface 
Murine TCRβ-chain PB Cell surface 
PD-1 APC Cell surface   
Viability 7-AAD Cell surface 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2: Gating strategy for analysis of transduction and electroporation efficiency of 
human activated T cells. 
Lymphocytes were selected according to their forward (FSC-A) and sideward scatter (SSC-A) 
characteristics. Viable (7-AAD-) and single cells expressing CD3 were analyzed for transduced 
TCR plus CD8 or CD4 expression. The transduced TCR contains a murinized constant region, 
which can be stained using anti-murine TCRβ antibody. Expression of chimeric signaling 
receptors in TCR+CD8+ and TCR+CD4+ T cells was detected by PD-1 expression. MOCK 
transduced T cells served as a control for TCR expression and water electroporated T cells as a 
control for chimeric signaling receptor expression. 
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6.4.3.2 Analysis of T cells isolated from melanoma xenografts in NSG 
mice 
Table 3: Staining combination for analysis of T cells isolated from human melanoma xenografts 
MARKER/FEATURE FLUOROCHROME STAINING 
CD4 APC-A780 Cell surface 
CD8 PB Cell surface 
CD45 PE-Cy7 Cell surface 
PD-1 APC Cell surface 
Proliferation CFSE Intracellular 
Viability 7-AAD Cell surface 
 
 
 
 
 
 
 
 
 
Figure 3: Gating strategy for characterization of TILs. 
CD45+ leukocytes were selected and viable, single cells analyzed for CD8, PD-1 and CFSE 
expression. 
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6.4.3.3 Analysis of transduction efficiency of murine T cells and 
characterization of murine TILs and splenocytes 
Table 4: Staining combination for analysis of transduction efficiency and T cell phenotype 
MARKER/FEATURE FLUOROCHROME STAINING 
Bcl-2 FITC Intracellular 
CD3 APC-Cy7 Intracellular 
CD4 A700 Intracellular 
CD8 BV421 Intracellular 
CD62L PE-Cy7 Cell surface 
PD-1 PerCP-Cy5.5 Intracellular 
Thy1.1 A647 Intracellular 
 
 
 
 
 
 
Figure 4: Gating strategy for analysis of transduction efficiency and T cell phenotype 
CD45+ leukocytes were selected and viable, single cells expressing CD3 and CD8 or CD4 were 
analyzed for expression of the transgenes Thy1.1 and mPD-1:28
tm
 (PD-1 expression). In 
addition, expression of CD62L, indicating the differentiation state and Bcl2, an anti-apoptotic 
protein, was determined. 
METHODS                                                                                                                                  60 
 
Table 5: Staining combination for characterization of murine TILs and splenocytes 
MARKER/FEATURE FLUOROCHROME STAINING 
CD3 APC-Cy7 Cell surface 
CD19 V450 Cell surface 
CD45 PE-Cy7 Cell surface 
PD-1 PerCP-Cy5.5 Cell surface 
Thy1.1 A647 Cell surface 
Viability PI Cell surface 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Gating strategy for characterization of murine TILs and splenocytes. 
CD45+ leukocytes were selected and the T (CD3) and B (CD19) cell composition of viable and 
single cells was determined. CD3+ T cells were analyzed for expression of the transgene Thy1.1 
indicating the transferred T cells. Additionally, the expression of PD-1 was analyzed. 
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6.4.3.4 Characterization of tumor and transduced HEK293 cells 
Table 6A-C: Staining combinations for melanoma, HEK/Tyr and HEK/Tyr/PD-L1 cells 
A 
MARKER/FEATURE FLUOROCHROME STAINING 
HLA-A2 unconjugated Cell surface 
Mouse IgG FITC Cell surface 
Viability 7-AAD Cell surface 
 
B 
MARKER/FEATURE FLUOROCHROME STAINING 
PD-L1 FITC Cell surface 
Viability 7-AAD Cell surface 
 
C 
MARKER/FEATURE FLUOROCHROME STAINING 
Tyrosinase unconjugated Intracellular 
Mouse IgG2a A647 Intracellular 
Viability 7-AAD Cell surface 
 
Table 7A-C: Staining combinations the hepatocellular carcinoma cell line 434. 
A 
MARKER/FEATURE FLUOROCHROME STAINING 
H2-Db PE Cell surface 
Viability 7-AAD Cell surface 
 
B 
MARKER/FEATURE FLUOROCHROME STAINING 
PD-L1 PE Cell surface 
Viability 7-AAD Cell surface 
 
C 
MARKER/FEATURE FLUOROCHROME STAINING 
Large T antigen FITC Cell surface 
Viability 7-AAD Cell surface 
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6.4.4 Staining of phosphorylated signaling proteins 
TCR-T58-transduced, chimeric signaling receptor-electroporated T cells were 
harvested, re-suspended in RPMI basic and 0.2 x 106 cells were transferred into 1 ml 
FACS tubes. The cells were centrifuged and supernatant removed leaving 50 μl in 
the tube. Antibodies to CD45 and CD8 as well as 7-AAD (table 8) were added and 
incubated for 20 minutes at room temperature. Cells were washed with 500 μl RPMI 
basic and stimulated with 0.2 x 106 HEK/Tyr/PD-L1 cells in 200 μl RPMI basic for 30 
minutes at 37°C. The reaction was stopped by adding 400 μl Phosflow Cytofix 
Buffer®. After incubation for 15 minutes at 37°C, cells were centrifuged, re-
suspended in 500 μl Phosflow Perm Buffer III®, incubated for 30 minutes on ice and 
centrifuged again. The cells were washed with 500 μl FACS buffer and the 
supernatant removed leaving 50 μl in the tube. Antibodies to p-ERK and p-RPS6 
were added and incubated for 30 minutes on ice. Cells were washed with 500 μl 
FACS buffer as described above. The samples stained for p-RPS6 were placed on 
ice. An A647-conjugated secondary antibody was added to the samples stained for 
p-ERK, incubated for 30 minutes on ice and then washed with 500 μl FACS buffer. 
The supernatant was removed and the samples acquired at the LSRII. 
 
Figure 6: Gating strategy for melanoma, 434, HEK/Tyr and HEK/Tyr/PD-L1 cells. 
Tumor cells were selected according to their forward and sideward scatter characteristics. 
Expression of HLA-A2, H2-D
b
, PD-L1, tyrosinase and large T antigen was determined in viable and 
single cells. As a negative control unconjugated antibodies were omitted and cells only stained with 
the secondary antibody. Alternatively, cells were stained with antibodies of the same isotype as the 
specific antibody but with an irrelevant binding capacity or the specific antibody was omitted 
(fluorescence minus one). 
 
 
METHODS                                                                                                                                  63 
 
Table 8A-B: Staining combinations for analysis of phosphorylated proteins. 
A 
MARKER/FEATURE FLUOROCHROME STAINING 
CD8 V500 Cell surface 
CD45 PE-Cy7 Cell surface 
p-ERK (pT202/pY204) unconjugated Intracellular 
Rabbit IgG A647 Intracellular 
Viability 7-AAD Cell surface 
 
B 
MARKER/FEATURE FLUOROCHROME STAINING 
CD8 V500 Cell surface 
CD45 PE-Cy7 Cell surface 
p-RPS6 (pS235/236) A647 Intracellular 
Viability 7-AAD Cell surface 
 
 
 
Figure 7: Gating strategy for analysis of ERK and RPS6 phosphorylation. 
CD45+ leukocytes were selected and viable, single CD8+ T cells were analyzed for 
phosphorylation of ERK and RPS6. 
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6.5 Cell sorting 
6.5.1 Principle of cell sorting using FACSAria IIIu 
The cell suspension to be sorted was stained with fluorochrome-conjugated 
antibodies and analyzed for fluorochrome signals (see section 6.4.1 Principle of flow 
cytometry). Once the photons emitted by the fluorochromes have been detected cells 
can be selected according to marker expression. After passing the laser beam cells 
are separated and independently charged. Individual drops then pass an electrical 
field, are attracted to their opposite polarity and collected. 
 
6.5.2 Sorting of T cells from human renal cell carcinoma TILs  
RCC tissue suspensions were transferred into 5 ml tubes, washed with 2 mM EDTA 
(in PBS) and the pellet re-suspended in 30 μl 2 mM EDTA. Tissue suspensions were 
stained with fluorochrome-conjugated antibodies (see table 9), sorted with the 
FACSAria IIIu applying the gating strategy depicted in figure 8 into 1.5 ml tubes 
supplied with TIL medium. CD11c-CD3+/CD3- cells were sorted applying “purity” 
(highest cell yield) or “single cell” (highest purity) mode. Characteristics of used 
fluorochromes, lasers and filters are depicted in table 10. Sorted CD11c-CD3+/- cells 
were centrifuged at 300 g for 10 minutes at room temperature, re-suspended in the 
appropriate medium, counted and used in experiments. 
 
Table 9: Staining combination for sorting CD11c-CD3+/- RCC-TILs 
MARKER/FEATURE FLUOROCHROME STAINING 
CD3 PB Cell surface 
CD11c APC Cell surface 
CD45 PE-Cy7 Cell surface 
Viability APC-Cy7 (“Near IR”) Cell surface 
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Table 10: Characteristics of used fluorochromes, lasers and filters for detection at the FACSAria IIIu. 
FLUORO-
CHROME 
EXCITATION 
MAXIMUM 
(NM) 
EMISSION 
MAXIMUM 
(NM) 
LASER LASER 
WAVE-
LENGTH 
(NM) 
DETECTION 
FILTER (NM) 
APC 650 660 Red 
laser 
633 660/20 
Near IR 
fluorescence 
reactive dye 
750 775 Red 
laser 
633 780/60 
PB 401 452 Violet 
laser 
405 450/40 
PE-Cy7 496 785 Blue 
laser 
561 780/60 
     
APC: Allophycocyanin   PB: Pacific blue   
PE-Cy7: Phycoerythrin – Cyanine 7   
 
 
 
 
 
 
 
 
Figure 8: Gating strategy for sorting CD11c-CD3+/- RCC-TILs. 
CD45+ leukocytes were selected and viable, single CD11c-CD3+/- cells were sorted. 
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6.6 Mouse models 
The animal experiments were approved by the local authorities according to the legal 
regulations for animal experiments. 
 
6.6.1 Human melanoma xenograft NSG model 
To select optimal experimental settings, 2 x 106 HLA-A2+ tyrosinase+ human 
melanoma cells SK-Mel23 were injected s.c. into age-matched 9 weeks old, female 
mice. When tumors were palpable, 2 x 106 TCR-D115 T cells were injected in 200 μl 
PBS i.v. per mouse. Blood, lungs, spleens and tumors were isolated and cell 
suspensions obtained as described in section 6.6.1.1-2. 
For assessing the impact of PD-1:28tm expression on T cell performance in vivo, age-
matched, 7-11 weeks old, male mice were injected s.c. with 5 x 106 HLA-A2+ 
tyrosinase+ human melanoma cells SK-Mel23. TCR-D115 and TCR-D115/PD-1:28tm 
T cells were labeled with 0.15 μM CFDA-SE for 8 minutes at 37°C. The reaction was 
stopped with FCS and cells were washed twice with PBS. Intracellular esterases 
remove acetate groups of CFDA-SE and thereby convert it to the fluorescent 
carboxyfluorescein succinimidyl ester (CFSE). With each cell division the 
fluorescence intensity of CFSE is halved allowing monitoring of T cell proliferation. 
When tumors reached a size of 802 mm3 (SEM = 83), 6 x 106 CFSE labeled TCR- 
D115 or TCR-D115/PD-1:28tm T cells were injected in 50 μl PBS per mouse i.t.. 
Tumors were harvested 4 hours, 1, 2, 4, 6 and 10 days after ATT and single cell 
suspensions were prepared for flow cytometry analysis. 
For studying the effect of PD-1:28tm expression on tumor size, age-matched, 12 
weeks old, male mice were injected s.c. with 5 x 106 HLA-A2+ tyrosinase+ human 
melanoma cells SK-Mel23. When tumors were palpable (mean = 78 mm3, SEM = 5), 
6 x 106 TCR-D115 or TCR-D115/PD-1:28tm or TCR-T58 or TCR-T58/PD-1:28tm 
T cells (n = 4 mice per group) or PBS (n = 3 mice) were injected in 50 μl PBS per 
mouse i.t.. Tumor size (mm3) was calculated using the formula for determining 
ellipsoid volumes: π/6 x length + width + height.   
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6.6.1.1 Isolation of adoptively transferred T cells from murine lung, 
spleen and blood  
Mice were sacrificed, spleens and lungs isolated and dispersed through a 40 μm filter 
with the plunger of a 10 ml syringe into a 50 ml tube. The filter was rinsed twice with 
RPMI-1640 and the cells centrifuged at 472 g for 5 minutes at room temperature. The 
cell pellet was re-suspended in 2 ml erythrocyte lysis buffer and incubated for 2 
minutes at room temperature. Adding 20 ml of PBS stopped the lysis reaction. Cells 
were centrifuged as before, washed once with PBS, counted and analyzed by flow 
cytometry. 
Blood samples were taken by cardiac puncture of sacrificed mice with 26G needles 
and heparin-rinsed syringes. Blood samples were centrifuged at 472 g for 5 minutes 
at room temperature and the cell pellet re-suspended in 3 ml erythrocyte lysis buffer. 
After incubation for 5 minutes at room temperature, 20 ml of PBS were added and 
centrifuged as before. Cells were washed once with PBS, counted and analyzed by 
flow cytometry. 
 
6.6.1.2 Isolation of TILs from melanoma xenografts grown in NSG mice  
Mice were sacrificed, s.c. grown tumors isolated, placed in a Petri dish and cut to 
small pieces using scalpel and scissors. Tumor pieces were transferred to a 50 ml 
tube, filled up to 20 ml with HBSS (containing Ca2+, Mg2+) and centrifuged at 472 g 
for 2 minutes at room temperature. The supernatant was placed on ice and the pellet 
re-suspended in digestion buffer at 1 ml buffer/ml pellet and incubated for 30 minutes 
on a shaker at room temperature. The suspension was centrifuged at 472 g for 5 
minutes at room temperature, the supernatant placed on ice and the pellet washed 
with HBSS without Ca2+ and Mg2+. The supernatant was placed on ice and the pellet 
re-suspended in 5 mM EDTA in HBSS without Ca2+ and Mg2+ (6 ml/ml tissue pellet). 
After incubation for 5 minutes on a shaker at room temperature, the suspension was 
centrifuged as before, the supernatant placed on ice and the pellet dispersed through 
a 40 μm filter with the plunger of a 10 ml syringe. The filter was rinsed twice with 
HBSS (containing Ca2+, Mg2+). All supernatants were centrifuged at 472 g for 10 
minutes at room temperature, all pellets were pooled, counted and analyzed by flow 
cytometry. 
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6.6.2 Hepatocellular carcinoma model 
Age-matched 6 weeks old, male LoxP-TAg mice were injected with adenovirus 
coding for Cre recombinase (Ad.Cre) to activate the oncogenic process. 11.5 weeks 
after injection, splenocytes were isolated and transduced to express Thy1.1 or 
Thy1.1 plus mPD-1:28tm (Thy1.1/mPD-1:28tm) as described in section 6.6.2.1. 
Recipient mice received radiation (5 Gy) 1 day before ATT. Five x 106 transduced 
splenocytes were injected in 100 μl PBS r.o. into recipient mice (18-27 weeks old, 
male) who had received Ad.Cre 15 weeks before for induction of oncogenesis. 
11 mice received Thy1.1 splenocytes, 12 mice Thy1.1/mPD-1:28tm splenocytes and 
12 mice did not receive ATT. Mice were sacrificed when tumors reached a size of 
1.5 cm. Single cell suspensions of spleens and tumors were prepared as described 
in sections  6.6.1.1 and 6.6.2.2. 
 
6.6.2.1 Isolation, transduction and bead-based sorting of murine 
splenocytes 
The transduction of murine splenocytes comprised a 5 days-lasting protocol with 
day 0 being the day of splenocytes activation. The transduction was performed in a 
laboratory of S2 standard. All centrifugation steps of splenocytes were performed at 
400 g and room temperature for 10 minutes, unless otherwise stated. 
 
Day -2 
The packaging cells PlatE were seeded at 1 x 106 cells in 4 ml mHEK medium/well in 
a tissue culture treated 6-well plate.  
 
Day -1 
18 μg of plasmid coding for the transgenes (Thy1.1 or mPD-1:28tm) and 15 μl of 
sodium chloride were mixed and filled up to a total volume of 150 μl with Milli-Q® 
water. 150 μl of transfection buffer were added dropwise to the DNA-mix and 
incubated for 15 minutes. 
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Day 0 
Six LoxP-TAg mice (15 weeks after Ad.Cre) with multi-nodular HCC were sacrificed, 
spleens removed and dispersed through a 40 μm filter with the plunger of a 10 ml 
syringe into a 50 ml tube. The filter was rinsed twice with RPMI-1640 and the cells 
centrifuged at 472 g for 5 minutes at room temperature. The cell pellet was re-
suspended in 2 ml erythrocyte lysis buffer and incubated for 2 minutes at room 
temperature. Adding 20 ml of PBS stopped the lysis reaction. Cells were centrifuged 
as before, washed once with PBS, re-suspended in MTM supplemented with 
10 IU/ml IL-2, 1 μg/ml anti-CD3 and 0.1 μg/ml anti-CD28 antibodies and seeded at 
0.5 x 106/ml in T125 cm2 culture flasks. 
 
 
Day 1 
Non-tissue culture treated 24-well plates were coated with 12.5 μg/ml RetroNectin® in 
500 μl PBS per well and incubated at 37°C for 30 minutes. RetroNectin® was 
replaced with 2% BSA (in PBS). After incubation for 30 minutes at room temperature 
the plates were washed once with PBS. The virus-containing medium of the PlatE 
cells was harvested, replaced by fresh mHEK and the PlatE cells were placed back 
into the incubator. The virus supernatant was filtered through a 0.45 μm filter and 
added to the RetroNectin® coated plates at 1 ml/well. The plates were centrifuged at 
3000 g and 4°C for 90 minutes.  
Activated splenocytes were harvested and seeded in virus coated plates at 1.8 x 106 
cells in 1 ml per well in MTM supplemented with 10 IU/ml IL-2 and 0.4 x 106 
CD3/CD28 beads/ml. The plates were centrifuged at 800 g and 32°C for 30 minutes. 
Splenocytes were either seeded on plates coated with virus coding for Thy1.1, 
Thy1.1 plus mPD-1:28tm (Thy1.1/mPD-1:28tm, virus supernatants mixed 1+1) or on 
plates coated with virus-free medium (MOCK control). 
 
Day 2 
The virus-containing medium of the PlatE cells was harvested, filtered through a 
0.45 μm filter, supplemented with 10 IU/ml IL-2 and added to splenocytes at 1ml/well. 
The plates were centrifuged at 800 g and 32°C for 30 minutes. After incubation for 6 
hours at 37°C the splenocytes were harvested and seeded at 5 ml/harvested well in 
MTM supplemented with 50 ng/ml IL-15 in T75 cm2 tissue culture flasks. 
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Day 5 
Transduced splenocytes were harvested and Thy1.1 and Thy1.1/mPD-1:28tm cells 
were separated for Thy1.1. Magnetic beads and buffers for separation were cooled 
on ice. Cells were re-suspended in MACS buffer at 93 x 106 cells/ml and passed 
through pre-separation columns to remove cell clumps. Anti-Thy1.1 magnetic beads 
were added to the cells at 1 μl beads/1 x 106 cells and incubated on ice for 20 
minutes. Cells were washed with MACS buffer, re-suspended in MACS buffer at 
1 ml/150 x 106 cells. LS separation columns were placed in the magnetic field of a 
MACS separator, equilibrated with 3 ml MACS buffer and 500 μl of the cell 
suspension were added per column. Columns were rinsed 3 times with 3 ml MACS 
buffer, removed from the separator, placed on a 15 ml collection tube and cells were 
flushed out by pushing a plunger into the column. Cells were centrifuged, re-
suspended in 1 ml MACS buffer and underwent a second separation step.  
The magnetic separation achieved a purity of 81% for Thy1.1 transduced 
splenocytes and 83% of Thy1.1/mPD-1:28tm transduced splenocytes. Splenocytes 
were injected r.o. at 5 x 106 cells in 100 μl PBS per LoxP-TAg mouse. 
 
6.6.2.2 Isolation of TILs from hepatocellular carcinoma grown in LoxP-
TAg mice 
Mice were sacrificed and the liver was rinsed through the vena portae hepatis with 
PBS until it appeared bloodless. The liver tumors were isolated from surrounding 
healthy tissue and dispersed through a 100 μm filter with the plunger of a 10 ml 
syringe into a 50 ml tube. The filter was rinsed twice with RPMI-1640 and the 
suspension centrifuged at 472 g for 10 minutes at room temperature. The 
supernatant was discarded, the pellet re-suspended in 10 ml digestion buffer and 
incubated for 20 minutes in a water bath at 37°C. The suspension was centrifuged as 
before, the supernatant discarded and the pellet re-suspended in 4 ml 40% Percoll 
and layered over 4 ml 80% Percoll in a 15 ml tube. The suspension was centrifuged 
at 800 g without break for 20 minutes at room temperature. The interphase 
containing TILs was transferred to a 15 ml tube, 8 ml of erythrocyte lysis buffer was 
added and the suspension centrifuged at 472 g for 10 minutes at room temperature. 
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The pellet was re-suspended in MTM, counted and used in experiments or analyzed 
by flow cytometry. 
 
6.6.2.3 Co-culture of murine T cells, splenocytes and TILs with target 
cells and stimulation with phorbol-12-myristate-13-acetate and 
ionomycin 
434 cells were detached by trypsination, centrifuged at 472 g for 5 minutes at room 
temperature, re-suspended in MTM and counted.  
TILs and splenocytes were isolated, re-suspended in MTM and counted. They were 
cultivated at 0.1 x 106 cells in 100 μl with 0.1 x 106 434 cells in 100 μl. In addition, 
TILs and splenocytes were stimulated with 50 ng/ml phorbol-12-myristate-13-acetate 
(PMA) and 500 ng/ml ionomycin (I). As a control effector and target cells were 
cultivated alone. Supernatants were harvested after ~ 16 hours.  
Transduced T cells were harvested, re-suspended in MTM and counted. They were 
cultivated at 0.005 x 106 cells in 100 μl with 0.005 x 106 434 cells in 100 μl. As a 
control effector and target cells were cultivated alone. Co-culture supernatants were 
harvested after ~ 24 hours.  
Supernatants were stored at -20 °C until analysis by Bio-Plex or ELISA. 
 
6.7 Statistical analyses 
Statistical tests were performed using Graph Pad Prism 6 software. The significance 
level was set to 0.05. 
The Mann-Whitney U test (Wilcoxon rank sum test) is a nonparametric test for the 
comparison of unpaired groups. 
The Wilcoxon matched-pairs signed rank test is a nonparametric test for the 
comparison of paired groups. 
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7 RESULTS 
7.1 Design and expression of chimeric co-stimulatory receptors  
7.1.1 Design of chimeric co-stimulatory receptors 
The rationale of this dissertation was to develop strategies for endowing T cells with 
the capacity to receive co-stimulation in the tumor environment independent from the 
classical co-stimulatory molecule CD28. As effector T cells are largely CD28 negative 
and the majority of tumors do not express CD80 or CD86, co-stimulation cannot be 
mediated through a classical CD28/CD80 or CD28/CD86 interaction in the tumor 
environment. Therefore, the intracellular signaling domain of a co-stimulatory 
molecule, CD28 or 4-1BB, was joined with an extracellular protein domain whose 
ligand is present in the tumor environment. A protein commonly expressed by a 
variety of tumor entities is PD-L1 (57). The receptor of PD-L1 is PD-1. The 
physiological PD-1/PD-L1 interaction results in an inhibitory signal. A chimeric co-
stimulatory receptor consisting of the extracellular domain of PD-1 and the 
intracellular domain of CD28 or 4-1BB may possibly support T cells not only by 
facilitating co-stimulation but also by alleviating the native inhibitory PD-1 signal 
through ligand competition. Different receptors were designed and compared for 
surface expression and function (figure 9). The PD-1:8tm:28 receptor encompasses 
the entire extracellular domain of PD-1 (amino acids (AA) 1-170) followed by the 
CD8 sequence encoding the membrane proximal extracellular region, the complete 
transmembrane and the membrane proximal intracellular region (AA 128-210). The 
domain derived from CD8 was meant to function as a hinge region to improve 
flexibility and ligand binding of the intended chimeric protein. The PD-1:8 sequence 
was followed by the sequence coding for the entire intracellular domain of CD28 
(AA 180-220) encompassing the signaling motifs YMNM, PRRP and PYAP.  
The PD-1:cys28tm chimeric receptor was adapted from a publication by Prosser et al. 
(62). Here, the extracellular sequence of PD-1 (AA 1-155) was followed by the 
sequence of CD28 encoding AA 141-220 of CD28 including a section of the 
extracellular and the complete transmembrane and intracellular domains of CD28. 
The CD28 sequence included the cysteine residue at position 141, which may be 
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important to allow dimerization of the PD-1:cys28tm receptor as it is seen for the 
native CD28 protein (62). The native PD-1 is a monomeric receptor and thus, the 
chimeric PD-1:28 receptor is unlikely to dimerize if the CD28 encoded extracellular 
cysteine is absent.  
The PD-1:28tm receptor was adapted from Ankri et al. (63). The extracellular 
sequence spanning AA 1-165 of PD-1 was followed by the sequence encoding the 
complete transmembrane and intracellular domains of CD28. In contrast to PD-
1:cys28tm the extracellular cysteine from CD28 is absent.   
The PD-1trunc receptor encodes for the extracellular and transmembrane domains of 
PD-1 and lacks any intracellular signaling domain; thus, no signal transduction will 
occur. This allows determining whether alleviating the inhibitory signaling of the 
native PD-1 will have an impact on the anti-tumor T cell function.  
In addition to the CD28 co-stimulatory domain the co-stimulatory domain of 4-1BB 
was chosen as it has been proposed that the 4-1BB signaling cascade is particularly 
effective to support secondary T cell responses (64). The PD-1:BBtm receptor 
contains the same extracellular domain as PD-1:28tm, i.e. AA 1-165 of PD-1, yet 
joined to the transmembrane and intracellular domains (AA 187-255) of 4-1BB, 
including the signaling motif QEE.  
Moreover, a PD-1tm:BB was designed using the extracellular plus transmembrane 
sequences of PD-1 (AA 171-191) and only the intracellular domain of 4-1BB (AA 
214-255). 
 
 
 
 
 
 
 
 
 
 
 
 
 
PD-1:28tm	
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Figure 9: Design of chimeric co-stimulatory receptors. 
The amino acids (AA) correspond to the respective parental proteins. Abbreviations are: EXD for 
extracellular, TMD for transmembrane and ICD for intracellular domains.  
Domains derived from PD-1 are depicted in orange, from CD8 (=8) in blue, from CD28 (=28) in 
green and from 4-1BB (=BB) in red. The abbreviation “tm” in the receptors’ names indicates the 
use of the TMD of CD8, PD-1 and 4-1BB, respectively. 
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7.1.2 Expression of chimeric receptors 
To determine whether T cells can express the chimeric receptors, human activated 
T cells were electroporated with ivt-RNA coding for the receptors. Four, 24 and 48 
hours after electroporation T cells were analyzed for surface expression of chimeric 
receptors by flow cytometry using an anti-PD-1 antibody recognizing the extracellular 
domain of PD-1. Alive, single, CD3+ CD8+ or CD3+ CD4+ T cells were gated and 
analyzed for the percentage of T cells expressing the chimeric receptor. The intensity 
of receptor expression was deduced from the median fluorescence intensity (median 
FI). As depicted in table 11 and figure 10, 4 hours after electroporation, the PD-
1trunc receptor was most efficiently expressed in terms of both percentage of 
positive cells and the median FI. At 4 hours after electroporation, there was no 
significant difference in percentage of T cells expressing PD-1trunc and both PD-
1:cys28tm and PD-1:28tm. In contrast, the PD-1:8tm:28 receptor containing the 
transmembrane domain of CD8 showed significantly lower surface expression 
compared to PD-1trunc (p < 0.01), PD-1:cys28tm or PD-1:28tm (both p < 0.05). The 
PD-1:BBtm receptor was expressed on significantly less cells and with lower intensity 
compared to PD-1:28tm (p < 0.05), PD-1:cys28tm or PD-1trunc (p < 0.01). The pattern 
was similar for CD8+ and CD4+ T cells. 
 
Table 11: Percentages of surface PD-1 positive cells and median FI of PD-1 (mean ± SEM) 4 hours 
after electroporation. 
 CD8+ T cells CD4+ T cells 
%+ median FI %+ median FI 
PD-1trunc 83 ± 3 9692 ± 1584 80 ± 3 7450 ± 1251 
PD-1:cys28tm 77 ± 3 4951 ± 1216 71 ± 2 3960 ± 888 
PD-1:28tm 70 ± 6 3276 ± 904 60 ± 5 2300 ± 604 
PD-1:8tm:28 43 ± 3 1146 ± 364 33 ± 3 900 ± 298 
PD-1:BBtm 41 ± 5 1058 ± 231 32 ± 5 317 ± 84 
 
Concerning the kinetics of surface expression over 48 hours (figure 10), it was 
observed that PD-1trunc, PD-1:cys28tm, PD-1:28tm and PD-1:8tm:28 stayed stable for 
24 hours regarding the percentage of positive cells, while  the median FI decreased 
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on both CD8+ and CD4+ T cells. Compared to the other receptors, the PD-1:BBtm 
construct was the only one not expressed beyond 24 hours. 
 
 
 
 
To explore whether the observed differences in surface expression between the 
receptors were due to differences in base-pair-lengths of the constructs, all receptors 
were tested at equimolarity of electroporated ivt-RNA. The previously used 20 µg of 
ivt-RNA amounted to molar concentrations of 97 pmol for PD-1trunc, 83 pmol for   
PD-1:cys28tm and PD-1:BBtm, 84 pmol for PD-1:28tm and 66 pmol for PD-1:8tm:28. 
Three equimolar conditions (67, 96 and 146 pmol) were tested. As depicted in figure 
11, the differences in receptor surface detection remained with lower percentages of 
positive cells for PD-1:8tm:28 and PD-1:BBtm. Moreover, the percentage of positive 
 
Figure 10: Expression of chimeric co-stimulatory receptors.  
(A-C) Human PBMCs were activated with anti-CD3 plus anti-CD28 antibodies and 100 U/ml IL-2 
for 2 days, expanded for 14 days and electroporated with 20 g ivt-RNA coding for the chimeric 
receptors. Surface expression was detected by flow cytometry 4, 24 and 48 hours (A-B) after 
electroporation. The percentages of chimeric receptor positive cells (A) and the median FI (B) of 
receptors among alive, single, CD3+, CD8+ or CD4+ T cells are shown. Water electroporated 
T cells served as a control. Depicted is the mean + SEM of (n) numbers of independent 
experiments. 
(C) Exemplary histogram showing receptor expression in alive, single, CD3+, CD8+ T cells 4 hours 
after electroporation. 
Wilcoxon matched-pairs signed rank test, * p  0.05  ** p  0.01 
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T cells was similar across the concentration range tested while the median Fl slightly 
increased with increasing concentrations (not significant).  
 
 
 
 
In a next step it was tested whether the differences in surface presence were due to 
lower translation or intracellular retention of chimeric proteins. Therefore, T cells were 
stained for chimeric receptors on the cell surface and intracellularly. As shown in 
figure 12, there was no difference in the percentage of positive cells between cells 
that were surface stained and cells that were stained after cell permeabilization 
detecting surface plus intracellular receptor expression. Thus, the observed 
differences in surface expression were not caused by impaired trafficking of the 
chimeric proteins to the cell surface. 
 
Figure 11: Expression of chimeric co-stimulatory receptors.  
Human activated T cells (see figure legend 10) were electroporated with different concentration of 
ivt-RNA (67, 96 and 146 pmol) coding for the chimeric receptors. The percentages of PD-1 positive 
cells (A) and the median FI (B) of PD-1 among alive, single, CD3+, CD8+ or CD4+ T cells 4 hours 
after electroporation are shown. Water electroporated cells served as a control. Depicted is the 
mean of indicated (n) number of experiments + SEM. 
n.s. not significant, Wilcoxon matched-pairs signed rank test 
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The percentage of receptor positive T cells and the median FI of PD-1:8tm:28 and 
PD-1:BBtm remained low when stained intracellularly. Thus, no intracellular pool of 
receptors seemed to exist. 
 
 
 
To assess if the weak expression of PD-1:BBtm compared to PD-1trunc and          
PD-1:28tm is due to transient expression from ivt-RNA, chimeric co-stimulatory 
receptor sequences were cloned into the pMP71 vector for retroviral transduction. 
Retroviral transduction leads to integration of transferred DNA into the cell’s genome. 
This process should result in stable expression of the transduced sequences. T cells 
were stained with anti-PD-1 antibodies to detect chimeric receptor surface 
expression 13-15 days after transduction. As depicted in figure 13, expression 
profiles of chimeric co-stimulatory receptors after transduction were similar to those 
observed after electroporation and the transduced PD-1:BBtm construct was still 
significantly less expressed compared to PD-1trunc and PD-1:28tm (p < 0.05).  
 
Figure 12: Expression of chimeric co-stimulatory receptors.  
Human activated T cells (see figure legend 10) were electroporated with 20 g of ivt-RNA coding 
for the chimeric receptors. The percentages of PD-1 positive cells among alive, single, CD3+, 
CD8+ or CD4+ T cells 4 hours after electroporation are shown. Water electroporated cells served 
as a control. Depicted is the mean of indicated (n) number of experiments + SEM. 
n.s. not significant, Wilcoxon matched-pairs signed rank test 
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Figure 13: Expression of chimeric co-stimulatory receptors after electroporation and 
transduction.  
Human activated T cells (see figure legend 10) were transduced with chimeric receptors (black 
bars) or expanded for 14 days and electroporated with 20 g ivt-RNA coding for the chimeric 
receptors (white bars). Surface expression of PD-1 was detected by flow cytometry 13-15 days 
after transduction or 4 hours after electroporation, respectively. The percentages of PD-1 positive 
cells among alive, single, CD3+, CD8+ (A) or CD4+ T cells (B) are shown. MOCK-transduced and 
water electroporated cells served as a control. Depicted is the mean of indicated (n) number of 
experiments + SEM. 
* Wilcoxon matched-pairs signed rank test, p < 0.05 
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As all receptors containing the PD-1- or CD28-derived transmembrane domain were 
more efficient and more stably expressed compared to those with CD8- or 4-1BB- 
transmembrane domains, a PD-1:BB receptor was designed using the 
transmembrane domain of PD-1 (PD-1tm:BB). After electroporation, PD-1tm:BB was 
expressed by more CD8+ and CD4+ T cells compared to PD-1:BBtm (p < 0.05, figure 
14) and the median FI of electroporated PD-1tm:BB T cells was also higher compared 
to PD-1:BBtm in both CD8+ and CD4+ T cells (difference reached significance for 
CD4+ T cells).  
 
 
 
 
 
 
 
Figure 14: Surface expression of different PD-1:BB chimeric receptors.  
Human activated T cells (see figure legend 10) were electroporated with ivt-RNA coding for the 
indicated chimeric receptors. Surface expression of PD-1 was detected by flow cytometry 4 hours 
after electroporation. The percentages of PD-1 positive cells (A) and the median FI (B) of PD-1 
among alive, single, CD3+, CD8+ or CD4+ T cells are shown. Water electroporated cells served as 
a control. Depicted is the mean of indicated (n) number of experiments + SEM. 
* Wilcoxon matched-pairs signed rank test, p < 0.05 
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7.2 PD-1:28tm- and PD-1:cys28tm-engineering of T cells enhanced 
TCR-mediated IL-2 and IFN-γ secretion 
To analyze the effect of the chimeric receptors on T cell function, TCR-induced 
cytokine secretion of human T cells was analyzed. In a first step, human T cells were 
transduced to stably express the HLA-A2-restricted tyrosinase-specific TCR-T58 or 
TCR-D115 (65). In a second step, chimeric co-stimulatory receptors were 
electroporated into T cells stably expressing the transduced TCR. Expression of 
chimeric co-stimulatory receptors and TCRs is shown in figure 15A. Chimeric 
receptor expression was similar for TCR-T58 and -D115 T cells.  
 
For T cell stimulation 2 target cells were used: HLA-A2+ HEK293 cells retrovirally 
transduced to stably express either the target antigen tyrosinase alone (HEK/Tyr) or 
HLA-A2+ HEK293 expressing tyrosinase and the PD-1 ligand, PD-L1 (HEK/Tyr/PD-
L1). The transduced HEK293 cells were derived from single cell clones and selected 
for comparable HLA-A2 and tyrosinase expression (figure 15B). Stimulation with 
HEK/Tyr will elicit a TCR signal only, whereas stimulation with HEK/Tyr/PD-L1 
induces the TCR plus a co-stimulatory signal if the T cells express a chimeric 
receptor. The proposed experimental outcome of co-culture was that T cells without 
chimeric receptors should secrete a similar amount of cytokines independent of the 
stimulator cell. T cells expressing a chimeric receptor could receive co-stimulation 
when stimulated with HEK/Tyr/PD-L1 and might secrete more cytokines compared to 
stimulation with HEK/Tyr.  
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To test this hypothesis, T cells and target cells were co-cultured at ratio of 1:2 for 24 
hours and co-culture supernatants were analyzed for secreted IL-2 and IFN-γ.  
As the percentages of TCR+ T cells varied between transductions (ranging from 28-
97%) and the TCRs are functional in CD8+ T cells only, the amount of cytokine 
produced in each experiment was normalized to similar number (25.000) of 
TCR+CD8+ T cells, which was determined by flow cytometry before each 
experiment. As depicted in figure 16, TCR-T58- or TCR-D115 T cells electroporated 
with water secreted similar amounts of cytokines when stimulated with HEK/Tyr or 
HEK/Tyr/PD-L1 cells, as expected. TCR-T58 and TCR-D115 T cells expressing the 
chimeric receptors PD-1:28tm or PD-1:cys28tm secreted more IL-2 and IFN-γ when 
stimulated with HEK/Tyr/PD-L1 compared to stimulation with HEK/Tyr. The p-value 
was significant for PD-1:28tm with an observed increase of IL-2 secretion from 1.3 
ng/ml to 7.2 ng/ml for TCR-T58 T cells and from 0.08 ng/ml to 1.3 ng/ml for TCR-
 
 
Figure 15: Characteristics of T cells and target cells used for co-culture experiments. 
(A) Human PBMCs were activated with anti-CD3 plus anti-CD28 antibodies and 100 U/ml IL-2 for 2 
days, then retrovirally transduced with the tyrosinase-specific TCRs T58 or D115, respectively, and 
expanded for another 13-15 days. Thereafter, they were electroporated with 20 μg ivt-RNA coding 
for the chimeric receptors. Dot blots showing TCR and chimeric receptor expression in alive, single, 
CD3+, CD8+ T cells 4 hours after electroporation.  
(B) Histograms showing HLA-A2, tyrosinase and PD-L1 expression in live, single HEK/Tyr and    
HEK/Tyr/PD-L1 cells. The black line histograms show the specific antibody staining and the gray 
filled histograms depict the control staining. Median fluorescence intensity (FI) values of the specific 
antibody staining are shown. 
 
 
RESULTS                                                                                                                               82 
D115 T cells. The amount of secreted IFN-γ significantly increased from 47.2 ng/ml 
to 81.3 ng/ml (TCR-T58 T cells) and from 10.1 ng/ml to 28.9 ng/ml (TCR-D115 
T cells). These results provide evidence that chimeric PD-1:28 receptors can indeed 
enhance T cell cytokine secretion. 
 
 
Figure 16: Effect of chimeric receptor expression on TCR-induced cytokine secretion. 
TCR-T58- (A) or TCR-D115-transduced (B) and chimeric receptor-electroporated T cells (see figure 
legend 15) were stimulated with HEK/Tyr or HEK/Tyr/PD-L1 cells. Co-culture supernatants were 
harvested after 16 hours and analyzed for cytokine content. Depicted is the amount of IL-2 and   
IFN-γ secreted by 25.000 CD8+TCR+ T cells (mean of indicated number (n) of experiments + 
SEM). 
* Wilcoxon matched-pairs signed rank test, p < 0.05 
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The PD-1:28 chimeric receptor containing the transmembrane domain of CD8α 
showed no effect on IL-2 and IFN-γ production, for both TCRs tested. Since the other 
receptors with the CD28 signaling domain increased cytokine secretion, it can be 
speculated that the lack of an effect of PD-1:8tm:28 was due to low surface 
expression. 
No effects were seen with the PD-1:BB receptors. That the 4-1BB co-stimulatory 
domain had no impact on T cells in this experimental system could be due to low 
receptor expression as seen for PD-1:8tm:28. 
The expression of the truncated PD-1 receptor did not improve cytokine secretion of 
TCR-T58-transduced T cells when stimulated with HEK/Tyr/PD-L1. While, TCR-
D115/PD-1trunc T cells secreted more cytokine under the same stimulation 
condition. As for an explanation, it was considered that the truncated PD-1 receptor, 
which has no signaling domain, might alleviate inhibitory effects mediated by the 
native PD-1 protein that is up-regulated during T cell stimulation. Indeed, TCR-T58 
and TCR-D115 T cells up-regulated native PD-1 after stimulation to a similar extent 
(figure 17). As to why a benefit of PD-1trunc was observed only for TCR-D115 T cells 
might lie in the strength of the TCR signaling initiated from low- versus high-avidity 
TCRs, respectively  (see section 7.4). 
 
 
 
 
Figure 17: Expression of native PD-1 on TCR-T58 and TCR-D115 T cells after stimulation 
with target cells. 
TCR-T58 or TCR-D115 T cells (see figure legend 15) were stimulated for 16 hours with HEK/Tyr 
cells and surface expression of PD-1 was detected by flow cytometry. Scatter dot blots showing 
the median FI of PD-1 in CD45+, alive and single cells not stimulated (-) or stimulated with target 
cells (+). Bars indicate the mean values. 
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To provide evidence that the enhanced cytokine secretion of PD-1:28tm-engineered 
T cells was due to PD-1:28tm expression, blocking antibodies to PD-1 and PD-L1 
were added to the co-culture. In presence of the blocking antibodies, the cytokine 
amounts in co-cultures with HEK/Tyr/PD-L1 cells were similar to those with HEK/Tyr 
cells (figure 18) indicating that the supporting effect was due to PD-1:28tm/PD-L1 
interaction. 
 
 
7.3 Ligation of PD-1:28tm and PD-1:cys28tm chimeric receptors 
increased TCR-mediated phosphorylation of extracellular 
signal regulated kinase and ribosomal protein S6 
The observation that PD-1:28tm and PD-1:cys28tm expression by T cells enhanced 
TCR-mediated cytokine secretion led to the investigation of the underlying 
mechanism. To this end, TCR-T58-transduced T cells were electroporated with 
chimeric receptor ivt-RNA, stimulated with HEK/Tyr/PD-L1 cells and the 
phosphorylation of extracellular signal regulated kinase (ERK) and ribosomal protein 
S6 (RPS6), which are downstream targets of the CD28 and TCR signaling cascade, 
were analyzed by intracellular phospho-flow cytometry. The percentages of T cells 
with phosphorylated ERK and RPS6 were determined in CD8+ T cells, as the TCR-
T58 is only functional in CD8+ T cells. For analysis of ERK activation, the intensity of 
 
Figure 18: Effect of PD-1/PD-L1 blocking antibodies on IL-2 and IFN- secretion. 
TCR-T58-transduced T cells (see figure legend 15) were electroporated with 20 μg ivt-RNA 
encoding for the chimeric receptor PD-1:28
tm
. T cells were co-cultured with HEK/Tyr or 
HEK/Tyr/PD-L1 cells with (w) or without (w/o) blocking antibodies (AB) to PD-1 and PD-L1. Co-
culture supernatants were harvested after 16 hours and analyzed for IL-2 (A) and IFN- (B) 
content. Depicted is the amount of cytokine secreted by 25.000 CD8+T58+ T cells (mean + SEM, 
n = 3). 
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phosphorylated ERK (p-ERK) was additionally considered and used to derive a 
phospho index, which is defined as the percentage of p-ERK positive cells multiplied 
by the median fluorescence intensity of p-ERK positive cells. 
As shown in figure 19, phosphorylation of both ERK and RPS6 was enhanced in PD-
1:28tm T cells and PD-1:cys28tm T cells (yet significance was not reached as analyzed 
by Wilcoxon matched-pairs signed rank test). Compared to water electroporated 
cells, the phosphorylation of ERK was increased 4.4-fold in PD-1:28tm T cells and 
43% stained positive for p-RPS6 compared to 33% of the water control. 
For T cells expressing PD-1:cys28tm p-ERK increased 5.5-fold and 38% of T cells 
stained positive for p-RPS6. 
Phosphorylation of ERK and RPS6 was not increased in PD-1trunc T cells when they 
were stimulated with HEK/Tyr/PD-L1 cells suggesting that the effect seen with the 
PD-1:28 receptors was due to the CD28 signaling domain. 
 
 
Figure 19: Effect of chimeric receptors on phosphorylation of ERK (pT202/Y204) and RPS6 
(pS235/236). 
TCR-T58 T cells (see figure legend 15) were electroporated with 20 μg ivt-RNA coding for the 
chimeric receptors.  
(A-D) T cells were stimulated with HEK/Tyr/PD-L1 cells. Phosphorylation of ERK and RPS6 was 
analyzed by intracellular phospho-flow cytometry.  
(A) X-fold change of the ERK phospho index of CD8+ TCR-T58 T cells. ERK phospho index is 
defined as the percentage of p-ERK positive cells among CD8+ T cells multiplied by the MFI of p-
ERK positive cells (mean + SEM, n = 4). 
(B) Percentage of p-RPS6 positive CD8+ T cells in unstimulated (white bars) and HEK/Tyr/PD-L1 
stimulated (grey bars) cells (mean, n = 2).  
(C, D) Dot blots showing CD8 and p-ERK or p-RPS6 fluorescence intensity of T cells 
electroporated with water or chimeric receptor, either not stimulated or stimulated with 
HEK/Tyr/PD-L1 cells. Phosphorylation occurred in CD8+ T cells only, as the transgenic TCR is not 
functional in CD4+ T cells.  
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7.4 PD-1:28 receptors upgraded low-avidity T cells to approximate 
the cytokine response of high-avidity T cells 
The TCRs T58 and D115 recognize the same tyrosinase epitope (AA 366-377) 
restricted by HLA-A*0201 but are of different affinity: TCR-T58 T cells showed a half 
maximal IFN-γ response at a tyrosinase peptide concentration of 10-9 M. TCR-D115 
T cells required a peptide concentration of 10-7 M to induce the half maximal IFN-γ 
response (65). High-avidity T cells are considered superior in the anti-tumor 
response as in clinical trials adoptive therapy with high-avidity T cells yielded higher 
response rates compared to low-avidity T cells (59). However, high-avidity T cells are 
more likely to be tolerized in the tumor environment and to acquire negative 
regulatory functions (59). If the performance of low-avidity T cells can be improved 
their use in adoptive therapy might be advantageous.  
Comparing the low-avidity TCR-D115 with its high-avidity counterpart TCR-T58 
revealed that TCR-D115 T cells secreted significantly less IL-2 and IFN-γ (p < 0.05, 
figure 20) than TCR-T58 T cells when stimulated with the same target cell 
HEK/Tyr/PD-L1, despite similar levels of TCR expression (TCR-T58 T cells produced 
on average 1.3 ng/ml IL-2 and 39.4 ng/ml IFN-γ while TCR-D115 T cells 0.036 ng/ml 
IL-2 and 4 ng/ml IFN-γ). To determine whether chimeric PD-1:28 receptors will 
improve the function of low-avidity T cells, TCR-D115 T cells were engineered with 
PD-1:28tm and PD-1:cys28tm and stimulated with HEK/Tyr/PD-L1 cells. The cytokine 
secretion was compared to that of the high-avidity TCR-T58 T cells stimulated with 
the same target cell. TCR-D115 T cells expressing PD-1:28tm or PD-1:cys28tm 
secreted levels of IL-2 and IFN-γ close to those of the high-avidity TCR-T58 T cells. 
Thus, PD-1:28 receptors can approximate the response of low-avidity T cells to high-
avidity T cells. 
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Figure 20: Effect of chimeric PD-1:28 receptors on cytokine secretion of high- and low-avidity 
T cells. 
TCR-T58 or TCR-D115 T cells (see figure legend 15) were electroporated with 20 μg ivt-RNA 
coding for the chimeric receptors.  
(A-B) T cells were stimulated with HEK/Tyr/PD-L1 cells. Co-culture supernatants were harvested 
after 16 hours and analyzed for IL-2 (A) and IFN- (B) content. Depicted is the amount of cytokine 
secreted by 25.000 CD8+TCR-T58+ or CD8+TCR-D115+ T cells (mean ng/ml of indicated number 
(n) of experiments + SEM). 
* Wilcoxon matched-pairs signed rank test, p < 0.05 
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7.5 PD-1:28 receptors had no effect on tumor cell lysis 
Besides cytokine secretion cytotoxicity is an important effector function for the anti-
tumor response. As PD-1:28tm showed a beneficial effect on cytokine secretion and 
phosphorylation of ERK the effect on cytotoxicity was analyzed. TCR-T58- and TCR-
D115-transduced T cells with or without PD-1:28tm were tested against 51Cr-labeled 
HEK/Tyr/PD-L1 cells at various effector to target cell ratios (figure 21). The observed 
lytic activity against HEK/Tyr/PD-L1 was overall similar with a marginal higher activity 
for T cells expressing PD-1:28tm.  
 
 
 
That PD-1:28tm did not significantly enhance lysis of target cells in vitro cannot 
exclude its potency to support tumor eradication. As shown by Milone et al. 2009 
(32), although the CD19-directed CAR utilizing the 4-1BB signaling domain did not 
show a greater impact on T cell function than a CD19-CAR using CD3ζ, the 4-1BB 
CD19-CAR showed superior anti-leukemic effect in vivo.  
 
 
 
Figure 21: PD-1:28
tm 
did not affect tumor cell lysis. 
TCR-T58 (A) and TCR-D115 (B) T cells (see figure legend 15) were retrovirally transduced with 
PD-1:28
tm
 and expanded for 14 days. They were used as effector cells against 
51
Cr-labelled 
HEK/Tyr/PD-L1 cells at depicted effector:target cell ratios. Target cell lysis was assessed by 
detecting released 
51
Cr after 4h co-culture. Shown a mean values of indicated number (n) of 
experiments + SEM. 
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7.6 PD-1:28tm reinstated IFN-γ secretion in unresponsive tumor-
infiltrating lymphocytes from human renal cell carcinoma 
It was previously shown that tumor-infiltrating lymphocytes (TILs) isolated from 
human renal cell carcinoma (RCC) samples showed deficits in degranulation and 
IFN-γ secretion, in part due to insufficient activation of signaling molecules AKT, ERK 
and JNK (48). The deficits were reversible ex vivo, but required treatment with IL-2 or 
diacylglycerol kinase-α (DGK-α) inhibitor (48). As CD28 co-stimulation fosters 
activation of intracellular signaling molecules, including AKT, ERK and JNK, I thought 
to determine whether co-stimulation through PD-1:28tm can restore functionality in 
unresponsive TILs. To this end, sorted CD11c-CD3+/- TILs from human RCC tissues 
were electroporated with PD-1:28tm or water. PBMCs from healthy donors were 
analyzed in parallel. TILs and PBMCs were stimulated with target cells that 
presented PD-L1. TILs were derived from different patients. Tumor or target cells 
with cognate pMHC were not available. Had they been available, they likely would 
have expressed varied pMHC and PD-L1 levels resulting in different signaling 
strength. This would obscure comparison and evaluation of PD-1:28tm-mediated 
effects. Therefore, a surrogate target cell was used for all TILs and PBMCs. This 
surrogate target was the P815 mastocytoma cell line loaded exogenously with anti-
CD3 antibody and a PD-L1/Fc chimera, which bind to Fc receptors expressed by 
P815 cells.  
As shown in figure 22, TILs electroporated with water did not secrete IFN-γ upon 
stimulation. However, TILs electroporated with PD-1:28tm clearly produced IFN-γ at 
levels comparable to those of PBMCs from healthy donors. This provides evidence 
that stimulation through PD-1:28tm can reinstate functionality in T cells which had lost 
activity in the tumor microenvironment. 
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Figure 22: IFN- secretion of RCC-TILs and PBMCs from healthy donors electroporated with 
PD-1:28
tm
.  
TILs were FACS-sorted from RCC-tissue samples, electroporated with PD-1:28
tm
-ivt-RNA or water 
and stimulated with anti-CD3- plus PD-L1/Fc-loaded P815 cells. PBMCs of healthy donors were 
analyzed in parallel. Co-culture supernatants were harvested after 16 hours and analyzed for  
IFN- content by ELISA. Depicted is the mean + SEM. Each symbol is the IFN- value of a TIL-
population from an individual patient or donor. Lines connect the TILs/PBMCs of one 
patient/donor. * Mann-Whitney U test, p < 0.05 
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7.7 PD-1:28tm expressing T cells showed no aberrant cell 
expansion  
CD28 stimulation can support T cell proliferation (5) and the super-agonistic anti-
CD28 antibody TGN1412 led to hyperproliferation and cytokine storm in a phase I 
clinical trial (66). To assess the impact of PD-1:28 on T cell proliferation independent 
of TCR stimulation, T cells were transduced to stably express the PD-1:28tm receptor, 
which had shown the strongest effects in previous assays. PD-1:28tm T cells were 
expanded for 13-15 days and the increase in cell number was determined. As 
depicted in figure 23A, T cells expressing PD-1:28tm did not proliferate more than not-
transduced T cells.  
In addition to overall population expansion it was also determined whether the 
percentage of PD-1:28tm+ T cells in the population changed over expansion time. 
Therefore, the PD-1:28tm+ fraction was determined by flow cytometry using anti-PD-1 
antibody. The percentage of PD-1:28tm expressing cells did not change during 
expansion indicating that PD-1:28tm expression did not lead to preferential 
proliferation of PD-1:28tm+ cells (figure 23B). 
 
 
 
 
Figure 23: Effect of PD-1:28
tm
 on T cell proliferation. 
Human PBMCs were activated with anti-CD3 plus anti-CD28 antibodies and 100 U/ml IL-2 for two 
days, retrovirally transduced with PD-1:28
tm
 or left untransduced and expanded for 13-15 days.  
(A) Cell numbers were determined at day 2 and 13-15 by counting live cells in trypan-blue 
solution. X-fold expansion was calculated as cell number counted on day 13-15 divided by the 
number counted on day 2. Depicted is the mean of indicated (n) number of experiments + SEM. 
(B) Expression of chimeric receptor was detected by flow cytometry 3 and 10-12 days after 
transduction. The percentages of PD-1 positive cells among alive, single, CD3+, CD8+ and CD4+ 
T cells are shown. MOCK transduced cells served as a control. Depicted is the mean of indicated 
(n) number of experiments + SEM 
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7.8 PD-1:28tm expression enhanced T cell proliferation in the 
microenvironment of a human melanoma xenograft  
To study the effect of PD-1:28tm expression on T cells in vivo, a human melanoma 
xenograft mouse model was chosen, which involved the NSG mice carrying 
vascularized subcutaneous human melanoma tumors. 
To select a melanoma cell line for the subcutaneous xenograft, 4 melanoma cell 
lines, FM3, FM55, FM86 and SK-Mel23, were compared for HLA-A2, tyrosinase and 
PD-L1 expression (figure 24A). FM3 had the lowest tyrosinase expression and 
evoked the lowest cytokine response by TCR-D115 and TCR-D115/PD-1:28tm 
T cells. SK-Mel23 evoked the strongest IL-2 response (figure 24B) by TCR-D115 and      
D115/PD-1:28tm T cells and was, therefore, chosen to be injected into NSG mice. 
The cytokine response of TCR-D115/PD-1:28tm T cells was higher compared to that 
of TCR-D115 T cells indicating that tumor cell-expressed PD-L1 can induce co-
stimulation (figure 24B). 
Five x 106 SK-Mel23 cells were injected s.c. and after 15 days, when tumors were 
palpable, 2 x 106 human TCR-D115 T cells were injected i.v.. Blood, lungs, spleens 
and tumors were analyzed 7 and 10 days after adoptive T cell transfer (ATT) for 
presence of transferred T cells by staining with an anti-human CD45 antibody. As 
depicted in figure 24C, transferred human T cells (CD45+) were detected in blood, 
lungs and spleens, while they were barely detected in tumor cell suspensions. No 
further analysis was attempted due to low cell yield of the transferred human T cells. 
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Figure 24: Characteristics of human melanoma cell lines and detection of human T cells 
after ATT in NSG-human xenograft.  
(A) Histograms showing HLA-A2, tyrosinase and PD-L1 expression by human melanoma cell 
lines FM3, FM55, FM86 and SK-Mel23. The black open histograms show the specific antibody 
staining and the grey filled histograms the control staining. Median fluorescence intensity (FI) 
values are indicated for the specific antibody staining. 
(B) TCR-D115 and TCR-D115/PD-1:28
tm 
transduced T cells (see figure legend 21) were 
stimulated with the indicated melanoma cells in vitro. Co-culture supernatants were harvested 
after 16 hours and analyzed for IL-2 and IFN- content. Depicted is the amount of cytokine 
secreted by 25.000 CD8+D115+ T cells (n = 1). 
(C) 5 x 10
6
 SK-Mel23 cells were injected s.c. into the flank of NSG mice. When tumors were 
palpable, 2 x 10
6
 TCR-D115 T cells were injected i.v.. Blood, lung, spleen and tumor tissue 
suspensions were obtained 7 (top) and 10 days (bottom) after transfer. Exemplary dot blots 
showing human CD45 expression at depicted time points (n = 2 mice per time point). 
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As human T cells apparently poorly migrated into the human xenograft when injected 
i.v., a second experiment was performed where T cells were injected directly into the 
tumors (figure 25A). Before injection TCR-D115 and TCR-D115/PD-1:28tm T cells 
(figure 25B) were labeled with CFSE to allow cell tracing and assessment of 
proliferation in vivo. When tumors reached a size of 802 mm3 (SEM ± 83), 6 x 106 
TCR-D115 or TCR-D115/PD-1:28tm T cells were injected i.t.. Tumors were harvested 
at 4 hours, 1, 2, 4, 6 and 10 days after ATT. Tumor suspensions were prepared and 
analyzed by flow cytometry. It was observed that TCR-D115 T cells were PD-1 
negative before ATT but stained positive for PD-1 1 and 2 days after ATT, thus they 
up-regulated native PD-1 protein expression. After day 2 native PD-1 staining 
decreased but was never lost completely (figure 25C, E). This temporary expression 
of native PD-1 can be seen as a sign of T cell activation within the tumor 
microenvironment, which apparently lasted until day 2 after transfer. For TCR-
D115/PD-1:28tm T cells, a temporary expression of native PD-1 is not discernable 
from the transgenic PD-1:28tm signal. However, a temporary increase in the median 
FI of PD-1 in TCR-D115/PD-1:28tm T cells was observed. Both TCR-D115 and TCR-
D115/PD-1:28tm T cells showed down-regulation of CD8 with nearly complete loss at 
day 2 after ATT, again indicating activation (figure 25D, F). TCR-D115/PD-1:28tm 
T cells were starting to regain CD8 expression at day 4 while TCR-D115 T cells 
without PD-1:28tm stayed CD8 negative much longer with an indication of CD8 
recovery at the latest time point analyzed (day 10).  
Assessing the CFSE staining intensity revealed that at day 6 and 10 after ATT TCR-
D115 T cells retained significantly more CFSE than TCR-D115/PD-1:28tm T cells 
(p < 0.05), thus they did not proliferate as much as TCR-D115/PD-1:28tm T cells, 
although they appeared to be activated in situ as judged by up-regulated PD-1 and 
down-regulated CD8 (figure 25G-H).  
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Figure 25: Characteristics of TCR-D115 and TCR-D115/PD-1:28
tm
 T cells in the micro-milieu 
of a human melanoma xenograft. 
Figure legend continues on page 96. 
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To analyze whether PD-1:28tm expression on T cells has an effect on tumor control, 
TCR-D115 or TCR-D115/PD-1:28tm T cells were injected into xenografts when 
tumors were palpable (mean ± SEM = 78 mm3 ± 5) and tumor growth was measured 
over time. As depicted in figure 26A, i.t. injection of T cells with or without PD-1:28tm 
compared to PBS injection did not change tumor growth kinetics nor did it induce 
tumor shrinkage. Similarly, transfer of the high-avidity TCR-T58 T cells with or without 
PD-1:28tm did not show any effect on tumor growth (figure 26B).  
 
Figure 26: Growth kinetics of SK-Mel23 human melanoma xenograft in NSG mice receiving 
PBS or i.t. ATT. 
5 x 10
6
 SK-Mel23 cells were injected s.c. into NSG mice. When tumors were palpable 
(mean = 78 mm
3
, SEM ± 5), 6 x 10
6
 TCR-D115 or TCR-D115/PD-1:28
tm
 T cells (A, n = 4 mice per 
group), TCR-T58 or TCR-T58/PD-1:28
tm
 T cells (B, n = 4 mice per group) or PBS (n = 3 mice) 
were injected i.t..  
Tumor size (mean + SEM) was measured at indicated days after tumor cell injection. 
Figure 25: Characteristics of TCR-D115 and TCR-D115/PD-1:28
tm
 T cells in the micro-milieu 
of a human melanoma xenograft. 
(A) Experimental outline: 5 x 10
6
 human melanoma cells SK-Mel23 were injected s.c. into NSG 
mice. When tumors reached a size of 802 mm
3 
(± 83), 6 x 10
6
 CFSE labeled TCR-D115 or                         
TCR-D115/PD-1:28
tm
 T cells were injected i.t. (n = 2 mice per T cell and time point). Tumors were 
harvested 4 hours, 1, 2, 4, 6 and 10 days after ATT and single cell suspensions were prepared for 
flow cytometry analysis of PD-1, CD8 and CFSE. 
(B) Characteristics of T cells used for ATT: Human TCR-D115 T cells were activated with anti-
CD3 plus anti-CD28 antibodies and 100 U/ml IL-2 for two days, retrovirally transduced with PD-
1:28
tm
 or MOCK and expanded for 14 days. Dot plots showing PD-1 and TCR expression in gated 
alive, single, CD3+, CD8+ T cells. 
(C-F) Characteristics of T cells in the tumor microenvironment: Tumors were harvested on 
indicated time points after ATT, single cell suspensions were prepared and analyzed by flow 
cytometry. Scatter dot blots (C-D) and histograms (E-F) showing anti-human PD-1 (C, E) and 
CD8 (D, F) staining in gated human CD45+, alive and single cells. 
(G) Histogram showing CFSE staining of gated human CD45+, alive and single TCR-D115 
(black) and TCR-D115/PD-1:28
tm
 T cells (red) in tumor suspension prepared 10 days after i.t. 
injection.  
(H) Summary graph showing median FI of CFSE of gated human CD45+, alive and single TCR-
D115 and -D115/PD-1:28
tm
 T cells in tumor suspensions harvested before and 6 or 10 days after 
i.t. injection.  * Mann-Whitney U test, p < 0.05  
 
RESULTS                                                                                                                               97 
7.9 PD-1:28tm did not affect survival in an autochthonous 
hepatocellular carcinoma mouse model but suppressed 
Th2+Th17 polarization of TILs  
The failure of PD-1:28tm to cause tumor shrinkage or delay tumor outgrowth in the 
human melanoma xenograft NSG mouse model might have been due to the 
xenogeneic nature of the NSG model. In the mouse background, human T cells 
cannot receive supportive cytokine signals nor can they follow chemokine gradients, 
as these mediators are mouse-derived. This will limit human T cell trafficking, survival 
as well as effector function. In addition, effector cytokines secreted by the human 
T cells, such as human IFN-γ, cannot affect the tumor vasculature, which is of murine 
origin, and, therefore, insensitive to the destructive effect of human IFN-γ.  
Considering this, a fully murine model was chosen. The tumor model was the 
autochthonous hepatocellular carcinoma mouse model, LoxP-TAg, published by 
Willimsky et al. (60, 61). LoxP-TAg mice are transgenic for the oncogenic simian 
virus large T antigen (59), controlled by a stop cassette. Upon injection of 
adenoviruses coding for Cre recombinase (Ad.Cre) the stop cassette is deleted and 
TAg is expressed. Due to the hepatic tropism of adenoviruses TAg is predominantly 
activated in the liver and mice develop multinodular hepatocellular carcinoma (HCC) 
within 8-24 weeks after virus injection. In this model, the 3 phases of anti-tumor 
immune response, elimination-equilibrium-escape, can be observed (67). In the early 
phase of oncogenic activation tumor cells develop causing multiple malignant lesions 
in the liver. During this phase T cells are activated and eliminate most of the tumor 
cells. Then, around 6 weeks after oncogene activation, T cell exhaustion sets in and 
residual tumor cells grow out leading to death over a period of 8-35 weeks. 
Regarding the mechanism of immune escape, it is indicated that PD-1/PD-L1 
interaction contributes to the immune escape since survival could be prolonged when 
anti-PD-L1 antibody was applied (61).  
To analyze the effect of PD-1:28tm a murine construct (mPD-1:28tm) was generated 
and retrovirally transduced into LoxP-TAg mouse splenocytes (see below). Its 
capacity to enhance T cell function was assessed in vitro using splenocytes of TCR-I-
transgenic mice. The TCR-I recognizes epitope I of TAg presented on murine H2-Db. 
The HCC cell line 434, which expressed H2-Db, TAg and PD-L1 (figure 27B), was 
used as a target to stimulate TCR-I T cells. TCR-I T cells were transduced with mPD-
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1:28tm (figure 27A) and co-cultured with HCC 434 cells for 24 hours. As depicted in 
figure 27C, mPD-1:28tm enhanced the amount of secreted IL-2 and IFN-γ, thus 
seemed to be functionally expressed on TCR-I T cells. 
 
The effect of mPD-1:28tm in vivo was addressed by transducing splenocytes of LoxP-
TAg mice with mPD-1:28tm 15 weeks after initiation of oncogenesis and using them 
for ATT. According to published data (61), at this time point splenocytes should 
contain antigen specific T cells, which are exhausted and unable to control tumor 
outgrowth after the initial round of tumor cell killing. It was the question whether 
genetic engineering of these exhausted splenocytes with mPD-1:28tm could restore 
their function and enable them to control tumor outgrowth. 
 
Before ATT splenocytes were transduced with Thy1.1 to allow tracing in vivo and one 
part of cells was additionally transduced with mPD-1:28tm. Transduced splenocytes 
were enriched for Thy1.1 positive cells using magnetic bead separation. Thy1.1 and 
 
Figure 27: Effect of PD-1:28
tm
 on TCR-I T cells.  
TCR-I splenocytes were activated with anti-CD3 plus anti-CD28 antibodies and 10 IU/ml IL-2 for 1 
day, retrovirally transduced with mPD-1:28
tm
 and expanded for 14 days. 
(A) Dot blots showing CD8 and PD-1 expression in alive, single, CD3+ T cells among TCR-I and 
TCR-I/mPD-1:28
tm
 T cells. 
(B) Histograms showing H2-D
b
, large T antigen (TAg) and PD-L1 expression by the hepatocellular 
carcinoma cell line 434. Black open histograms show the specific antibody staining and grey filled 
histograms the control staining. Median fluorescence intensity (FI) values are shown for the 
specific antibody staining. 
(C) TCR-I and TCR-I/mPD-1:28
tm
 T cells were stimulated with the HCC 434 cell line. Co-culture 
supernatants were harvested after 24 hours and analyzed for IL-2 and IFN- content. Depicted are 
mean values of indicated number (n) of experiments + SEM. 
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Thy1.1/mPD-1:28tm splenocytes expressed Thy1.1 to 81% and 83%, respectively. 
The transduction efficiency of mPD-1:28tm was 60%. The cell populations used for 
ATT were composed of 85% CD8+ T cells and 12% CD4+ T cells. CD62L was 
expressed by 84% and 82% of Thy1.1 and Thy1.1/mPD-1:28tm splenocytes, 
respectively. All T cells were 100% Bcl-2 positive and 84% of Thy1.1 and 82% of 
Thy1.1/mPD-1:28tm splenocytes expressed CD62L (figure 28B). Given the similar 
expression of Bcl-2 and CD62L it was assumed that Thy1.1 and Thy1.1/mPD-1:28tm 
splenocytes were in a similar state of differentiation.  
The ATT experiment involved 3 arms, each with 11-12 mice: i) no ATT, ii) ATT with 
Thy1.1 transduced splenocytes, iii) ATT with Thy1.1/mPD-1:28tm splenocytes (figure 
28A). Blood was drawn at day 4, 7, 14 and 16 after ATT and analyzed for the 
presence of transferred T cells.  
The blood analysis showed that Thy1.1+ cells were hardly detectable (0.01-0.6% of 
all cells) at day 4 after ATT and remained at the detection limit at day 7, 14 and 16 
after ATT (not shown). Mice were observed for tumor growth by palpating the 
abdomen every second day. Mice were sacrificed when tumor size appeared to have 
reached a size of 1.5 cm or mice seemed to be in distress. After scarification HCC 
tumors and spleens were harvested and single cell suspensions prepared. TILs were 
separated from tumor cells and hepatocytes by Percoll density gradient 
centrifugation. 
The cumulative survival curves (using Kaplan-Meier analysis) were similar for all 3 
arms indicating that ATT using Thy1.1 and Thy1.1/mPD-1:28tm splenocytes had no 
effect on tumor growth (figure 28C).  
 
 
 
 
 
 
RESULTS                                                                                                                               100 
 
 
Figure 28: ATT with mPD-1:28
tm
-engineered splenocytes in an autochthonous HCC tumor 
model. 
(A) Experimental outline: 15 weeks after Ad.Cre injection splenocytes were isolated from donor 
mice, transduced with Thy1.1 or Thy1.1 plus mPD-1:28
tm
 and 5 x 10
6
 cells were injected r.o. into 
recipient mice, which had been injected with Ad.Cre 11.5 weeks earlier. Mice were palpated for 
tumor growth and sacrificed when tumors reached a size of 1.5 cm. Splenocytes as well as 
tumors were harvested for analysis. 
(B) Characteristics of T cells used for ATT: Dot blots showing CD8, CD4, PD-1, Thy1.1, CD62L 
and Bcl-2 expression of Thy1.1 and Thy1.1/mPD-1:28
tm
 splenocytes (gated on alive, single CD3+ 
T cells). 
(C) Kaplan-Meier survival curves of mice treated with Thy1.1 splenocytes (blue line), 
Thy1.1/mPD-1:28
tm
 splenocytes (red line) and of mice not receiving therapy (black line), n= 11-12 
mice per group. 
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Flow cytometry analysis was performed with TILs and splenocytes from sacrificed 
mice. The overall percentage of CD19+ B cells or CD3+ T cells in tumors or spleens 
were similar in all 3 treatment groups (figure 29A-B). Calculating the fraction of 
transferred T cells within the CD3+ T cells of spleens and tumors, i.e. the percentage 
of Thy1.1+ cells among all CD3+ T cells, revealed a higher percentage of Thy1.1+ 
cells in tissues of mice treated with Thy1.1 ATT (figure 29C). Among TILs on average 
3.4% of CD3+ T cells from mice treated with Thy1.1 splenocytes stained positive for 
Thy1.1, while 1.8% stained Thy1.1 positive when mice received Thy1.1/mPD-1:28tm 
ATT. In spleens, 0.6% and 0.3% of CD3+ T cells stained positive for Thy1.1 when 
mice were treated with Thy1.1 or Thy1.1/mPD-1:28tm ATT, respectively.  
 
 
Figure 29: Immune cell fractions in cell suspensions obtained of HCC tumors and spleens. 
(A-C) Spleens and HCC tumors of sacrificed mice were processed into single cell suspensions 
and analyzed by flow cytometry using a CD45, Thy1.1, CD3 and CD19 antibody combination. 
Scatter dot blots showing % CD19+ cells (A) and % CD3+ cells (B) gated on CD45+, alive and 
single cells (mean + SEM). Scatter dot blots showing % Thy1.1+ cells in CD45+, alive, single and 
CD3+ T cells (C). * Mann-Whitney U test, p < 0.05 
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TILs and splenocytes were additionally analyzed for their responsiveness to 
stimulation and cytokine profile. Specifically, cytokines IFN-γ, IL-2, IL-4, IL-5, IL-10, 
IL-13 and IL-17 were analyzed using the Bio-Plex method to determine the 
Th1/Th2+IL-17/IL-10 polarization. For T cell stimulation the TILs and splenocytes 
were stimulated with the autologous HCC cell line 434, which expresses TAg and 
PD-L1. The observed cytokine secretion should predominantly result from stimulation 
of tumor antigen-specific T cells. In parallel, TILs and splenocytes were stimulated 
with PMA/I as it was considered possible that the tumor cell line might inhibit the 
T cell response due to its PD-L1 expression. The cytokine response observed after 
PMA/I stimulation results from all T cells independent of antigen-specificity and can 
be used to interpret the overall tissue-associated T cell polarization. The results for 
TILs and splenocytes are shown in figure 30 and 31. As a general note, the amount 
of cytokines produced by TILs was much lower than that of splenocytes regardless of 
stimulation with the HCC cell line 434 or PMA/I. Th1 cytokines secreted by TILs were 
similar in all treatment groups. TILs from mice having received Thy1.1 ATT produced 
more Th2 cytokines and also more IL-17 than TILs of mice from the Thy1.1/mPD-
1:28tm ATT or no ATT arm. This finding was also observed when cells were 
stimulated with PMA/I indicating a reprogramming of TILs in tumors of the Thy1.1 
ATT group. On the other hand, TILs of mice having received Thy1.1/mPD-1:28tm ATT 
secreted higher amounts of the regulatory cytokine IL-10. The secretion of IL-10 was 
more prominent when TILs were stimulated with the HCC cell line 434. 
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Figure 30: Cytokine response of HCC-TILs. 
HCC tumors were harvested from sacrificed mice and single cell suspensions prepared. TILs 
were separated from tumor cells and hepatocytes by Percoll gradient centrifugation. TILs were 
stimulated with the HCC cell line 434 or PMA/I for 16 hours. Co-culture supernatants were 
analyzed for cytokine content by Bio-Plex.  
(A) Stacked bars showing the mean of each cytokine (+SEM). P-values of Th1 to Th2+Th17 
cytokines to IL-10 are shown. Th1: IL-2, IFN-γ; Th2: IL-4, IL-5, IL-13; Th17: IL-17. Wilcoxon 
matched-pairs signed rank test. 
(B) Scatter dot bars showing levels of indicated cytokines, dots represent individual mice and bars 
the mean of all mice (+ SEM) 
 
RESULTS                                                                                                                               104 
As indicated before, the cytokine response of splenocytes was higher compared to 
TILs and was dominated by IL-2 in all treatment groups (figure 31). When stimulated 
with the tumor cell line 434, splenocytes from the mPD-1:28tm ATT arm secreted 
clearly higher amounts of IL-2 and IFN-γ. In contrast to splenocytes of the Thy1.1 
ATT treatment group, splenocytes of the mPD-1:28tm ATT and no ATT arm did not 
tend to secrete Th2 cytokines. 
When splenocytes were stimulated with PMA/I, less IL-10 was observed compared to 
stimulation with the HCC cell line 434.  
These findings indicate that ATT with mPD-1:28tm positive T cells might prevent the 
induction of Th2+IL-17 cytokines and retain the capacity to secrete high amounts of 
IL-2 upon stimulation with tumor cells. 
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Figure 31: Cytokine response of splenocytes isolated from HCC bearing mice.  
Spleens were harvested from sacrificed mice and single cell suspensions prepared. Splenocytes 
were stimulated with the HCC cell line 434 or PMA/I for 16 hours. Co-culture supernatants were 
analyzed for cytokine content by Bio-Plex.  
(A) Stacked bars showing the mean of each cytokine (+SEM). P-values of Th1 to Th2+Th17 
cytokines to IL-10 are shown. Th1: IL-2, IFN-γ; Th2: IL-4, IL-5, IL-13; Th17: IL-17. Wilcoxon 
matched-pairs signed rank test. 
(B) Scatter dot bars showing levels of indicated cytokines, dots represent individual mice and bars 
the mean of all mice (+ SEM) 
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8 DISCUSSION 
Loss of function and poor persistence of T cells in the tumor environment are major 
hurdles for successful adoptive T cell therapy. Co-stimulation can enhance both 
T cell effector function and proliferation. In particular, it has been shown that co-
stimulation can extend the duration and effectiveness of the cytotoxic response in an 
environment of high antigen load and can overcome TGF-ß-mediated repression of 
T cell proliferation (53, 68). These are desirable and much needed characteristics for 
ATT that should help to augment the efficacy of ATT. However, a large proportion of 
human CD8+ effector T cells, in contrast to murine T cells, are CD28 negative (54) 
and most epithelial tumors do not express the co-stimulatory ligands CD80 or CD86 
(55, 56). Thus, human T effector cells cannot receive the classical co-stimulatory 
signals in the tumor environment. With the advent of genetic engineering (69) the 
idea to equip T cells with desired characteristics is becoming reality. In this thesis, I 
explored the concept whether engineering of T cells with a chimeric co-signaling 
receptor consisting of the extracellular domain of PD-1 linked to an intracellular 
stimulatory domain could be a strategy to initialize co-stimulation in the tumor 
microenvironment. Facilitated co-stimulation through chimeric co-signaling receptors 
with the extracellular domain of PD-1 is conceptually attractive for cancer 
immunotherapy as the ligand for PD-1, PD-L1, is commonly expressed at high levels 
on solid tumor cells (57) and absent or poorly expressed by healthy tissue (70). Thus, 
activation of the co-signaling pathway from the PD-1:28 chimeric receptor will occur 
in the tumor milieu and T cells should receive co-stimulation when interacting with 
tumor cells thus at the time and place stimulation is required. In addition, the chimeric 
receptor should counterbalance the inhibitory effect of the native PD-1. Thereby, 
chimeric co-stimulatory receptors could turn tumor-mediated inhibition into activation. 
The field of chimeric immune receptors is currently best known for chimeric antigen 
receptors (CAR), which are highlights of cancer immunotherapy (16). Here, an 
antibody domain is fused via a hinge region to the TCR signaling domain of CD3ζ 
and one of several co-signaling domains. T cells expressing a CAR are equipped 
with the recognition specificity of an antibody and activate T cell effector functions, 
such as cytotoxicity and cytokine secretion, when recognizing the target structure. A 
design linking the antibody specificity of CD19 to the co-signaling domain of 4-1BB 
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has caught attention due to remarkable clinical efficacy in patients with relapsed or 
refractory acute lymphoblastic leukemia patients (34). This clinical trial was the first to 
show tumor clearance concomitant with long-term persistence of the adoptively 
transferred CD19-CAR-T cells. It is speculated that this unique achievement was due 
to the 4-1BB signaling sequence of the CAR, although comparative side-by side trials 
with otherwise identical chimeric receptors encoding the CD28 versus the 4-1BB co-
signaling domain are only now being performed.  
4-1BB is a co-stimulatory molecule for activated T cells that has been reported to 
increase CD4+ and CD8+ T effector function and to provide survival signals and 
expansion mainly for CD8+ T cells. Its particular value for cancer immunotherapy 
may lay in the capacity to sustain ongoing T cell responses as well as to enhance or 
rescue suboptimal immune responses (6, 10).  
 
While it is still contentious which co-stimulatory signal or combination thereof might 
be optimal, the necessity of co-stimulation is without question, at least in the CAR 
field. Facilitated co-stimulation has not been explored for TCR-engineered CD8+ 
T cells that are being used in clinical trials with efficacies remaining behind 
expectation (37). Given the lack of CD28 expression on most human CD8+ T effector 
cells, facilitated co-stimulation could be a step towards improving efficacy. 
 
8.1 Design influences chimeric receptor expression 
In this dissertation, different chimeric co-signaling receptors were created utilizing the 
extracellular domain of PD-1 and the signaling domain of either CD28 or 4-1BB. One 
receptor design (PD-1:8tm:28) closely followed the domain arrangement of CARs, 
utilizing the CD8 hinge and transmembrane region to link the extracellular domain of 
PD-1 to the intracellular CD28 signaling domain. Hinge regions in CARs are meant to 
increase receptor flexibility and facilitate the binding of membrane-proximal epitopes 
(28). Surprisingly, the PD-1:8tm:28 chimeric protein was poorly expressed on the 
surface of T cells. The receptor did not accumulate intracellularly, thus excluding 
poor ER-Golgi transport. Rather, the translation efficacy of the ivt-RNA seemed 
limited for as yet unknown reasons. Similarly, poor expression, and, additionally, poor 
retention on the cell surface, was observed for the chimeric protein PD-1:BBtm, which 
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consists of the transmembrane domain and the intracellular signaling domain of 
4-1BB. Here, the short surface presence might be due to features of the 4-1BB 
protein, which exhibits fast recycling when expressed under native conditions (7, 71). 
A new construct containing the transmembrane domain of PD-1 instead of 4-1BB 
(PD-1tm:BB) was created to address this hypothesis. Indeed, preliminary results 
suggest better surface expression and future experiments will be performed to study 
the kinetics and functionality of the chimeric receptor.  
Regarding chimeric receptors containing the CD28 signaling domain, 2 variants were 
compared, PD-1:cys28tm and PD-1:28tm, whereby the former contained the CD28 
membrane proximal sequence that encodes the cysteine at position AA 141. The 
native CD28 protein is expressed on the surface as a homodimer while PD-1 is a 
monomer. It was considered possible that the dimerization through the cysteine 
might be required for proper surface expression and CD28 signaling activity of a 
chimeric PD-1:28 receptor. Yet, there was no evidence for this proposition as 
PD-1:cys28tm and PD-1:28tm showed similar patterns for both expression and activity. 
 
8.2 PD-1:28 chimeric receptors can enhance functionality of 
human T cells and restore tumor-inhibited TIL function 
After it was shown that chimeric PD-1:cys28tm and PD-1:28tm receptors could be 
stably detected on the T cell surface it was assessed whether these receptors can 
enhance T cell function. Indeed, it could be demonstrated that T cells expressing the 
PD-1:cys28tm or PD-1:28tm receptor secreted more IFN-γ and IL-2 when stimulated 
with PD-L1 expressing target cells. The increased cytokine secretion will likely be 
beneficial for the anti-tumor response as both cytokines are important components 
for effective tumor control. IFN-γ can up-regulate MHC expression (72) and thereby 
increase the visibility of tumor cells for T cells. Furthermore, IFN-γ can foster 
infiltration of NK cells and macrophages by inducing the production of chemokines. In 
addition, IFN-γ can target tumor stroma and inhibit angiogenesis (73).  
The beneficial effect on cytokine secretion was more profound for IL-2 than for IFN-γ. 
This is conceivable since the IL-2 promotor is a primary target of the CD28 co-
stimulation pathway (5). Furthermore, as the activation threshold for IL-2 transcription 
is higher compared to IFN-γ, i.e. stronger TCR signals are required to elicit an IL-2 
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response (74) and IL-2 transcription may be more susceptible to CD28 co-stimulation 
than IFN-γ. Epigenetic alterations of the IL-2 promotor upon CD28 stimulation, such 
as reduced cytosine methylation and increased histone acetylation (75) could be 
underlying mechanisms for the effect of CD28 co-signaling receptors on IL-2 
expression. 
Regarding T cell effector activity, facilitated secretion of IL-2 by CD8+ T cells is 
particularly valuable as CD8+ T effector cells often do not produce IL-2 themselves 
but are dependent on IL-2 secreted by concurrently activated CD4+ T cells. 
Becoming independent of CD4+ T cell help is a major asset for effector CD8+ T cell 
function as many tumor cells are MHC class II negative (76) and thus cannot activate 
CD4+ T cells. IL-2 provision helps CD8+ T cell proliferation and might promote tumor 
localization (77). 
 
Co-stimulation has a major impact on the T cell response by enhancing signaling 
cascades downstream of the TCR, such as increasing the activation level of the MAP 
kinase pathway including ERK. ERK is implicated in cytokine secretion and 
degranulation (1, 2). In addition, co-stimulation can enhance the mTOR pathway 
leading to RPS6 activation (5, 78). RPS6 supports proliferation and is involved in 
protein synthesis (4). Thus, through facilitating enhanced TCR signaling, PD-1:28 
might overcome known deficits of TILs including reduced effector function and low 
perforin expression (48). Indeed I could demonstrate that T cells expressing chimeric 
PD-1:28tm or PD-1:cys28tm receptors elicited higher phosphorylation of ERK and 
RPS6 when stimulated with PD-L1+ target cells compared to T cells not expressing 
the chimeric receptors. Since it has been observed previously that blockade of ERK 
and AKT phosphorylation is one mechanism that causes loss of function of T cells in 
human renal cell carcinoma tissue (48), I hypothesized that co-stimulation might 
restore these deficits and allow TILs to regain function. Indeed, TILs engineered to 
express PD-1:28tm did secrete IFN-γ when stimulated with PD-L1+ target cells while 
the same TILs without PD-1:28tm did not secrete cytokine under the same stimulation 
conditions. In future experiments it will be analyzed whether gain of function is 
associated with de-blocking of the ERK and AKT signaling cascades. TILs are being 
used in adoptive T cell therapy of melanoma and RCC with clinical response rates of 
56% and 11%, respectively (16, 79). Given the results of this thesis, it might be 
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interesting to explore whether genetic engineering of TILs before transfer might 
improve efficacy.    
In addition to TILs, T cells genetically engineered to express a tumor-specific TCR 
are used in adoptive T cell therapy. High-avidity TCRs are desired as it is thought 
that they confer superior effector function compared to low-avidity TCRs (80, 81). 
Published studies indeed suggest that low-avidity T cells can remain ignorant of 
antigen expressing target cells and may not mount a successful tumor-specific 
response (82). Efforts are therefore taken to modify TCR sequences to increase their 
affinity for antigen recognition (25, 83). However, results with affinity-enhanced TCRs 
are controversial, demonstrating no or improved responses compared to low-avidity 
counterparts (21, 59). Moreover and of concern for clinical application are observed 
serious adverse effects with adoptively transferred T cells expressing affinity-
enhanced TCRs (26, 27). These adverse reactivities are attributed to the genetically 
altered TCR sequence that created unpredicted reactivity to new target structures 
expressed by vital organs. Less risk of autoimmunity is expected with naturally 
occurring TCRs as they have been thoroughly selected by the thymus and are under 
peripheral control mechanisms. However, as a drawback of thymic selection, those 
TCRs participating in the anti-tumor response are of intermediate to low avidity (84).  
Genetic engineering with PD-1:28 receptors appears to be an interesting strategy 
that allows utilizing low-avidity T cells isolated from cancer patients, as it has been 
shown that expression of PD-1:28 receptors enhanced the cytokine response of low-
avidity T cells to levels comparable to high-avidity T cells. 
Transgenic expression of a chimeric co-stimulatory receptor does not alter the TCR 
sequence and thus will not change the T cell specificity. Therefore, the occurrence of 
unpredicted off-target recognition is not to be expected. Co-stimulation by enhancing 
the TCR signaling cascade might, however, lower the threshold for T cell activation, 
thus T cells expressing the chimeric co-stimulatory receptor might respond to cells 
with lower levels of cognate pMHC. This might be advantageous as tumor cells often 
down-regulate MHC I molecules, antigens and molecules of the antigen-presentation 
pathway (85, 86). Future experiments will address this question. 
 
Co-inhibition strongly opposes an effective antitumor response. Counteracting co-
inhibitory signals will be of value and enhance the function of anti-tumor immune 
responses. The importance of blocking co-inhibition is convincingly documented in 
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several clinical trials achieving tumor regression in advanced stages of several tumor 
entities when blocking the PD-1/PD-L1 axis with therapeutic antibodies (43). 
Opposing co-inhibition might be an additional mode of action of PD-1:28 receptors as 
they can dilute native PD-1 signals. It is shown in this thesis that low-avidity T cells in 
particular might benefit from ameliorating co-inhibition as PD-1trunc, with no 
signaling capacity, enhanced cytokine secretion of low-avidity TCR-D115 T cells but 
not of high-avidity TCR-T58 T cells. The difference between the two T cells regarding 
the effect of PD-1trunc was not explained by different levels of native PD-1 
expression. In the literature it is suggested that low-avidity TCRs activate the TCR 
signaling cascade less efficiently (22). Inhibitory signals, or their attenuation have a 
stronger impact as compared to situations of strong TCR signaling.  
In summary, it was shown that PD-1:28 chimeric receptors not only activated the co-
stimulatory pathway resulting in enhanced TCR signaling and effector function but 
additionally opposed native PD-1. These are strong assets of chimeric co-signaling 
receptors and may help ameliorating a major hurdle of efficient antitumor function in 
PD-L1+ tumor milieus. 
  
8.3 In vivo studies support the therapeutic potential of the PD-1:28 
receptor 
Co-stimulation also supports TCR-independent programs, such as survival, cell cycle 
progression and maintenance of lytic proteins (5, 53), all of which are particularly 
valuable in a challenging environment.  
To analyze the effect of PD-1:28tm on T cell function in a tumor environment I 
performed adoptive T cell therapy experiments using several mouse models. The first 
model was a human melanoma xenograft model that allowed utilizing human T cells 
expressing the human tyrosinase-specific TCR-D115 and the human PD-1:28tm 
construct. Despite several shortcomings of the xenograft system (detailed below) it 
was clearly observed that TCR-D115 T cells expressing PD-1:28tm proliferated better 
in the tumor milieu than TCR-D115 T cells without PD-1:28tm. This observation 
suggests that PD-1:28tm has the potential to increase the persistence of adoptively 
transferred T cells in the tumor milieu. 
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Additional evidence for a better performance of T cells expressing the PD-1:28tm 
receptor may be deduced from the observation that TCR-D115/PD-1:28tm T cells re-
expressed CD8 faster, while TCR-D115 T cells without PD-1:28tm remained CD8 
negative over the observation time of 10 days. CD8 down-regulation indicates 
activation but CD8 re-expression is required for the T cell to be again responsive to 
stimulation (87). Cytotoxic CD8+ T cells with down-regulated CD8 expression are 
reported to have higher levels of cleaved caspase-3 and may, therefore, be more 
prone to cell death (88).  
While stronger proliferation and CD8 regain of TCR-D115/PD-1:28tm T cells in the 
tumor milieu suggests that PD-1:28tm can provide support to T cells, there was no 
evidence that this translated into better tumor control. 
There are many explanations: One is the incompatibility of chemokines and cytokines 
important for lymphocyte migration. Indeed, the adoptively transferred human T cells 
were not found in the tumor when injected intravenously, while they could be 
detected in blood, lung and spleen. To circumvent this problem, i.t. injection was 
chosen.  
T cells were injected only once, which may not have been sufficient. Data from 
human clinical trials (89) and murine studies (90) provide evidence that multiple 
infusions of tumor-reactive T cells are more effective than a single infusion.  
As it was the aim to address whether PD-1:28tm can provide T cells with the capacity 
to persist and maintain effective tumor-directed functionality, no human cytokines 
were co-administered. Thus, T cells might have experienced cytokine deprivation. 
Literature data suggests that it is necessary to destroy the tumor stroma, i.e. 
vasculature and carcinoma-associated fibroblasts (CAFs), to achieve tumor 
shrinkage (91, 92). To this end, the activity of IFN-γ is required (49), which can be 
produced when T cells are activated by antigen recognition. 
In a xenograft model, the transferred T cells are of human origin and secrete human 
IFN-γ, while the tumor stroma is of murine origin. The incompatibility of human 
cytokines and murine stroma may be another reason why tumor shrinkage was not 
achieved despite signs of T cell activation.  
Given the outlined limitations of xenograft models an autochthonous HCC model was 
selected. This model was established by Gerald Willimsky and involved induction of 
the oncogenic process by activating SV40 large T antigen (TAg) through the Lox-
Cre-system (60, 61). Many characteristics of this model suggested that it might be 
DISCUSSION                                                                                                                         113 
close to human cancer. The tumor is not transplanted but develops through activation 
of an oncogene and the course of tumor progression is slow, spanning up to 35 
weeks from initiating the oncogenic process until death from tumor load. An initial 
phase of immune cell activation with clearance of tumor burden is followed by T cell 
exhaustion with indication of PD-1 involvement and loss of tumor control (61). 
A fully murine tumor model required the generation of a murine PD-1:28tm (mPD-
1:28tm) construct. This mPD-1:28tm receptor showed a beneficial effect on T cell 
cytokine secretion in vitro. As for tumor antigen-specific T cells to be engineered with 
mPD-1:28tm and used for ATT several options were available: TCR-transgenic T cells 
recognizing epitopes of the tumor antigen TAg or naturally induced TAg-specific 
T cells such as TILs from the HCC tumor or splenocytes, which would equal PBL in 
the human situation. With each T cell population different questions could be 
addressed regarding effect of mPD-1:28tm expression. These are prevention or 
reversal of acquired deficits and impact on the performance of T cells with a single or 
mixed specificity. In a first approach, TCR-transgenic T cells recognizing a TAg 
epitope were selected for ATT. Four epitopes (I-IV) are known for TAg. For epitope I 
(SAINNYAQKL) there is a transgenic mouse strain available that expresses the 
epitope I-directed TCR-I together with renilla luciferase, allowing trafficking of T cells 
after ATT via bioluminescence imaging (93), which appeared attractive. However, 
after transfer TCR-I T cells were not detectable at day 3 and 7. There is evidence in 
the literature that TCR-I T cells do not persist in vivo and may be tolerized in the 
periphery (94). This may be due to the high stability of epitope I/H2-Db pMHC (95), 
which may cause TCR-I T cell deletion (96). 
In a second experiment, naturally induced anti-tumor T cells were used. Based on 
published results (61) from 12 weeks on after tumor induction, exhausted T cells 
should be found in the spleen. Those splenocytes have been shown to be effective in 
ATT with additional improvement by anti-PD-L1 treatment (61). In this thesis, mPD-
1:28tm-transduced splenocytes were used for ATT and survival compared to ATT 
without mPD-1:28tm and no ATT. Although no effect was observed on tumor growth, 
mPD-1:28tm ATT showed a positive effect on T cell cytokine polarization. Most 
notable was the prevention of Th2 polarization in the tumor milieu. Th2 cytokines and 
IL-17 are associated with metastasis (97), liver cirrhosis (98), increased tumor 
vascularization (99) and proliferation of cancer cells (100). In addition to less Th2 
cytokines, more IL-10 was observed in ATT with mPD-1:28tm. IL-10 can have 
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conflicting effects such as suppression of anti-tumor immunity but also enhancement 
of cytotoxicity of and IFN-γ secretion by CD8+ T cells, thereby controlling tumor 
growth (101, 102). The suppression of Th2 by mPD-1:28tm ATT could be explained 
by the observation that native PD-1 signaling inhibits secretion of Th1 but not Th2 
cytokines (58) and that PD-1 blockade can suppress Th2 polarization (103). When 
transferred T cells express mPD-1:28tm, the inhibitory effect of native PD-1 can be 
counterbalanced by the chimeric receptor and thus a Th2 polarization can be 
prevented. 
Several possibilities are considered that may explain the failure to achieve tumor 
rejection. In this experiment, ATT in general, independent of mPD-1:28tm, did not 
show any effect over no ATT. One explanation might be that the splenocytes used for 
ATT lacked or contained only few tumor-reactive T cells or/and T cells were 
irreversibly inhibited. 
Moreover, the observation that transferred T cells could not be detected in the blood 
after injection supports the hypothesis that they did not persist. ATT was given as a 
single dose without administration of cytokines. However, injection of cytokines might 
have supported the persistence of transferred T cells. Injection of IL-2 might help 
T cell persistence as observed for human TILs (104) and its administration along 
transfer of autologous TILs is a standard protocol in the clinical setting (16). 
Moreover, administration of IL-7 and IL-15 as mediators of T cell proliferation and 
function might be beneficial. They might preferentially support memory T cells and 
thereby enhance long-lasting responses (105).  
The third option using TILs from HCC could not be explored within the time frame of 
this thesis. 
 
There is no model system perfectly matching the tumor milieu of human cancer 
patients. In the currently available models the potential impact of the PD-1:28tm 
receptor might have been obscured. As the human immune system is different from 
the murine one (106), data observed with the help of a mouse model system cannot 
be transferred straightforward to the human situation. The observation that murine 
T cells are almost 100% CD28 positive and that they do not lose CD28 expression 
with age or in the course of chronic disease is completely different to the human 
situation where only 50% of CD8+ T cells express CD28 and there is a down-
regulation of CD28 (107). Thus, it seems likely that murine and human T cells do not 
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share the same necessity of facilitated co-stimulation. The differences of human and 
murine immunity can only be circumvented by engraftment of NSG mice with human 
hematopoietic stem cells. This would allow the recruitment of engrafted leukocytes 
and might enhance migration of transferred cells to the tumor site. The means for this 
model were not available but this experimental setup might reveal the complete 
therapeutic potential of PD-1:28tm engineered T cell therapy. 
 
8.4 Outlook 
Co-stimulation and co-inhibition have a major impact on quality and quantity of 
immune responses. With a chimeric co-stimulatory receptor I hypothesized that both 
quality and quantity can be addressed and support be provided to T cells used for 
adoptive therapy of human cancer. Many of the observed effects of PD-1:28, 
including enhanced TCR signaling, stronger cytokine production, up-grading of low-
avidity T cells, restored function of TILs isolated from human RCC, better proliferation 
of T cells in the tumor milieu of a xenograft model and suppression of tumor-inflicted 
Th2 polarization in a model of murine HCC hint at its therapeutic potential.  
Although tumor shrinkage could not be detected in the analyzed models, the results 
still suggest that a PD-1:28 receptor might improve adoptive T cell therapy. Given the 
complexity of tumor immune escape mechanisms it is, however, not to be expected 
that PD-1:28 as a stand-alone intervention will enable tumor rejection. Rather 
combination of strategies targeting different escape mechanisms is likely necessary 
to achieve an optimal result (108). In this regard, a combination of PD-1:28tm 
engineered T cells or TILs and IL-2 to support T cell persistence may be beneficial. 
Blockade of additional inhibitory signals could add to the beneficial effect of 
PD-1:28tm facilitated co-stimulation, such as blocking antibodies to CTLA-4 could 
further increase TCR signaling and thereby strengthen T cell functionality. 
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9 ABBREVIATIONS 
7-AAD 7-Aminoactinomycin 
A Alanine 
A488, A647, A700 Alexa 488, 647, 700 
Ad.Cre Adenovirus coding for Cre recombinase 
ATT Adoptive T cell therapy 
Akt (= PKB) Protein kinase B 
APC Allophycyanin; antigen presenting cell 
APC-Cy7 Allophycyanin – Cyanine 7 
APC-eF780 Allophycyanin – eFluor 780 
Ca Calcium 
CAR Chimeric antigen receptor 
CD Cluster of differentiation 
C region Constant region 
D Aspartic acid 
DAG Diacylglycerol 
DGK-α Diacylglycerol kinase-α 
DGK-I Inhibitor of DGK-α 
DC(s) Dendritic cell(s) 
DMEM Dulbecco’s modified eagle medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
E Glutamic acid 
EDTA Ethylenediaminetetraacetic acid 
ERK Extracellular signal related kinase 
F Phenylalanine 
FACS Fluorescence activated cell sorting 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate  
FSC-A, -H Forward side scatter-area, -height 
G Glutamine 
Gy Gray 
H Histidine 
HBSS Hank’s buffered salt solution 
HEK 293 cells Human embryonic kidney 293 cells 
Hepes 4-(2-Hydroxyethyl)-1-piperazine-ethanesulfonic acid 
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HS Human serum 
ICAM-1 Intercellular adhesion molecule-1 
IFN-γ Interferon-gamma 
Ig Immunoglobulin 
IL Interleukin 
ITAM Immunoreceptor tyrosine-based activation motif 
ITK Interleukin-2 inducible T cell kinase 
IP3 Inositol-1,4,5-trisphosphate 
IU International units 
i.v. intravenously 
JNK C-Jun N-terminal kinase 
K Lysine 
kDa Kilo Dalton 
L Lysine 
LAT Linker for activation of T cells 
Lck Leukocyte C-terminal sarcoma kinase 
LCMV Lymphocytic Choriomeningitis Virus 
LTR Long terminal repeat(s) 
M Methionine 
MAPK Mitogen activated protein kinase 
MDSCs Myeloid-derived suppressor cells 
MESV murine embryonic stem cell virus 
MFI Median fluorescence intensity 
MHC Major histocompatibility complex 
MLV Mouse leukaemia virus 
MPSV Murine myeloproliferative sarcoma virus 
N Asparagine 
NFAT Nuclear factor of activated T cells 
NFκB Nuclear factor of kappa light polypeptide gene enhancer in B cells 
NK cell Natural killer cell 
P Proline; phosphorylated 
PB Pacific blue 
PBL Peripheral blood lymphocyte(s) 
PBMC Peripheral blood mononuclear cell(s) 
PBS Phosphate buffered saline 
PD-1 Programmed cell death protein-1 
PE Phycoerythrin 
PE-Cy7 Phycoerythrin – Cyanine 7 
PFA Paraformaldehyde 
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PH domain Pleckstrin homology domain 
PI3K Phosphatidylinositol-4-phosphate 3-kinase 
PIP2 Phosphatidylinositol-3,4-bisphosphate 
PIP3 Phosphatidylinositol-3,4,5-trisphosphate 
PKC-θ Protein kinase C-theta 
PLC-γ Phospholipase C-gamma 
pMHC Peptide MHC 
Q Glutamine 
R Arginine 
RCC Renal cell carcinoma 
r.o. retroorbitally 
RPMI Roswell Park Memorial Institute 
RPS6 40S ribosomal protein S6 
S Serine 
s.c. subcutaneously 
SEM Standard error of the mean 
SLP-76 SH2 domain-containing leukocyte protein of 76 kDa 
Src kinase Sarcoma kinase 
SSC-A Sideward scatter-area 
T Threonine 
TAg Simian virus large T antigen 
TCR T cell receptor 
TGF-β Transforming growth factor-beta 
TIL(s) Tumor infiltrating lymphocyte(s) 
TNF-α Tumor necrosis factor-alpha 
U Units 
V region Variable region 
Y Tyrosine 
ZAP-70 CD3zeta associated protein of 70 kDa 
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